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The importance of iron in physiological and metabolic pathways is well established 
in the literature. However, the literature is equally rife with studies highlighting the 
association of iron with cellular toxicities such as production of Reactive Oxygen 
Species and even the growth of intra-cellular pathogens. This study was based on the 
observation that in conditions of chronic inflammation, such as Rheumatoid 
Arthritis, cellular sequestration of iron leads to increased cell proliferation and tissue 
damage. The inability of the human body to physiologically excrete this excess iron 
highlights the need to develop a cheap yet effective iron chelator.  
Results indicate that CP655, an HPO iron chelator, specifically targets human CD4+ 
T cells and causes significant inhibition of proliferation of the cells along with 
significantly inhibiting production of inflammatory cytokine such as IFN-γ and IL-
17. A microarray conducted on stimulated human CD4+ T cells demonstrated that 
the genes most significantly modulated by iron chelation were those encoding for 
cell cycle regulators and inhibitors of DNA replication, hence preventing cell 
proliferation, as indicated by the in-vitro data. This was validated by cell cycle 
analysis. Finally, mechanistic experiments revealed that the chelator may be causing 
an up-regulation of the cell cycle inhibitor protein CDKN1A (p21) as one of its 
molecular mechanism of action.  
Since the depletion of iron can cause dysregulation of several cellular pathways, 
some of the other potential mechanisms suggested in this study include the reduction 
in STAT5 phosphorylation following CP655 treatment and inhibition of T cell 
Receptor downstream signaling molecules.  
In conclusion, this study demonstrates that intracellular iron has the ability to 
modulate CD4+ T cell responses and indicates that the use of novel iron chelators 
could prove to have therapeutic potential for RA and other diseases driven by 
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1.1 General Introduction: Iron in Biological Processes 
Iron, the most abundant metal by mass in earth’s crust, is also the most 
abundant metal within the human body. In adult humans, approximately 
40mg/kg of body weight is represented by Iron (Lieu et al, 2001). 
Approximately 60-70% of the body iron is found within the circulating 
erythrocytes and around 10% can be found within iron-containing proteins 
such as Myoglobin in the muscles and cytochromes. The remaining 20-30% 
of body iron is stored within storage molecules such as Ferritins and 
Haemosiderins found in hepatocytes and reticuloendothelial macrophages 
(Conrad et al, 1999). 
The most significant and highest turning-over pool of iron within the body is 
that of the Transferrin - bound iron even though it amounts to less than 1% of 
total body iron. On average, Transferrin - bound iron turns over 25mg of iron 
per day in healthy individuals. 80% of this iron is used up by erythroid cells 
for synthesising haemoglobin within the bone marrow (Conrad et al, 1999). 
The majority of iron that is required to fulfil the daily requirement for 
haemoglobin synthesis comes from the iron recycled from senescent Red 
Blood Cells (RBCs). These RBCs are phagocytosed by macrophages of the 
reticuloendothelial system and haem molecules are released into the 
circulation (May et al, 1995).  
Several prominent studies have highlighted the crucial role played by iron in 
cellular processes such as DNA, RNA and protein synthesis, cell growth, 
differentiation and proliferation, cellular respiration and electron transport, 
amongst others (Andrews et al, 1999; Boldt, 1999; Conrad et al, 1999; 
Wessling-Resnick, 1999). The transcription of certain genes that affect cell 
cycling and differentiation is also controlled by the levels of cellular iron 
(Boldt, 1999). Three prominent genes that are involved in this process and 
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are known to be iron dependent are Protein-kinase C-β, Tartare-resistant acid 
phosphatase and p21. Additionally, several cellular enzymes which include, 
oxidases, catalases, ribonucleotide reductase and peroxidases require iron for 
their proper functioning. These enzymes are not only essential for the proper 
functioning of cellular processes but a dysregulation of these enzymes and 
proteins can lead to the development of several serious disorders such as 
cancers and neurodegenerative diseases (Ponka, 1999). However, despite the 
large amount of literature highlighting the significant impact that iron has on 
key body functions, the molecular mechanisms underlying these cellular 
processes are not well defined (Lieu et al, 2001). 
The unique chemistry of iron is responsible for its important physiological 
role. As a result of its ability to exist in both Ferrous (Fe2+) and Ferric (Fe3+) 
oxidation states, iron can act as an electron donor as well as an electron 
acceptor. This characteristic of iron makes it capable of participating in the 





Due to the ability of iron to produce free oxygen radicals, it can prove to be 
extremely toxic if levels are not carefully controlled within the cells 
(McCord, 1998). The hydroxyl (OH-) and superoxide (.O2) radicals produced 
in the Fenton reaction can quickly react with several molecules in living cells 
leading to DNA damage, altered cell proliferation and improper synthesis of 
proteins, lipids.  
Apart from the Fenton reaction, free iron can also react with unsaturated fatty 
acids and produce lipid hydroperoxidases to form alkoxyl and peroxyl 
radicals which can also result in cell death (Gerlach et al, 1994). This toxic 
role of iron has been postulated to be responsible for carcinogenesis, 

























Parkinson’s. In order to keep these potentially toxic effects of iron under 
control the body has developed several specialised mechanisms that include 
specific molecules for acquisition, transport and storage of iron that help to 
meet the body’s cellular iron requirements, while reducing the chances of 
toxicity. The process of regulating iron uptake and metabolism takes place 
most actively within the proximal small intestine, although excretion of iron 
by the body also plays an important role in maintaining iron balance (Dexter 
et al, 1991; Connar et al, 1992; Jenner et al, 2003). 
 
1.2  Iron Regulation and Storage 
Due to the importance of iron in several diverse cellular functions, the 
transport, storage and utilization of iron needs to be carefully maintained, 
especially since excessive iron can lead to extensive damage. In humans, as 
well as in several mammalian cells, many of the molecules that are essential 
for iron metabolism are closely regulated by a feedback mechanism based on 
intracellular iron levels (Kuhn et al, 1996; Haile, 1999). These are the Iron 
Regulatory Proteins 1 and 2 (IRP 1 and IRP2). Under conditions of iron 
deficiency, the IRPs bind to special stem-loop like structures called the Iron 
Responsive Elements (IREs) in the mRNA of the target gene. The IRPs 
regulate the post-transcriptional expression of the target gene by increasing 
mRNA stability or inhibiting the translation of the genes that contain the 
IREs (Hentze et al, 2004). 
IRP1 can be found in all types of mammalian tissue however is highly 
expressed in the liver, kidneys and intestines (Guo et al, 1995). IRP2 has 
more than 50% homology to IRP1 and binds to IREs with similar affinity to 
IRP1. Additionally, just as IRP1, IRP2 can also be found on all mammalian 
tissue, but is often more scarcely expressed that the IRP1 (Henderson et al, 
1993). One of the main differences between the two proteins is that IRP2 is 
rapidly degraded under conditions of excessive iron (Pantopoulos et al, 
1995). Studies have showed that mice lacking IRP1 have no abnormalities in 
iron metabolism, suggesting that IRP2 may be capable of compensating for 
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the loss of IRP1 (Rouault and Klausner, 1997). However, IRP2-/- mice show 
abnormal distribution of body iron stores, along with neurodegenerative 
diseases (LaVaute et al, 2001; Galy et al, 2005). Furthermore, mice lacking 
both forms of the protein, show embryonic lethality highlighting the 




Figure 1.1: Post-transcriptional regulation of iron by Iron Regulatory Proteins and Iron 
Responsive Elements: Ferritin mRNA contains a single IRE in the 5’ untranslated region 
whereas the Transferrin Receptor 1 mRNA contains 5 IREs in the 3’ untranslated region. 
When intracellular iron levels are low, IRP binds to the IRE in the ferritin mRNA and 
prevents its translation. However, binding of IRP to the Transferrin Receptor 1 mRNA 
stabilizes the mRNA and increases synthesis. Contrary to this, under conditions of excess 
iron due to the absence of IRP and IRE binding Ferritin mRNA is efficiently translated and 
the translation of Transferrin receptor 1 is inhibited due to rapid degradation (Adapted from 
Lieu et al, 2001). 
 
The sequence and structure of the IRE control the affinity and specificity 
with which the IRPs bind to these regions (Samaniego et al, 1994; Kim et al, 
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1995). Based on the location of the IRE within the mRNA sequence, these 
regions can either act as translational repressors or enhancers (Ponka et al, 
1998). Genes such as the Ferritin light and heavy chains, iron exporter 
Ferroportin and mitochondrial aconitase have IREs in their 5’ Untranslated 
region (UTR) whereas Transferrin receptor 1 and Nramp2 have IREs in their 
3’ UTR of their mRNA. Under conditions of iron deficiency, the binding of 
IRPs to the IREs within the 5’ UTR of the mRNA sterically prevents the 
translation machinery from binding to the mRNA and hence inhibits the 
initiation of protein synthesis. However, when the IRPs bind to the IREs in 
the 3’ UTR of the mRNA, it increases the stability of the mRNA and hence 
promotes translation and protein synthesis (Gray and Hentze, 1994; 
Muckenthaler et al, 1998a). On the other hand, when the concentration of 
intra-cellular iron is high, genes that have IREs in their 5’ UTR get 
successfully translated whereas those with IREs in their 3’ UTR are rapidly 
degraded due to unstable mRNA (Muckenthaler et al, 1998a) (Fig 1.1). 
Another critical element that prevents free iron from producing reactive 
oxygen species and also forms the most important source of stored 
intracellular iron is the storage protein, Ferritin (Theil, 2003). It is made up of 
two subunits – a heavy chain and a light chain, that together form a protein 
shell that can store up to 4500 molecules of iron within it. As described 
above, Ferritin synthesis is induced when excessive iron is present and is 
suppressed in iron deficient conditions (Gdaniec et al, 1998; Ke et al, 1998). 
The synthesis of Ferritin is also controlled by inflammatory cytokine 
interleukin 1 (IL -1) in hepatic and endothelial cells. IL -1 causes a reduction 
in the levels of serum iron levels by increasing the synthesis of Ferritin. As a 
result of this mechanism, increased levels of Ferritin are often used as a 
diagnostic marker to help in detecting inflammation and other diseases 






1.3  Uptake of Dietary Iron 
The main site for absorption of dietary iron is the small intestine. Iron from 
the diet is taken in from the brush border of the apical membrane and enters 
the circulation by passing though the basolateral membrane of the intestinal 
endothelial cells. Within the intestine, iron is present in both its oxidation 
states – that is as Fe2+ and Fe3+. Most of the iron that is absorbed from the 
diet is in the form of Fe3+, however due to the fact that it is insoluble at pH 
values of more than 3, Fe3+ is poorly absorbed by the intestine. On the other 
hand, Fe2+ is readily absorbed by intestinal endothelial cells. Hence, in order 
to facilitate the absorption of dietary iron Fe3+ must first be reduced to Fe2+ 
via the function of mucosal ferric reductase that are present in the apical 
membrane of the intestinal cells (Ekmekcioglu et al, 1996; Conrad et al, 
1999)  
1.3.1 Non-Haem iron uptake 
The crypt cells of the duodenum and the jejunum in the small intestine are the 
main sites of haem as well as non-haem iron absorption. In order to enter the 
body circulation, the iron absorbed from the diet needs to successfully cross 
three cellular barriers – the apical membrane, translocate across the cytosol 
and lastly cross the basolateral membrane (Wood and Han, 1998). While in 
most cases, iron can enter the cell by Transferrin-receptor pathways, the cells 
in the apical membrane of the enterocytes lack the expression of transferrin 
receptors. As a result of this, the cells have to use different mechanisms in 
order to enter the cell cytosol (Pietrangelo et al, 1995). Therefore, the 
absorption of iron in these cells occurs via a specialist iron transporter known 
as the Divalent Cation transporter (DCT1, DMT1) also known as Nramp2 
(Fleming et al, 1997). 
Two isoforms of the protein are known to exist – Nramp2 isoform I and 
Nramp2 isoform II. The main difference between these 2 isoforms lies within 
the 3’ UTR of their mRNA. In isoform I, this region contains an IRE, similar 
to that found in the 3’ UTR of the transferrin mRNA. Isoform II, however, 
lacks this IRE region (Tandy et al, 2000). This suggests that in the condition 
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of iron deficiency, the expression of only isoform I of Nramp2 is increased 
leading to greater up take and absorption of iron, whereas isoform II is not 
affected (Fleet, 1998). 
Nramp2 has been implicated in transporting not only ferrous iron but is also 
involved in the transport of several other divalent cations such as Zn2+, Mn2+, 
Co2+, Cu2+, Ni2+ and Pb2+ (Gunshin et al, 1997). Nramp2 is found to be more 
highly expressed in the duodenum as compared to other tissues in of body. It 
is also found to be expressed at the sub-cellular level, within vesicles such as 
the late endosomes and lysosomes (Gruenheid et al, 1999; Tabuchi et al, 
2000). This sub cellular localization of Nramp2 is consistent with that of 
Transferrin, suggesting that Nramp2 may play a role in transporting 
Transferrin - bound iron across endosomal membranes as well (Su et al, 
1998). 
 1.3.2 Haem - iron uptake 
The second type of mechanism for the uptake of iron involves the absorption 
of haem bound - iron, which can be more efficient than inorganic iron 
(Parmley et al, 1981). Once in the intestinal lumen, haemoglobin is 
enzymatically digested leading to the release of haem molecules, which can 
then be absorbed by the enterocytes via haem-receptor mediated 
internalization (Mills and Payne, 1995). Following internalization, the 
enzyme Haem Oxygenase (HO) degrades haem and releases the iron into the 
cell cytosol. This iron can now either be stored with Ferritin molecules or be 
transported across the membrane by the action of Ferroportin1 (Hentze et al, 
2004; Steinbicker and Muckenthaler, 2013). 
So far, the only mechanism via which iron can cross the basolateral 
membrane of enterocytes is through the iron exporter Ferroportin1. As with 
most of the protein involved in iron regulation, Ferroportin also contains an 
IRE in its 5’ UTR (Donovan et al, 2000). It is found to be highly expressed in 
the tissues of the placenta, liver, spleen and kidneys (McKie et al, 2000). 
Also, the localization of Ferroportin1 to the basolateral membrane of 
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duodenal enterocytes strongly indicates its involvement in the export of iron 
from the enterocytes (McKie et al, 2000; Donovan et al, 2000). 
The efflux of iron via Ferroportin is suggested to require auxiliary feroxidase 
activity. The membrane resident Feroxidase, Hephaestin, along with 
Ceruloplasmin, which is present in the serum, are believed to be important in 
the functioning of Ferroportin1 (McKie et al, 2000). Their activity is 
essential for the release of iron into the blood and for loading it on to 
Transferrin, but do not play a role in the transport of iron out of the 
enterocytes (Harris et al, 1998).  
 
1.3.3 Regulation of absorbed dietary iron 
The first line of regulation involves the ‘Dietary regulation’ mechanism 
under which the enterocytes exhibit a ‘mucosal block’ which make them 
resistant to absorbing any additional iron for a few days after iron has been 
consumed in the diet. The mucosal block is believed to result from the 
accumulation of intra-cellular iron after body iron requirements have been 
met (Andrews, 1999). 
The second mechanism involved in regulating dietary iron absorption is 
based on sensing the body’s stored iron levels, rather than just looking at the 
levels of dietary iron intake. This ‘Store’s regulation’ mechanism is 
influenced by the extent to which plasma transferrin is saturated with iron. 
Finally, the third mechanism that can regulate the absorption of dietary iron 
is the ‘Erythropoietic Regulation’. This mechanism modulates iron 







1.4  Regulation via Hepcidin 
A specialised peptide hormone that recognizes and responds to all the 
regulatory cues discussed above, is Hepcidin, encoded by the HAMP gene. 
Hepcidin first received attention when it was identified in human urine and 
plasma samples due to its structural similarity with anti-microbial peptides, 
Defensins, which play an important role in host defence. The bioactive form 
of Hepcidin, which is a 25-amino acid peptide, is generated primarily by the 
hepatocytes but also in smaller quantities by other cell types such as 
Macrophages (Nemeth et al, 2006).  
The role of Hepcidin in iron homeostasis has been demonstrated in studies 
that have used Hepcidin knockout mice, which exhibit signs of iron overload. 
Additionally, iron overloaded mice have also show increased Hepcidin 
mRNA expression (Nicolas et al, 2001; Pigeon et al, 2001). Conversely, 
Hepcidin levels decrease under conditions of iron deficiency and hypoxia.  
Therefore, Hepcidin acts as a negative regulator of iron absorption and 
transport across the cell. It acts via its ability to bind to the exclusive iron 
export channel on mammalian cells, that is, Ferroportin1. When the amount 
of extra-cellular iron is high, Hepcidin is synthesised and binds to 
Ferroportin1 causing its internalization and lysosomal degradation, resulting 
in accumulation of iron within the cells. Similarly, when cells require iron, 
Hepcidin production is suppressed leading to the export of iron from the 
macrophages via Ferroportin to make it available for binding to Transferrin 
(Nemeth et al, 2006).  
Lee et al (2004) suggested that Hepcidin synthesis can also be initiated by the 
IL -6 pathway after lipopolysaccharide (LPS) stimulation. This elevated level 
of Hepcidin reduces the amount of iron leaving the enterocytes and 
macrophages, therefore decreasing the amount of serum iron that is available 
to invading pathogens and growing tumour cells. However, the increased 
level of Hepcidin is responsible for hypoferremia and the associated Anaemia 




1.5  Transport of Iron 
 
1.5.1 Transferrin-receptor mediated uptake 
Apart from the absorption, storage and utilization of iron, transport of iron 
within the body is an important aspect of iron-metabolism, as it is an 
important mechanism for controlling and reducing excessive iron-related 
toxicities (Hoefkens et al, 1996). In the plasma, the role of iron transporter is 
played by the protein Transferrin, which has a high affinity for ferric iron. 
Although, Transferrin is known to be involved in the transport of several 
other metals as well, such as Aluminium, Manganese, Copper and Cadmium 
(Moos et al, 2000). But, of these Transferrin has the highest affinity for iron, 
which is capable of displacing other metals bound to Transferrin. Within the 
plasma, Transferrin can exist in several forms namely Apotransferrin (iron-
free form), Mono-ferric Transferrin (bound to one molecule of iron) or Di-
ferric Transferrin (bound to two molecules of iron). The extent to which each 
is present in the plasma depends on the concentration of iron and transferrin 
in the plasma. For cells to be able to absorb the iron from Transferrin, it first 
needs to bind to Transferrin receptors present on the cell membrane. Two 
distinct types of Transferrin receptors known are – TfR1 and TfR2 (Munoz et 
al, 2009; Anderson and Wang, 2011). 
TfR1 is found to be expressed on the cell membrane of all cells apart from 
mature erythrocytes. TfR2, which is a homologue of TfR1, is expressed 
specifically in the liver and more so, on the cell membrane of hepatocytes. 
Once transferrin, is bound to the TfR, it is internalized via the classical 
endocytic pathway and iron is released once the complex is within acidic 
endosomal compartments. The iron that enters the cell, forms a part of the 
cellular labile iron pool. This is then used for the synthesis of iron containing 
proteins or is stored within Ferritin. Once free of iron, Transferrin and its 
receptor are recycled back to the cell surface (Dautry-Varsat et al, 1983; 
Gkouvatsos et al, 2011). 
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The expression of TfR1 is found to be higher on rapidly dividing cells, as 
compared to other non-dividing cells. Tumour and cancer cells can express 
up to 100,000 molecules of TfR1on their surface whereas, non-proliferating 
cells have a considerably lower expression of TfR1, with some cell types 
lacking it all together (Inoue et al, 1993). The link between cell proliferation 
and high expression of Transferrin can be traced back to the high requirement 
for iron by the DNA synthesising enzyme ribonucleotide reductase (RR) 
(Jordan and Reichard, 1998). Apart from tumour cells, TfR1 expression is 
high on erythroid cells that have a high need for iron in order to synthesise 
haemoglobin (Ponka and Lok, 1999). Other cell types such as placental cells, 
ensure transfer of sufficient iron from the mother to the foetus by expressing 
high levels of Transferrin receptor on their surface (Gambling et al, 2001) 
and similarly the brain's requirement for iron for its metabolic processes as 
well as repair and regeneration, is met by the high levels of transferrin-
receptors present on its cells (Moos and Morgan, 2000).  
 
1.5.2 Non-Transferrin bound Iron (NTBI) 
As described above, the body has several ways of ensuring that once inside 
the body iron is absorbed, stored and transported safely in order to minimize 
any potential toxic effects. Transferrin plays an important role in making 
certain that there is no free iron in the blood by binding to it in order to assist 
its transport. However, despite all these mechanisms, there are some 
physiological conditions under which free iron or non-Transferrin bound iron 
(NTBI) is found in the blood. This is common in iron overload disorders such 
as Haemochromatosis. NTBI is generated when the Transferrin in the blood 
has been completely saturated and through increased release of haem iron 
from catabolised haemoglobin (Beutler et al, 2003). 
This NTBI has been associated with excessive iron loading in tissues as well 
as the generation of Reactive Oxygen Species (ROS), causing cell damage 
and cell death. Hepatocytes are known to readily take up NTBI from the 
blood stream and store it within a transient pool of low-molecular weight 
30 
 
iron. This uptake of NTBI by the liver continues even under conditions of 
iron overload as no mechanisms exist for NTBI regulation. The low 
molecular weight iron stored in the iron pools within the hepatocytes is more 
prone to produce ROS via the Fenton reaction (Richardson and Ponka, 1997).  
The transport of NTBI is an elusive mechanism. It has been suggested that 
NTBI is transported to tissue by Transferrin-independent mechanisms. 
DMT1 has been implicated to be the main transporter for NTBI within the 
liver. The Zinc transporter Zip 14 and L-type voltage dependent calcium 
channels within the cardiomyocytes are also responsible for considerable 
amounts of NTBI uptake (Oudit et al, 2003; Gunshin et al, 2005; Liuzzi et al, 
2006). The pools of NTBI are known to be readily chelatable and iron 
chelating compounds have been successful in reducing the amount of NTBI 
in the body and reducing its toxic effects (Reviewed in Gkouvatsos et al, 
2011). 
 
1.6  Disorders of Iron Transport and Metabolism 
Due to its essential, but potentially toxic nature, the regulation of iron within 
the human body is very tightly controlled. However, at times a dysregulation 
in this system occurs which results in several serious disorders in humans 
(Munoz et al, 2011). 
1.6.1 Iron Deficiency Anaemia (IDA) 
Under healthy physiological conditions, iron absorption, transport and 
storage are closely balanced. However factors such as increased requirement, 
limited supply or blood loss can often upset this balance causing iron 
deficiency. The deficiency results from either the body iron stores getting 
depleted, or from the inability of the body to mobilize its iron stores. The 
physical manifestations of iron deficiency are linked to the general symptoms 
of anaemia which include pale colour of the skin, tiredness and an overall 
lack of energy and decreased work performance. The clinical symptoms of 
IDA include low haemoglobin, low levels of Transferrin saturation and low 
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Ferritin concentrations. This condition is often associated with cases where 
the dietary intake of iron is insufficient in meeting the demands of the body. 
Hence is common in children, who have a higher need for iron as compared 
to adults. It is also common in menstruating women due to the regular loss of 
blood from the body (Reviewed in Munoz et al, 2011).  
The treatments currently being commonly used in conditions of IDA include 
replenishment of body iron by external supplementation. This includes oral 
administration of iron salts, often given complexed with sulphates to increase 
their absorption. Severe cases of IDA are treated with intravenous injections 
of Iron Dextran. The intra-venous supplementation helps the iron to be 
processed and loaded onto Transferrin quicker and therefore reducing the 
chances of any associated toxicity (Beard, 2001).  
 
 1.6.2 Anaemia of Chronic Disease (ACD) 
Anaemia, apart from being a common symptom of iron deficiency, can also 
be a common complication in chronic inflammatory disorders such as 
Rheumatoid Arthritis, Cancer and Inflammatory Bowel Disorder (Munoz et 
al, 2011a). This type of iron metabolism disorder is known as Anaemia of 
Chronic Disease or Anaemia of Inflammation (AI). The clinical symptoms 
can often be similar to that of IDA such as low haemoglobin levels, low 
Transferrin saturation but high serum Ferritin concentration. Additionally, 
these symptoms are manifested in the presence of chronic inflammation 
(Beard, 2001; Munoz et al, 2011a,b). 
Anaemia under chronic inflammation occurs due to the underlying over-
activation of the immune system. The changes in iron homeostasis, 
proliferation of erythroid progenitor cells, life span of RBCs and 
Erythropoietin (EPO) production, all of which result in the development of 
Anaemia are caused by the cells and cytokines of the reticuloendothelial 
system. The disturbance of iron homeostasis is reflected by the retention and 
increased uptake of iron by the cells of the reticuloendothelial system. Instead 
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of being in the circulation, iron is diverted into the storage sites within these 
cells leading to limited availability of iron for erythropoiesis (Weiss and 
Goodnough, 2005). 
Under conditions of chronic inflammation, there are two prominent pathways 
by which macrophages acquire iron. Firstly, by the process of phagocytosing 
senescent RBCs and secondly, via the transmembrane iron importer DMT1. 
Inflammatory stimulants such as LPS and cytokines such as IFN -γ and TNF 
-α have been shown to cause an upregulation in the expression of DMT1, 
leading to the increased uptake of iron by the macrophages. Secondly, these 
stimuli are also responsible for causing the downregulation of the iron 
exporter, Ferroportin, from the cells leading to the retention of iron within the 
macrophages (Andrews, 1999; Ludwiczek et al, 2003).  
Hepcidin also plays an important role in the development of ACD. LPS and 
the inflammatory cytokine, IL -6 are known to stimulate the production of 
Hepcidin. Once IL -6 binds to its receptor, the complex further binds to 
glycoprotein 130, which activates the downstream signalling pathway 
causing Signal Transducer and Activator of Transcription 3 (STAT3) to bind 
to the regulatory region of the Hepcidin gene promoter. Another pathway for 
induction of Hepcidin, is via the regulator Haemojuvelin (HJV). HJV is an 
iron-specific ligand which binds to the Bone Morphogenetic Protein 
receptors (BMP). The interaction of the HJV and BMP receptors leads to the 
transcription of a group of specific proteins known as the Sma- and Mad 
related (SMAD) proteins. Binding of HJV to BMP, first induces SMAD4 
which then further regulates SMAD 1, 5 and 8 (Babitt et al, 2006). The 
complexity of the pathway is further increased due to the involvement of 
another important protein, Human haemochromatosis protein (HFE). Along 
with TfR1 and TfR2, HFE protein plays a role in sensing the level of 
holotransferrin in the plasma. When iron content in the plasma is high, TfR1 
binds with a stronger affinity to holotransferrin, due to which HFE binds to 
TfR2. This binding activates the BMP-SMAD signalling pathway and the 
synthesis of Hepcidin (Mollbrink et al, 2011; Pietrangelo et al, 2011). 
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Hepcidin controls the level of plasma iron by binding to the iron export 
channel Ferroportin, on the basal membrane of enterocytes and macrophages, 
causing its internalization and degradation. This prevents any iron from being 
exported out and thus accumulates within the cells (Weiss and Goodnough, 
2005). 
Apart from the accumulation of iron within the cells of the 
reticuloendothelial system, the signals provided by inflammatory cytokines 
are responsible for the impaired proliferation of erythroid progenitor cells. 
Interferon – α, β and γ cause the cytokine mediated apoptosis of these cells 
and also have a more direct toxic effect on the progenitor cells due to their 
ability to generate free radicals such as Nitric Oxide (NO) (Maciejewski et al, 
1995). 
The anaemia that results from chronic inflammation is responsible for the 
blunted responses of Erythropoietin. Inflammatory cytokine, IL -1, has been 
implicated in inhibiting Erythropoietin expression by its ability to produce 
ROS that damages Erythropoietin-producing cells (Jelkmann, 1998). Finally, 
inflammation is responsible for reducing the half-life of erythrocytes by 
increased phagocytosis by circulating macrophages (Gasche et al, 2004).  
Hence, the above described mechanism makes it evident that there is a close 
relationship between inflammation, inflammatory stimuli and iron 










1.7  Iron, Immunity and Inflammation 
Anaemia of Chronic Disease serves as one of the best examples to visualize 
the relationship between Iron homeostasis, Immunity and Inflammation 
(Weiss and Goodnough, 2005).  
Under normal physiological conditions, 95% of the body’s need of iron, for 
erythropoiesis and other biological functions, is met by iron recycling by the 
macrophages (Hentze et al, 2010). However, inflammatory conditions lead to 
alteration of this process. Inflammatory cytokines and acute phase proteins 
affect the body iron homeostasis and macrophage iron metabolism leading to 
low levels of circulating iron and high levels of iron accumulated within 
storage proteins, Ferritin (Thomas and Thomas, 2005).  
As discussed above, cytokines such as IL -1, IL -6, IL -22 as well as bacterial 
LPS, which are produced during autoimmune diseases such as cancer or 
infectious conditions, have been shown to induce the expression of Hepcidin 
(Nemeth et al, 2003). As a result of this, the export of iron into the 
circulation along with the absorption of iron from the diet is reduced. 
Furthermore, IL -6 and LPS stimulate macrophages to produce small 
amounts of Hepcidin that act in an autocrine manner to reduce iron egress. 
All of these mechanisms function as an immune strategy to restrict the 
availability of iron to extracellular pathogens (Theurl et al, 2009).  
In addition to this, inflammatory cytokines have a Hepcidin - independent 
influence on iron homeostasis within the body (Weiss and Schett, 2013). 
TNF -α, IL -1, IL -6 and IFN -γ increase the uptake of transferrin bound and 
non-transferrin bound iron in the macrophage via their effect on the 
expression of Transferrin receptor and DMT1, further adding to the retention 
of iron within the macrophages (Ludwiczek et al, 2003). IFN -γ and LPS can 
directly influence Ferroportin expression inhibiting the export of iron from 
the macrophages (Yang et al, 2002). These effects have been attributed to the 
effect of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species 
(RNS). The tissue damage that is caused due the production of ROS and RNS 
is responsible for anaemia of inflammation that limits the amount of iron in 
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the blood serum and increases the amount of intracellular stored iron. The 
accumulation of iron along with increase in ROS and RNS production that 
lead to more production of labile iron, further fuelling the vicious cycle of 
more ROS/RNS (Lehmann et al, 2015). Hence, the body has several 
mechanisms to control the levels of circulating iron, especially under 
conditions of infection and inflammation. While this is an important strategy 
to control the growth of extra-cellular pathogens, it can have harmful effects 
in certain other conditions. Olakanmi et al (2002) showed that 
Mycobacterium tuberculosis grew more slowly in patients with Hereditary 
Haemochromatosis as their macrophages showed lesser accumulation of iron, 
suggesting that iron-loaded macrophages play an important part in the growth 
of certain bacteria. Retention of iron within the macrophages, therefore 
impairs their ability to fight intra-cellular pathogens such as various bacteria, 
viruses and fungi via its inhibition of IFN -γ mediated and other anti-
microbial effector pathways (Weiss, 2002b; Oexle et al, 2003).     
Parallel to this, iron has several positive effects on immune effector 
functions, such as differentiation and proliferation of immune cells such as 
antigen presenting cells and lymphocytes (Cairo et al, 2011). Therefore, since 
iron is used by pathogens to survive within the body and also used by the 
host to mount an effective immune response – the host must be able to 
effectively sequester iron from the pathogens while still being able to provide 
enough iron so as not to limit the responses of the immune system (Hershko, 
1996).  
 1.7.1 Effect of Iron and Iron deficiency on Immunity 
While few studies report otherwise, most experimental and clinical data 
suggests that iron deficiency negatively impacts immunity leading to 
increased risk of infection. It has been suggested that experimental iron 
deficiency can limit almost every immune effector response. It has been 
shown to be important for proper cell differentiation and growth, as a critical 
part of several enzymes that are needed for the functioning of immune cells, 
and also plays a part in production of several cytokines (Hershko, 1996). Iron 
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deficiency can impact non-specific immunity by reducing bactericidal 
activity of macrophages, reducing neutrophil activity by inhibiting the 
activity of the iron-containing enzyme Myeloperoxidase that plays an 
important part in intracellular pathogen killing (Spear and Sherman, 1993). 
Iron deficiency has also been shown to inhibit T lymphocyte blastogenesis 
and mitogenesis as well as have an effect on decreasing the number of T 
lymphocytes overall (Kuvibidila et al, 1999).  
This effect of iron deficiency on the functioning of the immune system can 
be explained by several possible explanations. Firstly, due to its essential and 
rate limiting role in the cell proliferation process via the enzyme 
Ribonucleotide reductase. Secondly, not only cell proliferation but even 
differentiation of Th1 cells and B cells is under the control of iron 
homeostasis (Gasche et al, 2004). Lastly, Galan et al (1992) showed that iron 
deficiency can result in reduced IL -2 production from activated 
lymphocytes, which is an essential cytokine for cell proliferation and 
differentiation.  
Iron has been implicated in the several immune related disorders, as a result 
of which iron chelation can be used as a potential therapy for several of these 
disorders. Accumulation of iron within the body has been implicated in the 
pathogenesis of atherosclerosis via its ability to cause vascular oxidative 
stress as well as initiating the inflammatory immune response (Yuan and Li, 
2008). Studies in the past have shown that atherosclerotic lesions are often 
associated with high levels of iron. Additionally, use of DFO has been 
successful in delaying the onset of these lesions by reducing oxidative stress 
markers (Ishizaka et al, 2005; Ren et al, 2006).    
An interesting, but not often discussed effect of iron on health includes its 
effect on obesity. Iron has the ability to contribute towards obesity by 
stimulating and activating adipocytes. DFO has once again been successful in 
reducing adiposity by reducing oxidative stress related signalling (Tajima et 
al, 2012).  
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Furthermore, iron has also been implicated in certain autoimmune diseases. 
Studies on mouse models of Systemic Lupus Erythematosus (SLE) show that 
iron supplementation leads to increased severity of renal disease and an 
increased rate of mortality. One of the reasons behind this effect could be the 
ability of iron to produce ROS leading to oxidative stress and damage under 
inflammatory conditions (Leiter et al, 1995). It has also been shown that iron 
has the ability to uniquely fragment auto-antigens such as in the case of 
Scleroderma, and often exposes cryptic epitopes in the periphery as seen in 
Goodpasture’s Syndrome and Diabetes Mellitus I. This has been suggested to 
be responsible for the pathogenesis of autoimmunity (Casciola-Rosen et al, 
1997; Kalluri et al, 2000). In the case of Diabetes, iron can result in the death 
of pancreatic beta cells via the oxidative stress due to uptake of non-
transferrin bound iron (Masuda et al, 2014). Furthermore, the iron transporter 
NRAMP1 has been associated with several autoimmune diseases such as 
Rheumatoid Arthritis (RA), Juvenile RA, Multiple Sclerosis (MS) and 
Diabetes. Certain alleles in the NRAMP1 promoter are associated with 
increased susceptibility to both infectious diseases such as Tuberculosis, as 
well as autoimmune diseases such as RA (Bowlus, 2003). 
Finally, one of the main role that iron plays is binding of oxygen via 
Haemoglobin, which implies that the level of oxygen in tissue depends on the 
amount of iron that is available. Therefore, reduced oxygen content leads to 
increase in erythropoiesis, similarly, reduced iron results in hypoxia like 
conditions. Use of iron chelators such as DFO has been shown to result in 
hypoxic conditions, even under physiological normoxia, by inducing the 
Hypoxia inducible factor (HIF) 1α. DFO has been shown to bring about 
stabilization and increased transcription of HIF 1α (Triantafyllou et al, 2007). 
Peyssonnaux et al (2007) showed that iron deficient mice have increased 
expression of HIF 1α. Additionally, they also showed that HIF 1α and 
hypoxia result in reduced Hepcidin gene expression as well, suggesting a 
connection between HIF and iron metabolism. Hypoxia is also responsible 
for apoptosis via the activation of the tumour suppressor p53, that regulates 
several genes involved in growth arrest and apoptosis (Suzuki et al, 2001).  
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 1.7.2 Iron and T Lymphocytes 
 
While iron is important for all cell types, it is particularly important for 
metabolically active and proliferating cells such as thymocytes and activated 
T lymphocytes. Studies on T cells illustrate the relationship between the need 
for iron and cell proliferation. The presence of transferrin receptor on the cell 
surface is recognized as a marker for cell activation, as resting T cells lack 
transferrin receptor expression. Initiation of cell division is accompanied by 
an increase in the expression of transferrin receptor on the surface of T cells 
(Kuvibidila et al, 1983; Bowlus, 2003).  
Of the several immunological functions affected by iron deficiency, cell-
mediated immunity is one of those most notably affected. It shows a 
reduction in the number of circulating T lymphocytes along with a reduction 
in the blastogenic response to mitogens. This reduction in T cells has been 
attributed to thymic Atrophy. Several studies on rodent models have shown 
that iron deficiency leads to thymic atrophy and significantly reduces the 
number of circulating peripheral T cells. Alternatively, the effect of iron 
overload on immune functions and T cells is not well characterised and 
relatively controversial. While some studies suggest increase in the number 
of circulating CD8+ T cells, others have shown blunted T cell responses after 
iron overload, decreased CD4+ T cell and CD4/CD8 T cell ratios (Kuvibidila 









1.8  Cell Cycle and the Role of Iron 
The role of iron as an essential nutrient has been well established. It forms a 
part of several enzymes and proteins involved in cell growth and replication, 
a common example being ribonucleotide reductase (RR) (Lieu et al, 2001). 
The enzyme is responsible for conversion of ribonucleotides to 
deoxyribonucleotides. One of the two sub-units that make up the RR enzyme 
contains four non-haem iron molecules. In cases where there is not a constant 
supply of iron to this second sub-unit, a loss in function of RR is seen. Iron 
molecules help to stabilize the tyrosyl radical that is present at the core of the 
second sub-unit and hence are critical for the functioning of the enzyme and 
therefore also in the process of DNA synthesis and cell replication (Jong et 
al, 1998; Kayyali et al, 2001).  
Several studies over the past few years have indicated that depletion of 
cellular iron can result in inhibition of cell cycle progression, cell growth and 
division. A block at various stages of the cell cycle has also been 
demonstrated as a result of iron deprivation. Also, removal of iron from cells 
has been shown to have significant anti-tumour activity. Previously, some 
studies have shown the involvement of iron transport and regulatory proteins 
to be involved in the cell cycle. Kawabata et al (1999) showed that while 
TfR1 is regulated by intracellular iron levels, TfR2 is regulated as a function 
of the cell cycle. They showed that TfR2 is expressed highly in the late G1 
phase of the cycle but is completely lacking in the G0/G1 phase of the cell 
cycle. Also, the expression of TfR1 has been shown to be increased several 
fold during the S phase of the cell cycle. This increase has been attributed to 
the high need for iron by RR during the synthesis of DNA (Nyholm et al, 
1993; Yu et al, 2007). A study by Sanchez et al (2006) proved the presence 
of an IRE in the 3’ UTR of a cell cycle protein, Cell Division Cycle 14A 
(CDC14A). This further attested the involvement of iron within the 
regulation of the cell cycle. Despite the knowledge that iron plays a very 
important role in the cell cycle, little is known on how it can be regulated by 
iron. Hence it is evident that the study of the cell cycle and the role of iron in 
its regulation merits our attention. The following section will discuss the cell 
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cycle, specifically focussing on the role played by iron in its progression and 
regulation. 
 1.8.1 Overview of the mammalian cell cycle  
Several studies have demonstrated that deprivation of iron could prevent the 
proliferation of cells by arresting them in specific phases of the cell cycle and 
halting its progression (Le and Richardson, 2002; Fu and Richardson, 2007; 
Yu et al, 2007; Gharagozloo et al, 2008). The success of iron deprivation as a 
potential therapeutic mechanism for the control of tumour and neoplastic 
growths further emphasizes the important role played by iron in the cell 
cycle. A typical cell will go through four different phases of the cell cycle. 
Gap1 or G1 Phase, where the cell begins to prepare of DNA synthesis. This 
is followed by the S Phase, where the synthesis of DNA takes place. The 
Gap2 or G2 phase sees the cell preparing for cell division. And finally, the 








Figure 1.5: The various stages of the cell cycle controlled by the interaction of different 
cyclin-cdk complexes (Adapted from Le and Richardson, 2002) 
 
 
The transition of a cell from these four stages of the cell cycle is tightly 
regulated and controlled by specific cell cycle proteins, cyclins, which are 
believed to be positive regulators of the cell cycle. Different types of cyclins 
are known to regulate different stages of the cell cycle. The main role of 
cyclins is to function as regulatory sub-units for the Cyclin-Dependent 
Kinases (cdks), a family of serine/threonine kinases. Progression through 
each phase of the cell cycle is controlled by the activity of specific cyclin-cdk 
partner complexes. Entry and transition through the G1 phase of the cell 
cycle is controlled by D type cyclins. Three kinds of D type cyclins are 
known, cyclin D1, D2 and D3. Each of these is found in varying degrees in 
different tissues and in order to become active they need to complex with 
cdk4/cdk6. Movement through the late stages of G1 and entry into the S 
phase is controlled by cyclin E and cdk2 complexes. Transition through the S 
phase requires cyclin A and cdk2 complexes to be actively present. Cyclin A 
and cdk1 complexes are also important in the transition through the S phase, 
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but are implicated more strongly in the movement from the end stages of S 
phase and the entry into the G2 phase. The final two phases of the cell cycle, 
that is the progression through the G2 and M phase, is governed by cyclin 
B/A and cdk1 complexes (Liu et al, 2012).  
The expression of these critical molecules is however controlled by the level 
of intracellular iron. Experimental studies have shown that deprivation of 
iron from neoplastic cells as well as normal T lymphocytes reduces the 
expression of cyclin D as well as cyclin A from these cells. A more 
prominent reduction is seen in the expression of the three D-type cyclins as 
compared to the effect seen on both A and B type cyclins (Kulp et al, 1996; 
Black and Black, 2013). The mechanism behind the reduction in the level of 
cyclin D1 has been identified to be by proteasomal degradation of the 
protein, as no changes in the mRNA expression of cyclin D1 have been 
noticed under conditions of iron deprivation. Unlike normal ubiquitin-
dependent degradation of the cyclin, the degradation in this case is induced 
by an Ubiquitin – independent mechanism. Further, the involvement of iron 
in this reduction has been confirmed via experiments where under iron-
replete conditions the reductions in cyclin D1 can be reversed. Therefore, 
under conditions of iron deprivation, the reduction in cyclin D1 results in the 
G1/S phase arrest of the cells. The regulation at this restriction point is 
important as in the S phase the cell has a greater need for iron in order to 
allow for RR enzyme to be able to synthesise DNA. The excessive 
expression of cyclin D1 leads to over-activation of the cell cycle and releases 
the cells from the normal control of the G1/S phase restriction point, and thus 
acts as an oncogene. The control of cyclin D1, especially by iron deprivation, 
is a potential therapeutic anti-tumour mechanism. Apart from cyclin D, iron 
deprivation has a direct effect on the reduction of cdk2 and cdk4, further 
resulting in the G1/S phase arrest of the cell cycle progression (Golias et al, 
2004).  
Another cyclin that is modulated by the levels of intracellular iron is cyclin E. 
However, unlike the above described cyclins, cyclin E expression is 
increased under conditions of iron deprivation. This increase in expression is 
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believed to be an attempt from the cell to continue the progression of the cell 
cycle and push the cell into S Phase. However, cyclin E needs to complex 
with cdk2 to be activated, but due to the reductions in cdk2 levels under iron-
deplete conditions the increase in cyclin E is unable to overcome the G1/S 
phase block (Chaston et al, 2003). 
Iron deprivation is usually seen to result in a G1/S phase block of the cell 
cycle. However, in certain cell types and experimental conditions a block in 
G2/M phase has also been seen. This can be attributed to the reductions in the 
level of cdk1, along with changes in cyclin A/B levels, after iron deprivation 
(Reed, 1997; Golias et al, 2004). 
An important role played by the cdks in the regulation of the cell cycle is the 
phosphorylation of the Retinoblastoma Protein (pRb). This molecule is 
involved in assisting the cell to transit from the G1 phase to the S phase of 
the cell cycle (Sherr, 2000). pRb and the pocket proteins that are associated 
with it, namely p107 and p130, serve as the main targets of the cyclin D-cdk4 
complex (Cobrinik, 2005). Under normal conditions of the 
hypophosphorylated state, the pocket proteins p107 and p130 act as 
transcriptional repressors by binding to E2F transcription factor on the 
promoter region of the growth genes. These proteins are responsible for 
actively blocking the transcription of the genes that are required for DNA 
synthesis and cell cycle progression. Phosphorylation of these pocket 
proteins drives the expression of E2F-dependent genes such as cyclin E 
which are essential for the continuation of the cell cycle. In the initial stages 
of the G1 phase, the cell requires a mitogenic signal in order to promote the 
phosphorylation of pRb and the transcription of cyclin E and other cell cycle 
genes (DeGregori et al, 1995). However, over time, when sufficient amounts 
of cyclin E have been produced and accumulated, it is capable of driving its 
own production. At this point, the cell is ready to exit the G1 phase check 
point and proceed to the next phase of the cell cycle. In contrast, if mitogenic 
signal is lost before sufficient amounts of cyclin E have been accumulated to 
drive their own expression, the cell is unable to cross the first check point and 
the cell cycle is halted and cell goes into a quiescent stage or G0 stage (Sherr, 
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2000; Classon and Dyson, 2001). Since the Cyclin– cdk complexes during 
the G1/S phase are required for the phosphorylation of pRb, reduction caused 
by iron in the level of these cyclins and cdk is also responsible for the 
hypophosphorylation of pRb further leading to the inhibition at the G1/S 
phase (Gao and Richardson, 2001). The hypophosphorylated pRb prevents 
the release of the transcription factor E2F1, which is essential for the 
transcription of other cell cycle progression genes such as Cyclin A and E 
(Muller and Helin, 2000). 
1.8.2 Cell Cycle Regulation 
One of the most important regulators of the cell cycle that has several 
molecular targets and is an important player in the G1/S restriction point is 
p53. The p53 protein is activated under conditions of cellular stress and DNA 
damage and functions by either triggering DNA repair mechanisms or 
apoptotic pathways (Yu et al, 2007).  
Under conditions of iron deprivation, levels of p53 are increased post-
transcriptionally. That is, the level of p53 is increased only at the protein 
level and no changes in mRNA level have been studied. There are 4 distinct 
mechanisms that control the activation of the p53 pathway in response to 
reduced intracellular iron levels. Firstly, the increase in the level of p53 
protein is believed to be the main factor leading to activation of the DNA 
damage pathway. Secondly, the decrease in iron levels is believed to be 
responsible for converting dormant p53 into its active DNA-binding form. 
Following this, an increase in the phosphorylation of p53 has been witnessed 
in response to iron deprivation. This phosphorylation helps to stabilize the 
protein and prevent its proteasomal degradation. Finally, increase in other 
transcriptional molecules, such as Hypoxia-Inducible Factor 1α (HIF 1α), 
have also been implicated in the increased activation of the p53 pathway after 
iron deprivation (Fukuchi et al, 1997; Ashcroft et al, 2000; Liang and 
Richardson, 2003).  
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Furthermore, apart from its role in activation of the p53 pathway, iron 
deprivation has also been shown to have an important effect of the 
downstream targets of p53, such as p21CIP1/WAF1. 
Control and regulation of the activity of cyclin– cdk complexes, that are 
essential for the progression of the cell cycle, is carefully monitored by 
specific proteins belonging to two families of cdk inhibitors (CKI). These 
two inhibitor families are the INK4 inhibitors and the Kinase Inhibitor 
Proteins, CIP/KIP.  
The CIP/KIP family of inhibitory proteins consists of three main members, 
namely p21WAF1/CIP1, p27KIP1 and p57KIP2. These proteins are best known for 
their negative regulation of the cell cycle. These molecules are capable of 
preventing the progression of the cell cycle via their ability to directly bind to 
the cyclin– cdk complexes and thereby inhibiting their activity.  
p21CIP1/WAF1 is an important cdk inhibitor of the CIP/KIP family that plays an 
essential role in the regulation and control of the cell cycle and is present in 
low levels throughout the different stages of the cell cycle. It is usually 
induced as a consequence of cellular stress and DNA damage via a p53-
dependent pathway, but it can also be induced via a p53-independent 
pathway using other transcription factors such as AP-2 (Wajapeyee et al, 
2003; Yu et al, 2007). At low expression levels, p21 acts as a promoter of the 
cell cycle and is required for the assembly of the cyclin D/cdk complexes that 
help in G1/S phase transition. However paradoxically, when p21 expression 
is increased it acts as a potent inhibitor of the cell cycle (Weiss, 2003). High 
levels of p21 are responsible for binding to cyclin E - cdk2 complexes and 
therefore interfering with the phosphorylation of pRb, thereby halting the cell 
cycle progression. Additionally, at high levels p21 also acts on transcriptional 
factors such as E2F1 and c-myc to regulate cell cycle, and has also been 
shown to inhibit DNA replication (Luo et al, 1995; Kitaura et al, 2000, Yu et 
al, 2007).  
Similar to p53, the expression of p21 mRNA and protein levels is 
controversial under conditions of iron depletion. Several studies have 
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demonstrated that p21 mRNA levels are increased in response to low levels 
of intracellular iron. However, protein expression of p21 is reduced under the 
low iron conditions due to ubiquitin-independent proteasomal degradation of 
the protein along with low levels of nuclear translocation of p21 mRNA into 
the cytosol. The inhibition of p21 protein expression is an important 
mechanism for keeping its anti-apoptotic properties under control and hence 
is a novel anti-tumour target (Fu and Richardson, 2007). 
 p27KIP1 is a potent cdk inhibitor, that is regulated by body iron levels. It 
controls the progression of the cell cycle by modulating cyclin– cdk binding 
affinities by phosphorylation of the other KIP inhibitors, making them 
inactive (Wang et al, 2000; Wang et al, 2004). Unlike its other CIP/KIP 
family members, p27 mRNA and protein levels are both up-regulated on 
exposure to iron-deplete conditions (Wang et al, 2000). Increase in p27 
protein is responsible for inhibition of the cyclin D– cdk4/6 complex 
formation and therefore blocking the cell cycle in the G1/S restriction point 
(Cheng et al, 1999). The de-phosphorylation of p27 which is responsible for 
causing the cell cycle block has been suggested to be caused due to a cell 
cycle molecule known as CDC14A. The 3’UTR of the mRNA of CDC14A 
has an IRE that binds to IRP to control its expression levels. Under iron 
deprivation, the transcription of CDC14A mRNA is increased, which has the 
ability to dephosphorylate p27 as well as cyclin E therefore restricting the 
cell in the G1 phase (Kaiser et al, 2002; Sanchez et al, 2006).  
However, the regulation by CIP/KIP proteins is not limited to their inhibitory 
properties. Several studies have been able to show that CIP/KIP proteins are 
in fact, an essential component along with the cyclin D – cdk4/6 complexes 
ensuring the progression of the G1 phase of the cell cycle (Blain et al, 1997; 
Cheng et al, 1999; Alt et al, 2001). It has been demonstrated that the CIP/KIP 
molecules play a role in the assembly, nuclear accumulation and stabilization 
of the cyclin– cdk complexes. Furthermore, p21 and p27 are also believed to 
play a part in the hyperphosphorylation of pRb in the presence of cyclin E – 
cdk2 complex during mid-G1 phase of the cell cycle (LaBaer et al, 1997).  
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The second family of cdk inhibitors that regulate the cell cycle is the INK4 
proteins, which include p15INK4B, p16INK4A, p18INK4C and p19INK4D. The 
inhibitory effects of these molecules has been found to be limited to only 
cdk4 and cdk6 molecules, and hence their main role is restricted to arresting 
the cell in the G1/S phase of the cell cycle (Ruas et al, 1998).  
In addition to the different molecules and mechanisms described above there 
are several others mechanisms of cell cycle regulation that are affected in 
response to modulation of intra-cellular iron levels. Figure 1.6 summarises 
some of the main mechanisms, including those discussed above, by which 
iron depletion can influence normal cell cycle (Yu et al, 2007). 
Figure 1.6: Effects of iron deprivation on the cell cycle: Iron deprivation can cause cell cycle arrest, 
apoptosis as well as suppression of cell growth and metastasis by increasing IRP activity, upregulating 
TGFB1 signalling leading to inhibition of cdks via KIP1, activating p38 MAPK, activating inhibitors such 







1.9 Iron Chelation 
The damage caused by excessive iron accumulation to the heart, liver and 
other organs of the human body is well established. The inability of the 
human body to physiologically excrete iron highlights the need to develop a 
cheap yet effective iron chelator, which can bind and eliminate excess iron 
from the circulation (Siddique and Kowdley, 2012).  
Development of parenterally administrable iron chelators such as DFO was 
predominantly to treat patients with severe chronic anaemias, β-thalassemia 
and sickle-cell disease. These individuals are given regular blood transfusions 
which eventually leads to transfusional siderosis. Since phlebotomy is not an 
option for these patients, iron chelators were developed to reduce the iron 
overload. Currently, iron chelation as a therapy is being used extensively in 
patients with thalassaemia major as well as sickle cell anaemia 
(Kontoghiorghes et al, 2000; Flaten et al, 2012). Chelators are also a 
common form of therapy for Hereditary Haemochromatosis, however, their 
long term use is often limited due to the associated toxicities 
(Kontoghiorghes et al, 2005).  
With the tremendous advancements in latest technology to quantify tissue 
and body iron levels, there has been a more specific and targeted approach 
towards the use of iron chelating compounds for treating disorders of iron 
metabolism (Kalinowski and Richardson, 2005). From being restricted to 
iron-overload disorders such as Hereditary Haemochromatosis, iron chelation 
as a therapy is now being used in a myriad of disorders such as Rheumatoid 
Arthritis (Blake et al, 1985), Cancer and tumorogenesis (Becton and Roberts, 
1989), malaria (Gordeuk et al, 1992) and its use is even being studied in 
AIDS/HIV research (Sappey et al, 1995; Richardson, 1999). Especially over 
the last decade, iron chelation as a therapy has undergone drastic changes. 
Until very recently, Desferrioxamine (DFO) was the only clinically approved 
iron chelator for humans, but now within the last 10 years, the US Food and 
Drug Authority (FDA) has approved two new iron chelators – Deferasirox 
(DFX) and Deferiprone (DFP) for human use. Apart from these, several other 
novel chelators are currently being tested in different stages of clinical trials 
49 
 
and will be available for clinical use in the upcoming years. This heightened 
interest in iron chelation highlights the great potential it offers as a new form 
of therapy for a range of disorders (Richardson, 1999).  
Table 1.1, adapted from from Poggiali et al (2012), provides a comparison 





















Property Deferoxamine Deferiprone Deferasirox CP655 
          
Stoichiometry Hexadentate (1:1) Bidentate (3:1) Tridentate (2:1) Bidentate (3:1) 
          
Route Subcutaneous, 
intravenous 
Oral or solution Tablets for oral 
suspension 
Orally active 
          
Usual Dose 20-40 mg/kg/day over 8-
24 hours, 5 days a week 
75-100 mg/kg/day in 3 
doses daily 
20 - 40 mg/kg/day Not tested 
          
Excretion Urinary, Faecal Mainly urinary Faecal Unknown 
          
Half-life 20-30mins 3-4 hours 8-16 hours Unknown 
          




  Ophthalmological Arthralgia Rash Use in mouse 
models of Collagen-
Induced Arthritis  
  Auditory Elevated liver enzymes Rise in creatinine (CIA) do not show 
any adverse effects 
on total  
  Allergic reactions   Proteinuria iron levels, anaemia 
or weight loss  
  Growth retardation   Ophthalmological (Lloyd-Jones and 
Collins, unpublished 
data) 
  Bone abnormalities   Auditory   
  Pulmonary (at high doses)   Elevated liver enzymes   
  Neurological (at high 
doses) 
      
          
Challenges Adherence to parenteral 
administration; need for 
yearly ophthalmology and 
auditory examination 
Need for weekly blood 
count monitoring; not 
commercially available 
in all countries; limited 
data in children; 
variable efficacy in 
removal of hepatic iron. 
Cost, especially at 
higher doses; 
gastrointestinal side 
effects may limit 
dosing; Need for 




blood count for renal or 
hepatic failure and/or 
gastrointestinal 
haemorrhage 







for small doses thus 
reducing cost 
          
Status Licensed Licensed in USA and 
Europe 
Licensed in USA and 
Europe 
Not licensed 
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Indications Treatment of chronic iron 
overload due to 
transfusion-dependent 
anaemias (and for 
treatment of acute iron 
intoxication) 
Treatment of iron 
overload in thalassemia 
major when DFO is 
contraindicated or 
inadequate 
USA - Treatment of 
chronic iron overload 
due to transfusion-
dependent anaemias in 
individuals aged 2 years 





patient, 6 years and 
older, and approved for 
use when DFO is 
inadequate or 
contraindicated in 
patients with other 
anaemias, patients 2-5 




Could be used for 
treatment of 
diseases showing 





Table 1.1: Overview of Iron Chelators (Poggiali et al, 2012) 
 
 
1.9.1 Desferrioxamine (DFO) 
DFO was the first chelator to be approved for human use and has been in use 
for the last 40 years (Sheth, 2014).  
DFO is a bacterial siderophore obtained from Streptomyces pilosus. 
Structurally, it is made up of one molecule of acetic acid, two molecule of 
succinic acid and three molecules of 1-amino-5hydroxylamino-pentane. It 
has a molecular weight of 597Da, which is heavier in comparison to several 
of the novel iron chelators under trial and development (Fig 1.7). It is a 
hexadentate molecule that can bind one molecule of Fe3+ in a stable 




Figure 1.7: Structure of DFO (Kalinowski and Richardson, 2005) 
 
Although DFO has a higher specificity for Fe3+ than any other metal ion, it is 
still capable of binding to ions such as Cu2+, Zn2+, Co2+ and Al2+. Apart from 
not being specific to Iron, there are certain disadvantages and drawbacks 
associated with the use of DFO. Its high molecular weight and hydrophilic 
nature reduces its cellular permeability, as a result of which is enters the cell 
more slowly than its novel counterparts. Additionally, DFO as well as its 
iron-complexed form, have a net positive charge. This limits the ability of 
these compounds to get freely distributed within the cell and DFO gets 
restricted to the cell cytosol, hence highlighting the need to develop new iron 
chelators for clinical use (Hoyes et al, 1993). 
Several clinical trials have attested the effectiveness of DFO as a therapeutic 
approach towards treating iron-overload disorders and improving survival. 
However, there have been several reports of toxic side effects that cannot be 
ignored. Due to the poor absorption of DFO by the body, it cannot be 
administered orally and hence has to be given to patients parenterally. 
Furthermore, since DFO is rapidly excreted from the body, prolonged 
infusion of the drug is needed in order to elicit the desired therapeutic effect. 
This prolonged and cumbersome method of administration, limits 
compliance in patients. All these effects along with the high cost of the drug 
make it impractical to use to several parts of the developing world, where it 
is needed the most (Blake et al, 1985; Brittenham, 1992; Kalpatthi et al, 
2010; Algren, 2010; Poggiali et al, 2012). 
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In addition to the above drawbacks relating to the administration and 
absorption of the DFO, the drug by itself has been linked to severe biological 
side effects. A trial conducted by Blake et al (1985) used DFO to treat 
patients with Rheumatoid Arthritis. While some improvements in the clinical 
assessment of the patients were seen with regards to their RA, the trial had to 
be halted due to potentially serious cerebral and ocular toxicities. These were 
linked due to DFO binding to metals ions, specifically copper, in addition to 
Fe3+ and due to the ability of DFO to produce Nitric oxide free radicals. 
All of these factors, highlight the need to develop more specific and orally 
active iron chelators to succeed DFO. 
 
1.9.2 HPO Family chelators 
 
The 3-hydroxypyridine-4-one (HPO) family is a bidentate iron chelator 
group known for its high affinity, selectivity and specificity to intracellular 
iron (III) (Fakih et al, 2009). These compounds have relatively lower 
molecular weights as compared to many of the previously used iron 
chelators. Additionally, the presence of a neutral charge in both iron-free and 
iron complexed forms, provides them the ability to easily cross cellular 
membranes. This helps them to distribute more evenly and freely within the 
intra-cellular compartments (Hoyes et al, 1992). As a result of these 
properties of HPO chelators, they are considered to be one of the main 
candidates for the development of orally active iron chelators (Ma et al, 
2004). Another advantage of the HPO iron chelators is their ability to be used 
as chemosensors to determine the labile iron pool. Most of the existing 
methods to determine the distribution of labile iron were unsuitable to be 
used for living cells as they perturbed the nature and extent of the pool. 
Hence over the last few years, HPO iron chelators have been used to measure 
this chelatable iron pool within lymphocytes by making use of fluorescent 
probes (Fakih et al, 2009). The fluorescent probes are attached to HPO 
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chelators, which retain their iron binding capacity, and the fluorescent probes 
in turn undergo quenching when the compound interacts with intracellular 
iron. The fluorescence of the probe is increased under low/reduced iron 
conditions, whereas the fluorescence is decreased in the presence of 
excessive intracellular iron (Ma et al, 2007). Amongst the several different 
kinds of iron chelators, 7-diethylamino-N-((5-hydroxy-6-methyl-4-oxo-1,4-
dihydropyridin-3-yl)methyl)-N-methyl-2-oxo-chromen-3-carboxamide 
(CP655) is considered to be the most sensitive to intracellular iron levels.   
After generation of the HPO chelating moiety, the fluorescence is added by 
coupling the compound to an activated Coumarin acid. By itself, Coumarin, 
is not a fluorescent compound however addition of electron donating 
substituents result in enhancing its fluorescence intensity. Also, in 
comparison to previously used fluorescent dyes such as Calcein and 
Fluorescein, these novel probes are more selective sensors for iron (III). 
Furthermore, in contrast to Calcein, these Coumarin labeled probes are not 
prone to oxidative damage even in the presence of ferrous labile iron (Ma et 
al, 2006). 
 
Figure 1.8: Structure of CP655 (Ma et al, 2006) 
 
In the process of synthesis of CP655, the last step involves the removal of a 
protective methyl group by treatment with BCl3 (Ma et al, 2006). The 
presence of the protective methyl group renders the compound incapable of 
binding with iron, and hence can function as a fluorescent non-chelator. Due 
to its structural similarity but opposite effect to CP655, this compound has 




























1.10  Hypothesis, Aims and Objectives 
Having highlighted the essential, yet potentially toxic, role played by iron 
within the human body it is evident that iron metabolism must be very 
carefully regulated. With several diseases resulting due to the iron-overload 
conditions, iron chelators have been the therapy of choice for several years. 
However, with only a handful of chelators approved for human use, there is 
need to develop new iron chelators with higher efficiency and reduced 
toxicities and side effects.  
The hypothesis for this study was based on Evans et al (2009) who showed 
that synovial fluid and synovial membrane monocytes from patients with RA 
were capable of skewing the phenotype of CD4+ T cells cultured with them, 
by causing them to produce increased amounts of IL-17 and IFN γ as 
compared to CD 4+ T cells cultured with peripheral blood monocytes. It is 
well established in the literature that synovial fluid and synovial membrane 
monocytes of RA patients, those showing signs of Anaemia of Chronic 
Disease, have increased accumulation of iron suggesting that this excessive 
iron accumulation could be responsible for inflammation. Therefore, based 
on this, it was hypothesised that the use of iron chelators could reduce the 
inflammatory response shown by monocytes and the CD4 + T cells.   
The main aim of this study was: 
1. To test the effect of a novel class of HPO iron chelators on reducing 
inflammatory cytokine production and proliferation of primary 
human cells. 
2. Establish the mechanism behind their action. 
In order to achieve this, the main objectives of the study are detailed below: 
1. To test the panel of different iron chelators to determine the most 
suitable iron chelator for use in humans. 




3. To conduct micro-array analysis in order to isolate specific pathways 
being targeted by the chelator 
4. To confirm results of the micro-array by RT-PCR and Western Blots 














































MATERIALS AND METHODS 
 
2.1 Peripheral blood mononuclear cell isolation 
Blood samples of 60mls were routinely obtained from healthy volunteers 
after obtaining ethical approval and also obtaining consent from each of the 
donors. A list of all donors used along with age, gender and ethnicity has 
been provided in Table 2.1. Peripheral blood mononuclear cells (PBMCs) 
were isolated by density gradient centrifugation using Lymphocyte separation 
medium (LSM, PAA Austria). Blood was diluted 1:1 with sterile Dulbecco’s 
PBS (PAA, Austria) and 30mls of diluted blood was layered on top of 15mls 
of Lymphocyte Separating Medium. The tubes were centrifuged at 800 xg for 
20 minutes, with no brake. The buffy layer, which contains the mononuclear 
cells, is found at the interphase of the plasma and the LSM due to its density. 
The mononuclear cell layer was aspirated using Pasteur pipettes and diluted 
1:1 with PBS. The cell suspension was centrifuged twice at 300 xg for 10 
minutes at 4°C to remove any remaining LSM, plasma or platelets. The 












Donor   Age Gender Ethnicity 
1   48 F Caucasian 
2   52 M Caucasian 
3   52 F Asian 
4   30 M Asian 
5   40 F Caucasian 
6   40 M Caucasian 
7   32 M Caucasian 
8   28 F Caucasian 
9   32 F Caucasian 
10   32 F Caucasian 
11   23 F Asian 
12   23 F Asian 
13   22 F Asian 
14   27 M Caucasian 
15   29 M Caucasian 
16   30 F Asian 
17   31 M Caucasian 
18   31 M Asian 
19   27 M Asian 
20   27 F Caucasian 
21   30 M Caucasian 
22   30 F Caucasian 
23   28 F Caucasian 
24   36 F Hispanic 
25   32 F African 
26   34 M Caucasian 
27   35 F Caucasian 
28   27 F Asian 
29   28 F Caucasian 
30   42 M Caucasian 
31  60 F Caucasian 
32  24 M Asian 
33  22 F Caucasian 
34  29 M Caucasian 







2.1.1 CD14+ cell isolation from peripheral blood mononuclear cells  
CD14+ cells were positively selected using LS isolation columns (Miltenyi 
Biotec). 1x107 PBMCs were resuspended in 1ml of cold MACS buffer 
(Recipe in Appendix) and 10µl of CD14 microbeads (Miltenyi Biotec) were 
added per 107 cells. The reagents were scaled up or down according to the 
number of PBMCs obtained. The cells were resuspended by pipetting several 
times and incubated at 4°C for 15 minutes, following which, 10mls of cold 
MACS buffer was added to the cell suspension, and centrifuged at 300 xg for 
10 minutes at 4°C. During this time, the LS column was placed in the 
magnetic field by attaching it to the MACS separators. The columns were 
prepared by adding 3mls of cold MACS buffer and allowed to drip through. 
Once the cells were pelleted, they were resuspended in 500µl of cold MACS 
buffer and added to the LS column. The cells dripping through the column 
were depleted of CD14+ cells, which were retained in the column. The 
columns were washed three times with 3mls of MACS buffer while still 
attached to the magnetic separator. This CD14- fraction was used for 
isolation of CD4+ cells. Purity of the cells were assessed for each experiment 
and only isolations where purity was greater than 90% were used for 
experimental procedures. 
The CD14+ cells were eluted by first removing the column from the 
magnetic separator and then plunging 5mls of MACS buffer to flush out the 
CD14+ cells. The cells were counted and diluted to the required 
concentrations with RPMI 1640 (GIBCO, New Zealand) supplemented with 
2mM L-Glutamine (Lonza, Belgium), 100units/ml of Penicillin + 0.1mg/ml 
Streptomycin (Lonza, Belgium) and 10% FCS (GIBCO, UK).  
2.1.2 CD4+ cell isolation from CD14- cell fraction  
CD4+ cells were negatively isolated from the CD14- cell fraction using LD 
columns and CD4+ T cell isolation kit (Miltenyi Biotec). CD14- cells were 
centrifuged at 300 xg for 10 minutes and the pellet resuspended in 40µl of 
cold MACS buffer and 10µl of CD4+ T cell biotin-antibody cocktail per 107 
cells and incubated at 4°C for 10 minutes. Following this, 30µl of cold 
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MACS buffer and 20µl of CD4+ T cell microbead cocktail (Miltenyi Biotec) 
was added per 107 cells. Cells were mixed well and incubated for a further 15 
minutes at 4°C. Cells were washed with 10mls of cold MACS buffer. The LD 
column was placed in the magnetic separator and prepared by washing with 
3mls of MACS buffer. The labelled cell pellet was resuspended in 500µl of 
MACS buffer and applied to the column and then washed again with 3mls of 
MACS buffer. The flow-through unlabelled cells were collected as the 
enriched CD4+ T cells. Cells were counted and diluted to the required 
concentration with RPMI 1640 (GIBCO, New Zealand) supplemented with 
2mM L-Glutamine (Lonza, Belgium), 100 units/ml of Penicillin + 0.1mg/ml 
Streptomycin (Lonza, Belgium) and 10% FCS (GIBCO, UK).  
 
2.2 In vitro stimulation of primary human CD4+ T cells 
0.5x106 CD14+ cell and 1.0x106 CD4+ cells were cocultured in 1ml RPMI 
1640 (GIBCO, New Zealand) supplemented with 2mM L-Glutamine (Lonza, 
Belgium), 100units/ml of Penicillin + 0.1mg/ml Streptomycin (Lonza, 
Belgium) and 10% FCS (GIBCO, UK) in 48-well tissue culture plates, in a 
ratio of 1:2. For some of the experiments, cell cultures were stimulated with 
Tetanus Toxoid (kindly provided by Dr. L. Taams, KCL) in either the 
presence or absence of the chelator CP655 (5μM) or the control CP655OMe 
(5μM) (All chelators kindly provided by Prof. R. Hider, KCL). Cells were 
incubated at 37°C, 5% CO2 in a humidified atmosphere, for six days. 
Following this, the cells were stimulated with 750 ng/ml Ionomycin 
(SIGMA-Aldrich, Poole, UK) and 50ng/ml PMA (SIGMA-Aldrich, Poole, 
UK) for four hours, supernatants were harvested and used to measure 
cytokines by ELISA. The above protocol was adopted from Walter et al, 
2013 where double stimulation with PMA and Ionomycin was used to 
measure cytokine production from cultured CD4+ and CD14+ cells. 
Alternatively, in some experiments CD14+ cells and CD4+ cells were 
incubated separately overnight either with or without CP655 at 37°C, 5% 
CO2 in a humidified atmosphere. The following day, they were washed with 
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RPMI (supplemented as above) to remove the chelator and the cells were 
cocultured in different combinations in the absence or presence Tetanus 
Toxoid and further incubated at 37°C for six days. Following this, cells were 
stimulated with 750ng/ml Ionomycin and 50ng/ml PMA for four hours after 
which supernatants were harvested and cytokines measured by ELISA.  
For experiments conducted specifically on CD4+ T cells, purified 1 x 106 
CD4+ T cells were cultured in 1ml RPMI 1640 (GIBCO, New Zealand) 
supplemented as above in 48-well tissue culture plates. Cells were stimulated 
with anti-CD3/CD28 beads (Invitrogen, UK) in a ratio of 1:20 (Bead: CD4+ 
T cells) and treated with or without iron chelator CP655 (5µM) or control 
compound CP655OMe (5µM) for various time points ranging from 18 hours 
to six days post treatment.  
Routinely for all of the experiments, 100µl of cells from each culture 
condition were transferred onto a U-bottom plate (VWR, Lutterworth, UK) 
and incubated with tritiated thymidine for measuring proliferation as 
described below (Section 2.5.1). Carboxyfluorescein succinimidyl ester 
(CFSE) staining was used to assess cell proliferation in some experiments as 
described below (Section 2.5.2). 
 
2.3 Culturing Jurkat cells 
The human T lymphocyte cell line, Jurkat (kindly provided by Dr. Susan 
John, KCL), were used for analysing cell cycle and molecular studies such as 
Western blots. 10 x 106 cells were resuspended in 10mls of RPMI 1640 
(GIBCO, New Zealand) supplemented with 2mM L-Glutamine (Lonza, 
Belgium), 100 units/ml of Penicillin + 0.1mg/ml Streptomycin (Lonza, 
Belgium) and 10% FCS (GIBCO, UK). Cells were centrifuged at 300 xg for 
10 minutes and the pellet was resuspended in 15mls of RPMI (as 
supplemented above) and seeded into 75cm2 tissue culture flasks. Cells were 
maintained at 37°C in a 5% CO2 humidified incubator. Cells were split into 
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three flasks 2-3 times a week. At the time of experimentation, cells were 
pelleted and counted before the desired cell density was used. 
2.4 Supernatant ELISA 
Cytokines were measured using Human ELISA Ready-Set-Go kits 
(eBioscience, San Diego, USA).  
96-well NUNC Immunosorb plates (Maxisorp immunoplates, NUNC, 
Denmark) were coated with 100µl of pre-titrated capture antibody diluted 
1/250 using coating buffer (10x PBS ELISA coating buffer, eBioscience, San 
Diego, USA). Plates were incubated overnight at 4°C. Plates were washed, 5 
times, with ELISA wash buffer (PBS + 0.05% Tween-20) and blotted on 
absorbent paper before use. One part 5X assay diluent (eBioscience, San 
Diego, USA) was diluted with 4 parts of De-Ionized (DI) water and plates 
were blocked with 200µl of 1x Assay diluent and incubated for 1 hour at 
room temperature. After washing 5 times, the standard curve was set up using 
recombinant human cytokines (eBioscience, San Diego, USA). Starting 
concentration of the standard was 500pg/ml and serial doubling dilutions 
were made in 1x Assay diluent. 100µl of the sample supernatants were 
added, in triplicates, to the respective wells. The plate was incubated for 2 
hours at room temperature before again being washed 5 times with ELISA 
wash buffer. The biotin labelled pre-titrated detection antibody was diluted 
1/250 with 1x assay diluents, and 100µl of the solution was added to the 
wells and incubated for 1 hour at room temperature. The plates were washed 
5 times with ELISA wash buffer. Detection enzyme, Avidin-HRP 
(eBioscience, San Diego, USA) was diluted 1/250 with 1x Assay diluent and 
100µl was added to the wells and plate incubated for 30 minutes at room 
temperature. Plates were washed 7 times with wash buffer and 100µl of the 
Substrate, Tetramethylbenzidine (TMB) solution was added to the wells. 
Once the reaction was fully developed, 50µl of 2N H2SO4 was used to stop 
the reaction. Plates were read on MRX II ELISA plate reader (Dynex 




2.5 Proliferation Assays 
2.5.1 3H Thymidine Proliferation assay 
100μl of cultured cells were transferred to 96 well U-bottomed plates (VWR, 
Lutterworth, UK) and pulsed with 0.5μCi/well of 3H Thymidine and 
incubated for 24 hours at 37°C, 5% CO2. The plates were harvested using a 
Tomtec harvester and the glass fibre filter mats (PerkinElmer, MA, USA) 
were left to dry for at least 24 hours. The filter mats were treated with liquid 
scintillation fluid (Scintillant-Beta plate scint, Wallac) and then counted 
using a Wallac Scintillation counter to measure proliferation.  
2.5.2 CFSE incorporation Proliferation assay 
1 x 106 CD4+ cells were resuspended in PBS and stained with 5µM 
Carboxyfluorescein succinimidyl ester (CFSE) (Sigma-Aldrich, UK), by 
incubating for 5 minutes in the dark at room temperature. The cells were then 
washed twice with PBS containing 10% FCS by centrifuging at 300 xg for 10 
minutes at 4°C. The cell pellet was finally resuspended in RPMI media and 
cultured as above. Routinely, 10,000 cells were acquired and CFSE 
incorporation was analysed on the FL1 channel on the FACS calibur (Becton 
Dickinson) using CellQuest software and the data was analysed using the 
FlowJo software. 
 
2.6 Cell Cycle Analysis 
After 24, 48 and 72 hours of culture with or without anti-CD3/CD28 beads in 
the presence of absence of either the iron chelator CP655 (5µM) or control 
compound CP655OMe (5µM), 2 x 106 cells were lysed with 3mls of  cold 
absolute ethanol for at least one hour at 4°C. Cells were washed with cold 
PBS before staining with 50µg/ml Propidium Iodide (PI) (Sigma, Catalogue 
number: P4864) and 0.1mg/ml Ribonuclease A (Sigma-Aldrich, UK) in PBS 
for 20 minutes at 37°C, 5% CO2 in a humidified atmosphere. After 
incubation, the cells were resuspended in the same solution and 10,000 cells 
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were acquired immediately by FACS Canto flow cytometer (Becton 
Dickinson). The data was acquired as a Histogram on a linear scale where the 
x-axis represented the DNA content and the y-axis showed the relative cell 
number. Analysis was conducted using the FlowJo software and the 
histogram was divided into G0/G1, S and G2/M phase based on the amount of 
DNA content. 
 
2.7 Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Primary human CD4+ T cells, as cultured above (Section 2.2) were mixed 
with 5x SDS sample loading buffer boiled at 95°C for 10 minutes. The 
samples were then further boiled at 95°C for 5 minutes and the lysates were 
used for western blotting (Section 2.8). 
8-16% Pre-cast Tris-glycine protein gels (NuSep) were loaded into the 
electrophoresis tank along with 1x Running Buffer (Recipe given in Table 
2.1). Samples were boiled for 5 minutes and then 15-20µl of the samples was 
loaded into the respective wells. To determine the molecular weight, the 
Precision Plus Dual-Colour protein standard (Bio-Rad, UK) was run along 
with the samples. The electrophoresis system was run at 135V for 
approximately 2 hours. The protein samples on the gel were transferred on to 
a Polyvinylidene fluoride (PVDF) membrane (GE Healthcare, UK) and used 
for western blotting as described in the section below.  
2.8 Western Blotting 
The gel was washed in transfer buffer following which it was stacked 
between layers of scotch pads, 3mm Whatmann filter paper and a PVDF 
membrane which had been activated by washing with 100% methanol before 
use. The stack was placed inside the transfer tank and filled with 1x transfer 
buffer with 20% methanol (Recipe given in Table 2.2). The tank was kept 
cool using distilled water and ice packs. A current of 400mA and 35V was 
applied for 1.5hours and once the transfer was complete the membrane was 
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blocked in 5% dried milk in PBS with 0.1% tween (Thermo-Scientific, UK), 
with constant shaking for 1 hour at room temperature. The membrane was 
then transferred to primary antibody in 5% milk in PBS + 0.1% tween 
overnight at 4°C. The membrane was washed 3 times in PBS+0.5% tween 
and then incubated for 1 hour at room temperature in Horseradish-peroxidase 
(HRP) conjugated IgG antibody. The membrane was again washed three 
times in PBS+0.5% tween-20.  
Detection of HRP conjugated antibodies was carried out using SuperSignal 
West Femto  ECL Western Blotting system (ThermoScientific,, USA). The 
membrane was incubated in the enhanced chemiluminescent (ECL) reagents 
for 2-3 minutes at room temperature, wrapped in a plastic sheet and 
immediately imaged using Bio-Rad Chemi-Doc XRS Molecular imager. 
 
10 x Running Buffer 35 mM SDS (10.08 g) 
250 mM Tris (30.3 g) 
1.92 M glycine (144 g) 
 
20% Methanol Transfer Buffer 25 mM Tris (3.03 g) 
192 mM glycine (14.4g) 
 
In 800 mL final volume of water. 
Add 200 mL of methanol 100% 









Antibody (Clone) Manufacturer Dilution 
Rabbit anti-human p21 
mAb (12D1) (Primary) 
Cell Signalling, UK 1:1000 
Rabbit anti-human 
pSTAT5 mAb (4694) 
(Primary) 
Cell Signalling, UK 1:5000 
Rabbit anti-human 
GAPDH mAb (9485) 
(Primary) 
AbCam 1:2000 
HRP Goat Anti-Rabbit 
IgG (84369) (Secondary) 
Jackson ImmunoResearch 1:10000 
Table 2.3: List of western blot antibodies 
 
2.9 RNA isolation from CD4+ T cells 
Isolated CD4+ cells were either left unstimulated or stimulated with anti-
CD3/CD28 beads (1:20 bead:cells ratio) and treated with or without CP655 
(5µM) or CP655OMe (5µM) for 18 hours. RNA from these cells was isolated 
using Qiagen RNeasy Microkit (Qiagen, UK) following the manufacturers 
instructions. Briefly, at various time points, 5x105 cells were pelleted and 
homogenized using 350µl of Buffer RLT. Following this, an equal volume of 
70% ethanol was added and mixed well by pipetting several times. The 
sample was then transferred to the RNeasy MinElute spin column and 
centrifuged at 8000 xg for 15 seconds and the flow through was discarded. 
350µl of RW1 buffer was added to the column which was centrifuged at 
8000 xg for 15sec and the flow through was discarded. 70µl of buffer RDD 
was mixed with 10µl of DNase I stock solution, 80µl of this mixture was 
added to the membrane of the RNeasy MinElute spin column and incubated 
at room temperature (20-30°C) for 15mins. Following this, 350µl of RW1 
buffer was once again added to the columns before centrifuging at 8000 xg 
for 15sec and the columns were placed in a new 2ml collection tube, 
69 
 
provided along with the Qiagen kits. 500µl of buffer RPE was added to the 
spin column and centrifuged at 8000 xg for 15sec, the flow through was 
discarded, and 500µl of 80% ethanol was added to the column and 
centrifuged at 8000 xg for 2mins. The collection tube was replaced with a 
new one and the column was centrifuged with the lid open at 15000 xg for 
5mins to dry the membrane.  Finally, the column was placed into a 1.5ml 
collection tube, 14µl of RNase-free water was added to the spin column 
membrane and centrifuged at 15000 xg for 1 min to elute the RNA. The RNA 
was stored at -80°C till further use. 
 
2.10 Quantitative Reverse Transcriptase – Polymerase Chain Reaction (qRT-
PCR) 
RNA isolated using Qiagen RNeasy microkit (Qiagen, UK), as described 
above (Section 2.9) was quantified using the NanoDrop 1000 
Spectrophotometer (Thermo Scientific) and the quality of the RNA was 
assessed using Agilent 2100 Bioanalyser (Agilent technologies). For cDNA 
synthesis, 0.4µg of Random Hexamers were added to 100ng of RNA in a 
final volume of 22µl with RNA-free water. This was incubated at 70°C for 5 
minutes and then transferred to ice following which, 16µl of the Master Mix, 
described below, was added to each of the samples. 
 
Master Mix Volume 
5 x RT Reaction Buffer 8 µl 
dNTPs (25mM) 1.6 µl 
Riboblock RNase inhibitor (40U/ µl) 1 µl 
RNase free water 5.4 µl 




Samples were incubated at room temperature for 5 minutes. Following this, 
400U of Revert-Aid Reverse Transcriptase enzyme (Life technologies, UK) 
were added to each sample, to obtain a final volume of 40µl. This was first 
incubated for 10 minutes at room temperature, then for 1 hour at 42°C and 
lastly at 70°C for 10 minutes to inactivate the Reverse Transcriptase enzyme. 
cDNA was diluted to 10x by adding 360µl of RNase free water and stored at 
-80°C till further use. 
The cDNA was used for qRT-PCR with a TaqMan® detection system on a 
ViiA™ 7 Dx Real-Time PCR instrument (Life technologies). Each reaction 
contained 1.5µl of previously prepared cDNA and 8.5µl of the Master Mix 
described below.  
Master Mix Volume 
2 x TaqMan PCR Master mix 5 µl 
Gene of interest 0.33 µl 
18srRNA (Housekeeping gene) 0.17 µl 
RNase free water 3 µl 
Total 8.5 µl 
 
Relative expression of each of the target genes was calculated by normalizing 








Pre-designed TaqMan primers for the genes of interest were used (Table 2.4): 
Gene of 
Interest 
Catalogue number Supplier 
CDC6 Hs00154374_m1 Life technologies 
CDKN1A Hs00355782_m1 Life technologies 
RRM1 s01040698_m1 Life technologies 
GADD45G Hs00198672_m1 Life technologies 
ANAPC1 Hs00224096_m1 Life technologies 
Table 2.4: List of RT-PCR primers 
 
 
2.11 Flow Cytometry 
1 x 106 cells were washed twice with FACS buffer (PBS + 1%BSA + 
0.1%NaN3) by centrifuging them at 300 xg for 5 minutes. Cell pellet was 
resuspended in 100µl of the FACS buffer and either left unstained or stained 
with the respective FACS antibodies, on ice for at least 40 minutes. 3mls of 
cold FACS buffer was added to the cells after the incubation period and the 
cells were again washed by centrifugation at 300 xg for 5 minutes. Following 
this, cells were resuspended in 500µl of cold FACS buffer and 2% 
Paraformaldehyde (PFA) (Alpha Aesar). Routinely, 10,000 cells were 
acquired by the FACS Calibur (Becton Dickinson) using CellQuest software 


















eBiosciences 1 µl/test 
Table 2.5: List of FACS antibodies 
 
2.12 Micro-array analysis of CD4+ Cells 
CD4+ T cells were isolated as per the protocol above (Section 2.1). Isolated 
cells were stimulated with either anti-CD3/CD28 beads in a ratio of 1:20 
bead:cells or left unstimulated in the presence or absence of CP655 or 
CP655OMe for 18 hours following which, RNA was extracted (Section  2.9) 
and Affymetrix Gene 1.0 ST array was performed as per Ambion’s and 
Affymetrix’s instructions, which have been briefly described below. The 
experiments were conducted in collaboration with Dr. Matthew Arno 
(Genomics Centre, KCL).  
2.12.1 Synthesizing 1st Cycle cDNA 
RNA was prepared as per the protocol described above using RNeasy 
Microkit (Qiagen, UK) (Section 2.9). Control RNA that is 1 mg/ml total 
RNA from HeLa cells (provided with kit), was used to normalize the samples 
and reagents used. Quality and quantity of RNA was determined using 
NanoDrop1000 spectrophotometer (Thermo Scientific). RNA used for the 
experiment was considered to be of good quality when it demonstrated a 
A260/A280 ratio between the range of 1.7 to 2.1, as determined by the 
spectrophotometer. The integrity of the RNA was further assessed using the 
Agilent 2100 Bioanalyzer using the LabChip Kit. Assessing the integrity of 
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the RNA helps to establish the proportion of the sample that is full length. 
This is essential as reverse-transcribing partially degraded RNA can produce 
cDNA that is lacking part of the coding region. Following this, first strand 
cDNA was synthesized from the experimental RNA as well as the control 
RNA, using the First-Strand master mix that was provided along with the kit. 
The single-stranded cDNA was converted into a double-stranded cDNA, to 
act as a template for transcription. DNA polymerase and RNase H were used 
to degrade the RNA and simultaneously generate the second cDNA strand. 
This was done by using the second-strand Master mix provided along with 
the kit.  
 
 
2.12.2 Synthesizing cRNA and 2nd Cycle cDNA 
 The second strand cDNA was used to synthesize the antisense cRNA, which 
was then amplified by in-vitro transcription (IVT), the master mix for which 
was supplied along with the kit. cRNA was purified according to the 
procedure described in the Affymetrix protocol and the yield was assessed 
using the NanoDrop1000 spectrophotometer (Thermo Scientific). Following 
this 10µg of cRNA was then used to synthesize sense-strand cDNA by 
reverse-transcription using random primers.  2nd cycle Master mix was used 
to generate the cDNA and RNase H was used to degrade the cRNA and 
produce single stranded cDNA. In order to prepare the cDNA for further 
fragmentation and labelling, the cDNA was purified to remove any 
incorporated salts, enzymes and unincorporated dNTPs, as per the protocol 
defined by Affymetrix. The quality and yield of the cDNA was reassessed by 
the NanoDrop1000 spectrophotometer (Thermo Scientific). The Affymetrix 
GeneChip® WT Terminal Labeling Kit (Part no. 900671) was used for the 





2.12.3 Terminal labelling, Hybridization and Processing 
The cDNA samples were used for fragmentation using the Fragmentation 
Master Mix and then were labelled using the GeneChip® WT Terminal 
Labeling Kit. The labeling reagents produced using the Master Mix provided 
were added to the fragmented DNA samples, which were then used for 
hybridizations for the cartridge arrays. Once the hybridization was set-up the 
arrays were stained as per the GeneTitan Setup protocol for Gene 1.1 ST 
Array Plates and processed on the GeneTitan® Instrument. The entire 




Figure 2.1: Assay Schematic For Generating Whole Transcript Sense Target                                     
(Affymetrix User Manual) 
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2.13 Iron Chelators 
The 3-hydroxypyridine-4-one (HPO) chelators (kindly provided by: Prof. R. 
Hider, KCL) were dissolved in Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich, 
UK) and stored at a concentration of 50µM at -20°C. The chelators were 
diluted to the respective concentrations with RPMI media before use. The 











Figure 2.2: Structure and Molecular weights of iron chelators used in this study (Ma et al, 2006; 















2.14 Statistical Analysis 
The results have been represented as Mean + SEM for the stated number of 
replicates. Statistical differences between the data have been calculated using 
Graphpad Prism 5 software using the appropriate statistical tests as described 
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DETERMINING THE EFFECT OF IRON CHELATION ON HUMAN CD4+ 
AND CD14+ CELLS 
3.1 INTRODUCTION  
HPO iron chelators, SF34 and CP28, were previously used in our laboratory to 
test their effect on a mouse model of collagen-induced arthritis. It was observed 
that both SF34 and CP28 were able to significantly reduce CD4+ T cell 
proliferation and production of pro-inflammatory cytokine, such as IFN-γ and 
IL-17, in response to collagen stimulation in vitro. This ability of the chelators to 
modulate inflammatory responses was seen in response to antigen stimulation, 
but was not observed when cells were stimulated with the mitogen, Concanavalin 
A (Con A). Further experiments to identify the target cell indicated that the 
chelators were exerting their effects on murine CD4+ T cells (Lloyd-Jones and 
Collins, unpublished observations). This was contrary to the initial hypothesis 
where it was suggested that the main target of the iron chelators would be the 
CD14+ monocytes. This was based on the observation that in chronic 
inflammatory conditions, Anaemia of Chronic Disease is a common underlying 
problem. Patients with ACD have been shown to have accumulation of iron 
within the monocytes of the reticuloendothelial system, which drives 
inflammation in these individuals. Hence our original hypothesis proposed that 
the use of iron chelators would be able to reduce this accumulation of iron and 
thereby reduce the inflammatory conditions associated with sequestered iron. 
Additionally, SF34 and CP28, were tested in an in-vivo collagen-induced 
Arthritis (CIA) disease model. When given prophylactically, both chelators were 
able to significantly delay the onset of arthritis as compared to the control groups 
which were given either PBS or the control compound SF36, which is similar in 
structure to SF34 but does not chelate iron. However, when the chelators were 
given as a therapy to test their effect on established disease, only CP28 was able 
to significantly reduce the mean clinical disease score as compared to the control 
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groups, whereas SF34 did not show any significant effect (Lloyd-Jones and 
Collins, unpublished observations) (Fig 3.1).  
 
 
Figure 3.1: In-vivo prophylactic and therapeutic effect of iron chelation on disease score: A) 
C57Bl/6 mice were given either SF34 in 200µl at 250µM or control compounds SF36 and PBS i.p on 
Day -1, Day 0, Day 1 and twice per week from disease induction for 2 weeks. Disease was induced by 
i.d injections of chicken collagen in CFA. B) C57Bl/6 mice had disease induced as above. When 
symptoms became visible, 22 days post disease induction, mice were treated with either chelator 
CP28 or PBS twice weekly till the end of the trial. Mean clinical disease was assessed by visual 
scoring 3 times a week until the end of the trial. Data represented as Mean + SD. n=7 for each group, 








In the following chapter, I examined a panel of novel HPO chelators for their effect 
on human antigen stimulated or T- cell receptor (TCR) stimulated cells. I began by 
analysing the effect of different HPO chelators, namely CP655, CP28, CP803 and 
SF34, on Tetanus toxoid stimulated human CD4+ and CD14+ cells. Once the most 
effective chelator was identified, I conducted a titration to determine the appropriate 
concentration that the chelator should be used at. This was followed by conducting 
viability and purity assays to ensure that the chelator had no adverse effects on the 
cell population. Finally, experiments were conducted to find out the target cell of the 
iron chelator.    
 
3.2 CHAPTER OBJECTIVES 
 
Based on the discussion above, the specific aims for this chapter are as listed 
below: 
 
a. Determining the effect of a panel of HPO chelators on cultures of human 
CD4+ and CD14+ cells 
b. Identifying the most effect HPO chelator to be used for all future experiments 
c. Identifying  most suitable dose of chelator chosen for experimentation 
d. Analysing effect of chelator on cell viability 











3.3.1 Purity of CD14+ and CD4+ cells after PBMC isolation from fresh 
blood 
For each of the experiments conducted, CD14+ monocytes and CD4+ T cells 
were isolated from freshly isolated human PBMCs by MACS separation 
protocols and their purity was assessed by flow cytometry in order to ensure that 
a pure population of CD14+ and CD4+ cells were used for the experiments. 
Figure 3.2 depicts the flow cytometry analysis for assessing CD4+ cell purity 
(Fig 3.2 A) and CD14+ purity (Fig 3.2 B) from one donor. Obtaining a high 
purity was essential since one of the main aims of the project included 
identifying the target cell of the chelator.  
 
 
Figure 3.2: CD4+ and CD14+ cells purity:  Cells were isolated from fresh PBMCs using Magnetic 
columns as per the MACS separation protocol. 1x106 cells were stained with the respective FACS 
antibody and then analysed by flow cytometry. (A) Purity of isolated CD4+ T cells. (B) Purity of 
isolated CD14+ monocytes. Unlabelled = control cells; Labelled = Cells stained with antibody. 






In all of the following experiments, purity of both subsets was consistently 
greater than 85%. The average purity of CD4+ cells was 96.23% (n=19) and 
average purity of CD14+ cells was 88.75% (n=8). 
 
3.3.2 The effect of HPO iron chelators on human CD4+ and CD14+ co-
cultures. 
 
Several different kinds of HPO chelators have been synthesised to date. 
While most of the chelators have a similar structure, the main difference lies 
in the varying specificities and affinities of these chelators to intracellular 
iron. In order to establish which analogue was most effective on human cell 
cultures, several chelators were tested on a co-culture of human CD4+ and 
CD14+ cells stimulated with Tetanus toxoid. The concentration of Tetanus 
toxoid to be used was determined by conducting a titration of the antigen, 
tetanus toxoid (Fig 3.3).  
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0
1 0 0 0
2 0 0 0
3 0 0 0


















































N O  C H E L A T O R














 Figure 3.3: Titration of Tetanus toxoid on human CD4+ and CD14+ cells: CD4+ and CD14+ cells 
were isolated from fresh blood of healthy donors. Cells were mixed in a ratio of 2:1, stimulated with 
or without Tetanus Toxoid at either 1:5000, 1:10000 or 1:20000 dilution and treated with or without 
iron chelator CP655. After 6 days of incubation, cells were stimulated with 750ng/ml Ionomycin and 
50ng/ml PMA for four hours. (A) Proliferation was measured by incorporation of 3H thymidine. (B, 
C) Cytokines were measured by ELISA. Results depicted as Mean + SEM, n=3 individual donors. 
CONC = concentration. 
 
 
(C) (A) (B) 
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Based on the results of this experiment, it was decided to use the antigen at a 
concentration of either 1:20000 or 1:10000 dilution. Both concentrations 
were tested in each of the following experiments, and results where strongest 
stimulation was observed, were used for analysis. 
The panel of chelators which were tested for their effect on proliferation, 
IFN-γ and IL-17 production from CD4+ and CD14+ cells stimulated with 
Tetanus Toxoid, consisted of CP655, CP28, CP803 and SF34. Results shown 
below are from tetanus concentrations at which maximum response was seen, 
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Figure 3.4: Effect of chelators on human T cell proliferation and cytokine production: CD4+ 
and CD14+ cells were isolated from fresh blood of healthy donors. Cells were mixed in a ratio of 
2:1, stimulated with or without Tetanus Toxoid at either 1:10000 or 1:20000 dilution and treated 
with or without chelators. After 6 days of incubation, cells were stimulated with 750ng/ml 
Ionomycin and 50ng/ml PMA for four hours. (A) Proliferation was measured by incorporation of 
3H thymidine. (B,C) Cytokines were measured by ELISA. Cumulative results from donors tested 
shown as a percentage of cells from untreated cultures. Each symbol represents individual donor. 
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Figure 3.5: Effect of CP655 on human T cell proliferation and cytokine production: CD4+ and 
CD14+ cells were isolated from fresh blood of healthy donors. Cells were mixed in a ratio of 2:1, 
stimulated with or without Tetanus Toxoid at either 1:10000 or 1:20000 dilution and treated with 
or without chelators. After 6 days of incubation, cells were stimulated with 750ng/ml Ionomycin 
and 50ng/ml PMA for four hours. (A) Proliferation was measured by incorporation of 3H 
thymidine. (B,C) Cytokines were measured by ELISA. Individual raw data for donors tested only 
with CP655. Each symbol represents an individual donor. UT = Untreated cells. * indicates 
p<0.05 between cultures with absence and presence of CP655 calculated using Wilcoxon 
nonparametric matched pairs test.  
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Out of all the chelators tested, only CP655 significantly reduced cell 
proliferation, in response to tetanus toxoid stimulation to approximately 50% 
of untreated control cells in 7 out of the 11 donors tested (Fig. 3.4 A). 
Moreover all the chelators tested were successful in reducing, IFN-γ and IL-
17, production by the cells, although to varying degrees (Fig. 3.4 B, C). 
However, CP655 was noted to be most consistent and significantly reduced 
IFN-γ to 85% of control and IL-17 to 90% of control group. 
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Figure 3.6: Effect of SF34 on proliferation: CD4+ and CD14+ cells were isolated from 
fresh blood of healthy donors. Cells were mixed in a ratio of 2:1, stimulated with or without 
Tetanus Toxoid at either 1:10000 or 1:20000 dilution and treated with or without SF34. After 
6 days of incubation, cells were stimulated with 750ng/ml Ionomycin and 50ng/ml PMA for 
four hours. Proliferation was measured by incorporation of 3H thymidine. Data represented 
as Mean + SEM from n=3 individual donors. 
 
In contrast to previous data obtained from murine cells, SF34 did not have 
any effect on reducing proliferation in response to antigenic stimulation of 
the cells. In fact, proliferation after SF34 treatment was found to be four 
times more than that of the untreated groups (Fig 3.6). Cytokine production 
after treatment with SF34 was also found to be consistently higher than after 





3.3.3 Titration of CP655  
As seen in the section above, the HPO chelator CP655 was found to be more 
effective than any of the other chelators tested in reducing cell proliferation 
and inflammatory cytokine production. In fact, CP655 has been previously 
shown to be the most sensitive to the presence of iron amongst all other HPO 
chelators (Ma et al, 2007). Therefore, based on those results it was decided to 
use CP655 in all of the future experiments. The next step required 
ascertaining the right concentration at which CP655 must be used in order to 
avoid any potential toxicity while still retaining the strong suppressive 
results.  
Once again isolated human CD4+ and CD14+ cells were stimulated in 
culture with tetanus toxoid antigen in the presence of absence of varying 
concentrations of CP655 (Fig 3.7). 
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Figure 3.7: Dose titration for CP655: CD4+ and CD14+ cells were isolated from fresh 
blood of healthy donors. Cells were mixed in a ratio of 2:1, stimulated with or without 
Tetanus Toxoid at either 1:10000 or 1:20000 dilution and treated with or without CP655 at 
concentrations ranging from 1µM to 10µM. After 6 days of incubation, cells were stimulated 
with 750ng/ml Ionomycin and 50ng/ml PMA for four hours. Proliferation was measured by 
incorporation of 3H thymidine. * indicates p<0.05 between cultures with absence and 
presence of CP655 calculated using students paired t-test. Data represented as Mean + SEM 
from n=3 individual donors. 
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As seen in figure 3.7, the ability of CP655 to suppress proliferation of cells 
was best noticed when CP655 was used at 5µM concentration. Hence, based 
on these results all further experiments use CP655 at 5 µM concentration.  
 
3.3.4 Measuring viability with CP655 
Having established CP655 as the main chelator of choice, it was essential to 
ensure that it is not responsible for any unexplained cell death and excessive 
toxicity that can influence the interpretation of the data. To confirm this, 
isolated CD4+ and CD14+ human cells were treated with varying 
concentrations of CP655 in the presence of tetanus toxoid to maintain the 
same experimental conditions, and then viability of the cells were analysed 
after treatment with Propidium Iodide (PI) (Fig 3.8). 

















Figure 3.8: Viability of CD4+ and CD14+ cells: CD4+ and CD14+ cells were isolated from 
fresh blood of healthy donors. Cells were mixed in a ratio of 2:1, stimulated with or without 
Tetanus Toxoid at either 1:10000 or 1:20000 dilution and treated with or without CP655 at 
concentrations ranging from 1µM to 10µM. After 6 days of incubation, cells were stimulated 
with 750ng/ml Ionomycin and 50ng/ml PMA for four hours. Cells were stained with Propidium 
Iodide and viability was assessed by Flow Cytometry. Graph represents percentage of dead cells. 




Results indicated that treatment with the iron chelator, at all the 
concentrations tested, did not cause any statistically significant cell death. In 
fact, lower concentrations of the chelator ranging from 1µM to 5µM showed 
reduced cell death as compared to cells that were not treated with CP655 (Fig 
3.8). These results confirmed the use of 5µM of CP655 for all experimental 
set-ups. 
 
3.3.5 To determine iron-dependent effect on suppression caused by 
CP655 
In order to confirm that the effect of the chelators is iron dependent, that is, 
the effect is based on the ability of the compound to chelate iron from cell 
cultures, a non-iron chelating compound CP655OMe was developed and 
tested in the same experimental set-up as CP655.  
However, before this could be tested, the concentration of CP655OMe to be 
used in future experiments was determined. Similar to the set-up in Section 
3.3.3, isolated human CD4+ T cells and CD14+ monocytes were stimulated 
with Tetanus Toxoid in the presence or absence of varying concentrations of 
the control compound CP655OMe and proliferation was measured by 
tritiated thymidine incorporation (Fig 3.9). 
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Figure 3.9: Dose titration for CP655Ome: CD4+ and CD14+ cells were isolated from fresh 
blood of healthy donors. Cells were mixed in a ratio of 2:1, stimulated with or without 
Tetanus Toxoid at either 1:10000 or 1:20000 dilution and treated with or without CP655Ome 
at concentrations ranging from 1µM to 10µM. After 6 days of incubation, cells were 
stimulated with 750ng/ml Ionomycin and 50ng/ml PMA for four hours. Proliferation was 
measured by incorporation of 3H thymidine. Data represented as Mean + SEM from n=3 
individual donors. 
 
The results indicated that at all concentrations of CP655Ome, no inhibition of 
proliferation was seen. Therefore, to maintain consistency it was decided to 
use CP655OMe at the same concentration as CP655, which is at 5µM in all 
further experiments. 
Once again, before CP655OMe was used in further experiments, the effect of 
the compound of cell viability was assessed. Varying concentrations of 
CP655OMe were added to cultures containing isolated CD4+ and CD14+ 
cells stimulated with Tetanus toxoid antigen. Cell viability was measured 





















Figure 3.10: Viability of CD4+ and CD14+ cells: CD4+ and CD14+ cells were isolated 
from fresh blood of healthy donors. Cells were mixed in a ratio of 2:1, stimulated with or 
without Tetanus Toxoid at either 1:10000 or 1:20000 dilution and treated with or without 
CP655OMe at concentrations ranging from 1µM to 10µM. After 6 days of incubation, cells 
were stimulated with 750ng/ml Ionomycin and 50ng/ml PMA for four hours. Cells were 
stained with Propidium Iodide and viability was assessed by Flow Cytometry. Graph 
represents percentage of dead cells. Solid line represents Mean from n=3 individual donors. 
 
Results indicated that CP655OMe treatment did not have any statistically 
significant effect on cell death as compared to cells that had not been treated 
with the chelator. At the previously decided concentration of 5µM, cell death 
seen was same as that caused in the absence of any treatment (Fig 3.10). 
Therefore, the concentration of CP655OMe to be used was also confirmed at 
5µM for all experimental set-ups.  
Following on, to confirm that the suppression caused by the chelator is due to 
its iron binding abilities both CP655, as well as, the control CP655OMe were 
tested for their effect on cell proliferation. Isolated human CD4+ T cells and 
CD14+ monocytes were stimulated with Tetanus Toxoid in the presence or 
absence of either CP655 or the control CP655OMe and proliferation was 
measured by tritiated thymidine incorporation (Fig 3.11).  
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Figure 3.11: Iron dependent effect of CP655 on human CD4+ T cell proliferation: CD4+ 
and CD14+ cells were isolated from fresh blood of healthy donors. Cells were mixed in a 
ratio of 2:1, stimulated with or without Tetanus Toxoid at 1:10000 dilution and treated with 
or without CP655 (5µM) or the control compound CP655Ome (5µM). After 6 days of 
incubation, cells were stimulated with 750ng/ml Ionomycin and 50ng/ml PMA for four 
hours. Proliferation was measured by incorporation of 3H thymidine. * p<0.05, ** p<0.01 
between cultures with absence and presence of CP655 or CP655OMe calculated using paired 
t-test. Data represented as Mean + SEM from n=3 individual donors. 
 
Experiments on three individual donors confirmed that while treatment with 
CP655 was able to significantly reduce proliferation of the cell cultures, 
treatment with the non-iron chelating compound, CP655OMe, had no effect 
on the proliferation of the cells. This confirmed that the inhibition of 
proliferation is caused due to the chelation of iron from the cell cultures (Fig 
3.11). 
Therefore, due to the higher effectiveness of CP655 as demonstrated above, it 
was the main chelator tested in all of the following experiments. Along with 
CP655, the methylated non-iron chelating compound CP655OMe was also 






3.3.6 Identifying the target cell for CP655 
Once CP655 was established as the most effective chelator in reducing pro-
inflammatory responses, we next determined the cell that is the main target 
for the action of CP655. Our initial hypothesis proposed that sequestration of 
iron within Antigen Presenting Cells (APCs) was responsible for driving the 
inflammatory response that is seen in ACD. Hence in order to address this, 
we examined whether treatment of either the CD14+ monocytes or the CD4+ 
T cells separately with the chelator could reduce proliferation and IFN-γ and 
IL-17 production. CD14+ and CD4+ cells were isolated as described above 
and were incubated separately with or without the chelator for 24 hours. 
Following this, cells were washed out of the chelator and mixed in various 
combinations of either chelator treated monocytes, chelator treated T cells or 
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Figure 3.12: Effect of CP655 on CD4+ cells versus CD14+ cells: CD4+ and CD14+ cells 
were isolated from blood of healthy donors. Cells were incubated separately with or without 
CP655 for 24 hours. The cells were then mixed in different combinations, stimulated with or 
without Tetanus Toxoid at either 1:10000 or 1:20000 dilution. After 6 days of incubation, 
cells were stimulated with 750ng/ml Ionomycin and 50ng/ml PMA for four hours. (A,D) 
Proliferation was measured by incorporation of 3H thymidine. (B,C,E,F) Cytokines were 
measure by ELISA. Upper Panel: Results representative of 1 donor. Lower Panel: 
Cumulative results from individual donors. US = Unstimulated cells TT=Tetanus Toxoid 
stimulated cells. Each symbol represents an individual donor. Horizontal bars indicate the 
Median values. Dotted line represents control cultures were both CD4+ and CD14+ cells 
were untreated. * p < 0.05 calculated using Wilcoxon non-parametric test.  
 
Contrary to the initial hypothesis, when the CD14+ monocytes were treated 
with CP655 prior to culture with CD4+ T cells, there was no reduction in cell 
proliferation in response to tetanus toxoid. In fact, an increase in proliferation 
was seen as compared to the control group (Fig. 3.12 A, D). However, a 
pronounced reduction in proliferation was consistently seen when the CD4+ 
cells were treated overnight with CP655. This reduction was even more 
prominent than the one seen when both CD4+ and CD14+ cells were treated 
(F) (E) (D) 
(B) (A) (C) 
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with the chelator overnight (Fig. 3.12 A, D). A similar pattern was observed 
with the production of the pro-inflammatory cytokines. Treatment of CD4+ T 
cells with CP655 overnight led to a marked reduction in IFN-γ and IL-17 
production in all of the donors. In comparison, cultures where the CD14+ 
monocytes had been individually treated overnight with CP655 did not show 
a similar consistent reduction in cytokine production (Fig. 3.12 B, C, E, F).  
Hence, these results indicated that the cell type that is specifically targeted by 
CP655 is in fact the CD4+ T cells and not the CD14+ monocytes as 
hypothesized.  
To reconfirm and establish that the suppressive effects caused by CP655 are 
indeed due its ability to chelate iron, the experimental set-up explained above 
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Figure 3.13: Iron-dependent effect of CP655 on CD4+ cells versus CD14+ cells: CD4+ and     
CD14+ cells were isolated from fresh blood of healthy donors. Cells were incubated separately 
with or without CP655 or CP655OMe for 24 hours. The cells were then washed out of the 
treatment and mixed in different combinations, stimulated with or without Tetanus Toxoid at 
1:10000 dilution. After 6 days of incubation, cells were stimulated with 750ng/ml Ionomycin 
and 50ng/ml PMA for four hours. Proliferation was measured by incorporation of 3H thymidine. 
A=CD14+cell, T=CD4+ cells, CH=CP655, OME= CP655OMe. * p<0.05 calculated using 
paired t-test. Results represented as Mean + SEM from n= 3 individual donors. 
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In agreement with the previous results, a reduction in proliferation was only 
observed in cultures where the CD4+ T cells had been pre-treated with the 
iron chelator (Solid red column, Fig 3.13). No significant reduction was seen 
in the cultures where CD14+ monocytes were pre-treated with CP655. 
Treatment of the T cells with the control compound had no effect, with 
proliferation comparable to the untreated control cell cultures. Additionally, 
cell cultures where both CD14+ cell and CD4+ cells were pre-treated with 
CP655 a non-significant but consistent reduction in proliferation was seen 
(Fig 3.13). Treatment of only the CD14+ monocytes with either the chelator 
or the control compound did not show any differences as compared to the 
untreated cell cultures.  These results were in accordance to data generated 
previously from murine experiments in our laboratory, where CD4+ T cells 
were also indicated to be the main target cells of SF34 and CP28 chelators. 
 
3.3.7 Identifying the concentration of anti-CD3/CD28 beads for 
optimal stimulation of CD4+ T cells 
 
Once experiments revealed that the target for CP655 were CD4+ T cells 
rather than the previously hypothesized CD14+ monocytes, purified CD4+ T 
cells were used for further experiments to identify the mechanism of action of 
the iron chelator.  
Therefore, to determine the stimulation required to activate CD4+ T cells in 
the absence of the CD14+ monocytes, they were stimulated with a range of 
bead:cell ratios in the presence of either CP655 or the control compound 
CP655OMe (Fig 3.14).  
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Figure 3.14: Titration of anti-CD3/CD28 beads on CD4+ cells: CD4+ cells were isolated 
from fresh blood of healthy donors. Cells were stimulated with anti-CD3/CD28 beads in 
ratios 1;5, 1;10 and 1:20 in the presence of 5µM CP655and 5µM CP655OMe 24 hours of 
culture proliferation was measured by incorporation of 3H thymidine. **p<0.02, * p<0.05 
calculated using paired t-test. Results represented as Mean + SEM from n=5 individual 
donors. 
 
A dose-dependent effect on proliferation was seen on stimulating with 
varying concentration of anti-CD3/CD28 beads. Results showed that the 
level of stimulation had no significant effect on the extent of suppression 
caused by the chelator on the CD4+ T cells. Approximately 75% inhibition 
was seen after treatment with CP655 with all three concentrations of the anti-
CD3/CD28 beads. The amount of stimulation also had no effect on the action 
of the control, CP655OMe, as its results were comparable to the untreated 
control cells in all three titrations.  
Hence, in line with this data, it was decided to use the lowest concentration of 
the anti-CD3/CD28 beads for stimulating CD4+ T cells that is 1:20 bead: 






3.3.8 Titration of CP655 and CP655OMe to identify most effective dose 
In order to maintain consistency of data and experimental set-up, titrations of 
CP655 and CP655OMe concentration were conducted once again, but this 
time in the presence of anti-CD3/CD28 stimulated CD4+ T cells to ensure 
that CP655 continued to inhibit CD4+ T cell proliferation in the absence of 
CD14+ monocytes.  
CD4+ cells were isolated from freshly isolated PBMCs using the MACS 
protocol described above. The cells were stimulated with anti-CD3/CD28 
beads in a ratio of 1:20 and treated with varying concentrations of CP655 and 
CP655OMe, ranging from 1µM to 20 µM. 24 hours after incubation the cells 
were incorporated with Tritiated thymidine and used to measure cell 
proliferation. 
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Figure 3.15: Dose titration of CP655: CD4+ cells were isolated from fresh PBMCs using 
Magnetic columns as per the MACS separation protocol. 1x106 cells were treated with 1:20 
anti-CD3/CD28 beads in the presence or absence of the chelator concentrations ranging from 
1µM to 20µM. After 24 hours of culture, proliferation was measured by incorporation of 3H 
thymidine. ns= non significant, ** p<0.01 calculated using paired t-test. Results represented 





A dose dependent effect of CP655 was seen on the suppression of 
proliferation of anti-CD3/CD28 stimulated CD4+ T cells (Fig 3.15). At the 
lowest concentrations of 1µM and 2 µM, non-significant reductions in 
proliferation of the CD4+ T cells were observed. However, on increasing the 
concentration to 5 µM, a highly significant inhibition of proliferation, of 
almost 80% was observed. Further increasing the concentration to 10 µM and 
20 µM showed a dose-dependent significant increase in suppression of 
proliferation in response to the chelator. At the highest concentration of 
20µM, an almost 100% inhibition was noticed.  
Based on the above titration of the chelator, the lower concentrations of 1µM 
and 2µM were ruled out due to insignificant effects. The higher 
concentrations of 20µM were also not used as it was associated with non 
significant, but slightly higher cell death as compared to cells not treated with 
chelator (See Fig 3.17). Therefore, for future experiments, the median dose of 
5µM was chosen as the appropriate dose for testing.  
Similarly, isolated CD4+ T cells were treated with varying concentrations of 
CP655OMe after stimulation with anti-CD3/CD28 beads and proliferation 
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Figure 3.16: Dose titration of CP655OMe: CD4+ cells were isolated from fresh PBMCs 
using Magnetic columns as per the MACS separation protocol. 1x106 cells were treated with 
1:20 anti-CD3/CD28 beads in the presence or absence of CP655OMe, concentrations ranging 
from 1µM to 10µM. After 24 hours of culture, proliferation was measured by incorporation 
of 3H thymidine. Calculated using paired t-test. Results represented as Mean + SEM from n= 
3 donors. 
 
The varying concentrations of CP655OMe had no significant effect on the 
level of cell proliferation observed. In each of the cases, a slight non-
significant increase in proliferation as compared to the untreated cells was 
seen (Fig 3.16). To maintain consistency with previously conducted 
experiments, it was decided to continue using 5µM concentration of 








3.3.9 Measuring viability of CD4+ T cells post CP655 and CP655OMe 
treatment 
 
In order to ensure that treatment with both the compounds CP655 and 
CP655OMe did not cause cell death, viability of the cells was established 
after treatment with varying concentrations of the compounds in the presence 
of anti-CD3/CD28 beads. Additionally, this also helped to confirm that the 
ability of the chelator to inhibit cell proliferation and inflammatory cytokine 
production, was not a by product of any toxicity or cell death.  
CD4+ T cells were isolated as per the protocol described earlier. The cells 
were stimulated with 1:20 anti-CD3/CD28 beads and treated for 24 hours 
with either CP655 or CP655OMe, ranging from 1uM to 20uM (Fig 3.17). 
Propidium Iodide staining was used to determine the percentage of dead 
cells. 


















Figure 3.17: Viability of CD4+ T cells post CP655 treatment: CD4+ cells were isolated 
from fresh PBMCs using Magnetic columns as per the MACS separation protocol. 1x106 
cells were treated with 1:20 anti-CD3/CD28 beads in the presence or absence of the 
chelator concentrations ranging from 1µM to 20µM. After 24 hours of culture, cells were 
stained with Propidium Iodide and viability was assessed by Flow Cytometry. Graph 
represents percentage of dead cells as Mean + SEM from n=4 individual donors. 
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Approximately 1.3% cell death was seen in an average of four experiments 
where CD4+ T cells had not been treated with the chelator. Treatment with 
1µM of CP655 led to a slight decrease in percentage of dead cells. Following 
this, small but statistically insignificant dose dependent increases in the 
percentage of dead cells was seen with increasing concentrations of CP655 
iron chelator. The highest amount of cell death, 1.66%, was observed after 
treatment with the highest concentration tested (20µM). Therefore, the effects 
demonstrated by CP655 cannot be attributed to cell death and toxicity but are 
in fact specific effects due to iron chelating properties of the compound. 
Therefore based on these, CP655 was used at a concentration of 5µM for all 
the following experiments. 
Finally, the last check was to ensure viability of CD4+ T cells stimulated 
with anti-CD3/CD28 beads and treated with varying concentrations of the 
control compound, CP655OMe (Fig 3.18). 
















Figure 3.18: Viability of CD4+ T cells post CP655OMe treatment: CD4+ cells were 
isolated from fresh PBMCs using Magnetic columns as per the MACS separation protocol. 
1x106 cells were treated with 1:20 anti-CD3/CD28 beads in the presence or absence of 
CP655OMe concentrations ranging from 1µM to 10µM. After 24 hours of culture, cells were 
stained with Propidium Iodide and viability was assessed by Flow Cytometry. Graph 




Similar to the results obtained previously, no significant cell death was seen 
at any of the concentrations of CP655OMe used. The average cell death seen 
in the absence of any treatment was 2.5% and at all other concentrations the 
percentage of dead cells was found to be lower than this. The cell death seen 
on treatment with 5µM of CP655OMe was around 1.9%, and was lower than 
that seen at any other concentration of CP655OMe used.  
Therefore, keeping in line with all previous experiments and results, 
CP655OMe was also used at a final concentration of 5µM. 
 
3.3.10 Confirmation of CD4+ T cell proliferation by CFSE staining 
 
So far, the proliferation of CD4+ T cells had been measured using Tritiated 
Thymidine (3H) incorporation. However, since 3H measures DNA replication 
via its ability to be incorporated within the DNA, it is therefore not a true 
measure for actual cell division (Lašt’ovička et al, 2009). In order to confirm 
the results obtained so far by 3H thymidine incorporation, another method for 
measuring cell proliferation was adopted. CD4+ cells were labelled with 
5µM CFSE and the dilution of the dye was measured to determine the 
amount of proliferating CD4+ cells (Fig 3.19). 
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Figure 3.19: Proliferation of CD4+ cells by CFSE: CD4+ cells were isolated from fresh 
blood of healthy donors. Cells were stimulated with anti-CD3/CD28 beads in the ratio of 
1:20 in the presence of 5µM CP655 or CP655OMe. Proliferation was measured by coating 
the surface of the cells by 5µM CFSE and measuring dilution of the dye by flow cytometry. 
(A) Results from one representative donor after 4 days of culture. (B) Cumulative results 
from n=3 individual donors Results shown as Mean + SEM. ** p<0.01 calculated using 
Mann-Whitney non-parametric test. 
 
CFSE dye dilution confirmed the tritiated thymidine proliferation results. 
Results verified that treatment with CP655 is able to inhibit CD4+ T cell 
proliferation by 40-50%, whereas the control compound CP655OMe has no 
effect on the proliferation of the cells. Results also showed that the inhibitory 
effect of the chelator was maintained up till 6 days post stimulation of the 





However, in contrast to the previously conducted proliferation assays using 
3H thymidine, cell proliferation was only seen from 48 hours after 
stimulation of the CD4+ cells with anti-CD3/CD28 beads. A significant 
impact of CP655 on inhibition of proliferation was visible only 72 hours post 
stimulation of the cells (Fig. 3.19 B). However, using 3H thymidine as a 
measure of cell proliferation, the effect of CP655 on the inhibition of this 
proliferation was visible from as early as 12 hours post stimulation.  
In order to maintain consistency with previous experiments, tritiated 



















3.4    DISCUSSION AND CONCLUSION 
 
The aim of this first chapter was to establish the basic effect of HPO 
chelators on freshly isolated human lymphocytes.  
Bi-dentate 3-hydroxypyridine-4-one (HPO) iron chelators were developed in 
order to overcome the short comings and drawbacks of previously used iron 
chelators and are currently are the best alternative candidates to DFO (Liu 
and Hider, 2002). Studies in the past have suggested that DFO can cause 
toxicities in cells leading to apoptosis, cell shrinkage and chromatin 
fragmentation (Pan et al, 2004). In comparison to DFO, HPO iron chelators 
display greater selectivity, specificity for iron and have not known to be 
associated with any cellular toxicities. Additionally due to their lower 
molecular weight and neutral charge, they exhibit quicker diffusion across the 
cell membrane and diffuse more freely and within the cell (Hoyes et al, 
1992). Their greater cell permeability and the ability to cross the blood-brain 
barrier has made it possible to use them in treating neuro-degenerative 
diseases that are associated with iron deposition in the brain. Zorzi et al, 2011 
showed that treatment of patients with pantothenate kinase–associated 
neurodegeneration with Deferiprone resulted in a significant reduction in the 
iron deposition in the brain as determined by MRI scans, although no 
significant changes were seen in the clinical symptoms of the disease. 
However, a previous study by Forni et al, 2008 showed improvements in 
clinical symptoms and amelioration of disease in a patient suffering from 
neuro-degeneration after Deferiprone treatment for 10 months. This led to an 
on-going Phase II clinical trial to test the effect of Deferiprone on patients 
with Parkinsons Disease (Forni et al, 2012).  
In order to investigate the effects of novel HPO chelators, four different 
analogues SF34, CP28, CP655 and CP803 were tested on human 
lymphocytes. CD4+ T cells and CD14+ monocytes, isolated from healthy 
donors, were activated by stimulating them with Tetanus toxoid in order to 
mimic an inflammatory condition. These cells were treated with each of the 
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HPO chelator analogues and cytokine production from and proliferation of 
these cells was analysed. The experiments revealed that although all the 
compounds were analogues they differed in the effects that they exerted on 
cells due to their varying specificities for intracellular iron. It was found that 
7-diethylamino-N-((5-hydroxy-6-methyl-4-oxo-1,4-hydropyridine-3-
yl)methyl)-N-methyl-2-oxo-2H-chromen-3-carboxamide (CP655) 
consistently and significantly reduced cell proliferation with a concomitant 
decrease in IFN-γ and IL-17 production from cell cultures. This was 
consistent with other studies conducted by Ma et al (2004) where the 
fluorescent iron chelators were used as iron sensors, and demonstrated that 
out of several HPO chelators tested, CP655 demonstrated the maximum 
sensitivity to intra-cellular iron. In another study by Ma et al (2006), CP655 
was found to be the most effective chelator for hepatocytes due to its ability 
to most effectively reach the chelatable labile iron pool. This was due to the 
greater permeability displayed by CP655 in comparison to the previously 
used iron chelators.  
Previously iron chelation has been shown to cause cell death due to their 
ability to promote cellular apoptotic pathways. Therefore, in order to ensure 
that the suppression caused after CP655 treatment was not associated with 
increased cell death, the viability of CD4+ and CD14+ cell cultures was 
assessed after treatment with CP655. Staining with Propidium Iodide 
confirmed that CP655 was not responsible for any excessive cell death when 
compared to cells that had not been treated with the chelator. In fact, 
treatment with lower concentrations of CP655 (1µM - 5 µM) seemed to be 
protective in nature to the cells, as there was a trend towards increased cell 
viability when compared to untreated cells. This is consistent with other 
reports where it has been suggested that iron chelation does not lead to 
increased apoptosis of cells, and in some cases as also been shown to inhibit 
TRAIL-mediated apoptosis (Bowlus, 2003; Moon et al, 2015).  
Having established that the reduced cytokine production and reduced 
proliferation was not as a result of excessive toxicity or cell death, it was 
essential to prove that these effects were due to the iron chelating ability of 
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CP655 and not caused due to any structural or chemical effects of the 
compound. CP655OMe was developed on special request (Kindly provided 
by: Robert C.Hider, King’s College London) to act as a control compound to 
CP655. The two compounds are similar in structure, however the main iron 
binding moiety in CP655 has been masked by methylation in CP655OMe, 
making it incapable of chelation iron (R.C. Hider, personal communication). 
Therefore, CP655OMe was used as a control in parallel with to CP655 in 
order to confirm that the effects of CP655 were due to its ability to chelate 
iron and not any other structural or physiological property of the chemical 
compound. The use of CP655OMe in cultures of stimulated CD4+ and 
CD14+ cells showed that it had no effect on cell proliferation, which was 
maintained at the same level as the stimulated but untreated cells. These 
results, along with the results of the viability experiments, made it evident 
that the significant and consistent inhibition in proliferation and cytokine 
production after treatment with CP655 was as a result of its ability to chelate 
intra-cellular iron and cannot be attributed to toxicity or 
physiological/structural properties of the compound being used. 
While the results from experiments so far had provided an insight into the 
range of effects caused by the novel iron chelator, CP655, they had not 
provided an indication towards the mechanism that was responsible for the 
visible effects. It was decided that the first step towards identifying the 
mechanism of action of the chelator would be to identify and isolate the cell 
type on which it had its most prominent effect.  
CD4+ T cells and CD14+ monocytes were treated separately with CP655 
overnight before being mixed in culture and stimulated using tetanus toxoid. 
The aim of these experiments was to determine the main target cell of CP655. 
Results consistently suggested that treating CD4+ T cells, rather than CD14+ 
monocytes, with CP655 exhibited a stronger effect on inhibition of 
proliferation as well as cytokines production. In fact, treatment of CD14+ 
monocytes with CP655 led to a small increase in proliferation of cells and 
had no effect on IFN-γ and IL-17 production as compared to untreated cells. 
Whereas, cultures where only CD4+ T cells were treated with CP655 showed 
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a pattern similar to previous experiments, with significant reductions in 
proliferation of more than 50% and reductions in cytokine production of 
25%-30%. These findings were consistent with murine experiments, which 
also implicated CD4+ T cells to be the main targets of chelator treatment. 
 Hence it was evident that the main target cells of CP655 treatment were 
CD4+ T cells. Several studies have highlighted the significant role played by 
iron in cellular proliferation, however this need for iron is more prominent in 
rapidly dividing, metabolically active cells such as lymphocytes (Golding 
and Young, 1995; Mullick et al, 2006). When lymphocytes are given a 
stimulus to proliferate, most of them respond to the stimulus by up-regulating 
the expression of TfR1 on their surface in order to acquire enough iron to fuel 
their proliferation. But, the increase in the expression of Transferrin receptors 
on the surface of T cells is more rapid and of greater magnitude than any 
other lymphocyte sub-sets (Neckers and Cossman, 1983; Brock, 1989; 
Seligman et al, 1992). In another study by Kumagai et al (1988) a 
comparison between B cells and T cells once again confirmed that T cells 
express increased levels of Transferrin receptor mRNA after a proliferative 
stimulus indicating their greater dependence on iron (Bowlus, 2003). Whitley 
et al (1993) also demonstrated that the effect of iron deficiency on host 
immunity is pre-dominantly due to the effects on functions and migratory 
patterns of T lymphocytes. Therefore, the literature clearly highlights the 
high dependence of T cells on iron for growth, differentiation and 
functioning. Based on this, it is evident that upon depletion of intra-cellular 
iron CD4+ T cells will be significantly affected, as described by the results 
discussed above.  
So far, the proliferation of cells in all of the experiments was measured by 
incorporation of Tritiated thymidine into the cells. Tritiated thymidine 
incorporation into DNA is one of the most commonly used methods for 
measuring cell proliferation, and often considered the gold standard for 
proliferation assays (Bading and Shields, 2008). 3H-thymidine is taken up by 
the cell, and with each cell division this radio-labelled DNA precursor gets 
replicated into the DNA strands. However, the problems associated with this 
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technique arise due to the fact that the extent of DNA synthesis does not 
always represent the exact extent of cell divisions (Maurer, 1981; Naito et al, 
1987). As a result of these discrepancies, alternative methods of assessing 
cellular proliferation have been developed such as CFSE staining. CFSE is a 
non-fluorescent cytoplasmic dye that can track proliferation of lymphocytes 
by passively diffusing into their cytoplasm. Once inside the cell, specific 
esterases convert it into a fluorescent compound. With each cellular division, 
CFSE gets equally distributed to each of the daughter cells as a result of 
which the fluorescence of the dye is halved with each cell division. Hence, in 
comparison to 3H-thymidine incorporation that measure DNA synthesis, 
CFSE staining assess actual cell division and proliferation (Weston and 
Parish, 1990).  
To confirm the results that were obtained by 3H-thymidine proliferation 
assays, CD4+ T cells stimulated with anti-CD3/CD28 beads and treated with 
either CP655 or CP655OMe, were stained with CFSE and proliferation was 
analysed by flow cytometry. In the absence of CD14+ cells to provide co-
stimulation, anti-CD3/CD28 beads were used to stimulated CD4+ T cells. As 
expected, CP655 treated cells showed significantly reduced proliferation as 
compared to untreated or CP655OMe treated cells. Although the trend 
observed in both proliferation assays were similar, there was a stark 
difference in the kinetics. When 3H-thymidine incorporation was used to 
measure cellular proliferation, significant inhibition of proliferation was 
observed from time points as early as 18hours post stimulation. However, 
when CFSE was used, cellular proliferation was visible only from 72 hours 
post stimulation, which was significantly inhibited following CP655 
treatment and continued till up to six days post stimulation. 
Furthermore, an observation made during these initial experiments was that 
while IFN-γ and IL-17 production from cell cultures after chelator treatment 
was reduced by 25%-35% on average, proliferation was consistently 
inhibited by 70%. This indicated that one of the key pathways that was being 





Therefore, based on these results the aim for the following chapter was to 
determine the mechanism of action behind the effect of CP655 on human 




























IDENTIFYING THE MECHANISM 



















The results from the first chapter led to the identification of CP655 as the 
compound that was most potent in reducing inflammatory cytokine 
production from and proliferation of human CD4+ T cells, from the panel of 
different chelators that were tested. Additionally, we also determined that the 
main target cells of the chelator were CD4+ T cells rather than the previously 
hypothesised CD14+ monocytes.  
From all the experiments that were conducted in the previous chapter, one of 
the observations that stood out was that while IFN-γ and IL-17 production 
were reduced by 25%-35% each time, proliferation was consistently 
suppressed by more than 75%. This observation, clearly suggested that the 
mechanism of action of CP655 may involve interfering or altering with 
pathways involved in cell proliferation and cell growth. 
In order to further elucidate the mechanism of action of CP655, a whole-
genome microarray analysis was conducted to identify specific genes or 
pathways that may be affected by CP655. Conducting a micro-array analysis 
is considered to be a useful approach when trying to identify changes in a 
large number of genes in response to treatment with either the chelator or 
control compound. The understanding of gene interactions and regulation can 
provide insights into the underlying mechanisms responsible for cellular 
effects of chelator treatment. The micro-array was conducted with the hope 
that it would help to identify novel target genes that were potentially 




4.2 CHAPTER OBJECTIVES 
 
Based on the discussion above, the specific aims addressed in this chapter are 
as follows: 
 
a. Determining a suitable time point for conducting microarray 
experiment 
b. Conducting microarray on RNA isolated from human CD4+ T cells 
c. Identifying pathways and genes being differentially modulated after 

















4.3.1 Determining ideal time point for microarray experiment 
Results from the first chapter identified CD4+ T cells as the main target of 
the chelator, CP655. Therefore, in order to identify the main pathways and 
specific target molecules of the chelator, isolated CD4+ T cells were used for 
the microarray. In the absence of the CD14+ monocytes to provide co-
stimulation to the cells, anti-CD3/CD28 microbeads were used to stimulate 
the cells. 
In order to determine the time point most suitable for conducting the 
microarray, the kinetics, of the effect of CP655 and CP655OMe, were 
examined from 4 - 48 hours post stimulation (Fig 4.1). 
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 Figure 4.1: Kinetics of effect of CP655 on CD4+ T cells: CD4+ cells were isolated from 
blood of healthy donors. Cells were stimulated with anti-CD3/CD28 beads in a ratio of 
1:20 in the presence or absence of either of 5µM CP655 or 5µM CP655OMe from 4 hours 
– 48 hours. At each time point proliferation was measured by incorporation of 3H 
thymidine. **p<0.01, * p<0.05 calculated using paired t-test. Data represented as mean 





The results of the proliferation analysis revealed that while a trend in reduced 
proliferation of T cells was seen on treatment with the chelator as compared 
to the control or the untreated cells from as early as 4 hours post stimulation 
and treatment of the cells, the inhibition was not significant in the first three 
early time points, that is between 4 and 12 hours post stimulation. However, 
from 18 hours onwards a highly significant reduction in proliferation of 
CD4+ T cells was seen on treatment with CP655 in comparison to 
CP655OMe and untreated cells. 
In order to elucidate the mechanism of CP655, a microarray was conducted at 
the earliest time point at which significant inhibition in proliferation was 
observed in all donors, that was, 18 hours post stimulation and treatment. 
 
4.3.2 Confirming samples for micro-array analysis 
Once the time point to conduct the microarray was determined, the next step 
was to ensure that the samples taken from the healthy controls for conducting 
the microarray show the same patterns of proliferation as had been observed 
so far in previous experiments. Therefore, before RNA was extracted from 
the cells and used for microarray, tritiated thymidine incorporation was used 
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Figure 4.2: Proliferation of CD4+ T cell samples used for microarray. CD4+ T cells 
were isolated from PBMCs of healthy donors. Cells were stimulated with either anti-
CD3/CD28 beads (1:20) and left untreated or treated with either CP655 (5µM) or the 
control CP655OMe (5µM) for 18hours. Proliferation was measured by 3H thymidine 
incorporation. * p<0.05calculated using paired t-test. Data represented as mean +SEM 
from n=5 individual donors. 
 
 
The proliferation results from the five donors chosen for micro-array 
analysis showed that, as before, CP655 significantly reduced CD4+ T cell 
proliferation as compared to untreated cells as well as CP655OMe treated 









4.3.3 Quality analysis for isolated RNA 
 
In order to ensure reliable and valid results of gene expression, good quality 
RNA was required throughout the experimental process to guarantee 
successful hybridization and reliable results, as a result of this the quality and 
quantity of the RNA being used was carefully assessed. The concentration 
and quality of the RNA sample was assessed by using the Agilent 
Bioanalyzer. RNA from each of the five samples was isolated as per the 
Qiagen protocol described earlier. The results from the Agilent Bioanalyzer 
were used to ascertain the quantity of RNA in each sample and also to 
maintain a consistent quality of the RNA before it was used for micro-array 




















Figure 4.3: Quality Check of RNA for whole-genome micro-array. CD4+ cells were isolated 
from fresh blood of a healthy donor. Cells were left either unstimulated or stimulated with 1:20 
anti-CD3/CD28 beads in the presence of absence of 5µM CP655 or 5µM CP655OMe. After 
18hours of culture, RNA was extracted as per Qiagen protocol. Quality of RNA was assessed by 








The quality of the RNA was assessed using the RIN scores generated by the 
Bioanalyzer for each sample. The software provides a score between 1 to 10 
for each sample, with 10 denoting good quality and fully intact RNA, and a 
score of 0 indicating inferior quality, degraded RNA.  
The results for each sample used in this microarray showed a RIN score of 
greater than 9, indicating good quality and intact RNA, which was then used 
to conduct the micro-array. 
 
4.3.4 Statistical significance testing 
 
Since the aim of this experimental set-up was to assess whether treatment 
with CP655 or CP655OMe has any significant effect on the expression levels 
of various genes between 5 different individuals, it was decided to conduct a 
two-way analysis of variance (ANOVA) using Methods of Moments. This 
process helped in the identification of genes that were being differentially 
expressed when compared between CP655 treated, CP655OMe treated or the 
untreated cells. ANOVA compares the average gene expression level across 
all biological replicates of the chelator treated cells to the average gene 
expression level for control treated cells. 
 
4.3.5 Selecting differentially expressed genes 
For the experimental set-up described in this chapter, the genes that were 
classed as being differentially expressed were genes whose expression levels 
varied between cells treated with the chelator, CP655, as compared to cells 
treated with control compound, CP655OMe. Initially, genes showing a 
change of 1.2 folds, either up-regulated or down-regulated, with an 
unadjusted p value of less than 0.05 were selected, but these criteria produced 
a relatively limited list of 213 genes only. Additionally, several genes within 
this list were unknown genes. Therefore, in order to increase the scope of 
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genes being analysed, the criteria was expanded to include genes showing 
change in expression levels of 1.0 fold, either up-regulated or down-regulated 
and with a p value of less than 0.05. 
 
Normally, biologically meaningful changes in expression levels is considered 
to be 2-fold or more in assays such as Western blot and RT-PCR. However, 
no such specification exists for micro-array data. Therefore, since fold 
changes observed overall in this experiment were low, it was decided to focus 
on genes that were significantly modulated after CP655 or CP655OMe 
treatment. 
  
4.3.6 Heat Map and Principal Component Analysis (PCA) 
 
The results obtained from the whole genome micro-array produced a list of 
33297 genes in the first instance. The list of genes was generated based on 
the expression of differentially modulated genes following CP655 and 
CP655OMe treatment, with an unadjusted p value of less than 0.05 in each of 









Figure 4.4: Hierarchical clustering for genes differentially changed (p<0.05) on treatment 
with CP655 in comparison to CP655OMe: Cells from five individual donors were either left 
unstimulated or stimulated with anti-CD3/CD28 beads and left untreated or treated with 
eitherCP655 or CP655OMe for 18 hours. Extracted mRNA was used for microarray 
hybridization and analysis. Heat map prepared by GeneSpring Software shows hierarchical 
clustering using Pearson correlation. Each row represents results from an individual 
microarray chip (n=15) showing three treatment conditions for each of the five donors. Each 
column represents an individual gene. Genes have been clustered according to similarities in 
patterns of expression as shown by the horizontal axis, as well as, by treatment condition in 
the vertical axis. Treatment conditions are colour coded with red showing CP655 treated 
cells, Orange bar showing CP655OMe treated and yellow showing Untreated cells. 
Difference in expression level can be distinguished on the heat map based on colour with 
high expression genes in red, intermediate expression in black and low expression genes in 
blue. 
 
Figure 4.4 represents a Heat map which is a visual presentation of the 
changes in gene expression based on specific treatments. A heatmap is 
prepared by clustering the data to identify patterns in expression of altered 
genes. The heatmap in the figure above was generated by unsupervised 
hierarchical clustering of data. This displays genes that have similar or co-
ordinated expression patterns with respect to the specific treatments. Under 
hierarchical clustering genes are organized based on their similarities to each 
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other. This suggests that if the expression of two genes is altered at the same 
time due to the same treatment, their co-expression is probably required to 
observe the biological effect. The clustering used here was Agglomerative, 
using Euclidean dissimilarity and average linkage.  
The coloured bar on the left side of the heat map indicates the treatment that 
was provided and each row represents an individual donor. Each coloured 
column on the heat map represents an individual gene that was significantly 
modulated when comparing between CP655 and CP655OMe treated samples. 
The heat map in Figure 4.4 does not take into consideration the unstimulated 
CD4+ T cells. This was because there were too many differentially 
modulated genes when comparing between the unstimulated and the 
CD3/CD28 stimulated samples, as a result of which the effect of the chelator 
and the control was diminished. Therefore, in order to get a clearer picture 
showing the effect of CP655 it was decided to disregard the effect caused 
only due to stimulation of the cells. 
Principal Component Analysis 
The Principal Component Analysis (PCA) is a mathematical algorithm that is 
often used in Micro-array data analysis to illustrate and visually analyse the 
similarities and differences that exist between the samples being tested in 
order to group them together (Ringner, 2008). The algorithm assesses the 
direction along with maximum variation in the data is seen and then plots the 
sample on a 3-dimentional axis. 
The PCA of the data set did not highlight any specific patterns that could be 
used to group the samples together. No specific clustering patterns were 
noticed with differing effects of treatment or even with stimulation. 
However, one of the patterns that were identified showed clustering of the 





Figure 4.5: Principal Component Analysis based on donor differences: mRNA from the 
CD4+ T cells of five healthy controls were used for microarray hybridization and analysis. 
Clustering based on donor-derived differences.  
 
The three donors (HC1, HC2 and HC3) clustered together, all belonged to a 
similar age group (40years - 50years) and were significantly older than the 
two other donors (HC4 and HC5) who belonged to the 20 years – 25 years 
age group. 
Based on the results of the PCA, previous proliferation data was reanalysed 
in order to confirm whether there was a correlation between age of the donor 
and the effect on CP655 treatment on the cells. Proliferation results from 12 
of the donors used previously in the first result chapter, grouped according to 
age, were used to conduct a correlation analysis (Fig 4.6). The donors were 
grouped according to age, with six donors over the age of 40 and six donors 
under the age of 40. Correlation between age and the percentage of inhibition 
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of proliferation after treatment with CP655 was analysed using Spearman’s 
Correlation. 










Exact or approximate P value?

























Figure 4.6: Effect of CP655 based on age of donor (Age-Proliferation Correlation): CD4+ 
cells were isolated from fresh blood of healthy donors. Cells were left either unstimulated or 
stimulated with 1:20 anti-CD3/CD28 beads in the presence of absence of 5µM CP655 for 24 
hours. Proliferation was measured by 3H thymidine incorporation. Spearman’s correlation 
was conducted between age of each donor and percentage of proliferation inhibition for each 
donor. Each dot represents an individual donor (n=12).  
The analysis revealed that there was a significant negative correlation 
between age and level of inhibition caused by the chelator. Therefore, with 
increasing age the extent of CD4+ T cell inhibition caused by the chelator 
was reduced. The average inhibition of proliferation seen in donors below the 
age of 40 was 78.16% (Standard deviation + 15.93%) and that in donors 





4.3.7 Pathway Analysis and Identifying genes of Interest 
 
The list of genes that was generated after the first unsupervised clustering and 
analysis of data contained a large number of unknown genes. This has been 
reported earlier by Yu and Richardson (2011) where they show that 
microarray results after chelation using Dp44mT reveal large number of 
unknown genes on human whole-genome micro-array assays. 
Therefore, in order to uncover specific signalling pathways that may have 
been affected due to the treatment with CP655 or the control CP655OMe, 
Partek and GeneGo software were used to conduct pathway analysis of the 
data generated. However, while there were highly significant changes in gene 
expression when comparing between chelator and control treated cells, the 
fold change values were small. This prevented the software from clearly 
highlighting specific pathways that may have been altered by the treatment 







Figure 4.7: Pie-chart illustrating the most differentially modulated cellular pathways 
between CP655 and CP655OMe treatments: GO-ontology software was used to determine 
pathways to which most of the differentially modulated genes belonged. Maximum 
percentage of modulated genes belonged to Cell Signaling pathways (31.97%) followed by 
genes controlling developmental processes (19.83%). The top five pathways have been 
shown in the figure.  
 
The initial results from the pathway analysis showed that the pathway most 
affected by the treatment with CP655 as compared to CP655OMe was the 
cell signaling pathway, comprising of almost 32% of the total pathways 
affected. The second and third most affected pathways were those controlling 
cell developmental processes and cell killing pathways respectively (Fig 4.7). 
However, the analysis of the initial list of genes generated was unsuccessful 
in highlighting any statistically significant specific pathways. Therefore, the 
literature was consulted to uncover genes that may be modulated by altering 
intra-cellular iron levels using different iron chelators. A review of the 
literature on iron regulation and inflammation, and cross-linking it to the 
initial list of genes significantly modulated by chelator versus control 
treatment and fold change of 1.0, up-regulated or down-regulated, led to the 
identification of 20 genes of interest. These genes have been linked to iron 
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regulation, iron metabolism and inflammatory processes within the human 
body and were also found to be significantly changed in the results of our 





























    




Initiation of DNA replication 
and ensures complete replication 
of DNA before mitosis. It is 
found to be localized in the 
nucleus in G1 phase of the cell 
cycle. 
Interacts with 4, iron 4, sulphur 






Plays a role in carcinogenesis by 
potentially regulating the cell 
cycle. Knockdown of DLGAP5 
inhibits cell proliferation by 
increasing p53 (Kuo et al, 2012). 
Gene-Ontology Molecular 
functions includes iron binding 
(ncbi, gene database) 
CLSPN Claspin -1.1209 
 
Required for cell cycle 
progression and movement 
through S-phase (Broderick et 
al, 2013). Maintains replication 
fork rates and stability 
(Yoshimura et al, 2011). 




Required for initiation and 
progression of DNA replication, 
by moving ahead of the 
replication fork and unwinding 











Required for cellular iron 
homeostasis. Binds to Iron-
Responsive elements in the 5’ 
and 3’ UTR of Ferritin and 
Transferrin respectively (Kuhn, 
2015). 




Required for the transition from 
G1 to S phase of the cell cycle 
by activating cell dependent 
kinase, CDC2 and other cell 














E3-ubiquitin ligase that controls 
the progression of cells through 
G1 phase of cell cycle by 
ubiquitination and degradation 







Negative regulator of apoptotic 
processes. Inhibition of NAA35 
causes p53-dependent apoptosis 
(Starheim et al, 2009). 




Regulates and mediates several 
signalling pathways of cell 
growth, apoptosis and immune 
responses in response to BMP1 
(Liu et al, 2014). 
MIR320
A 
MicroRNA 320a -1.0314 
 
Inhibits cellular proliferation and 









ribonucleotides, necessary for 
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synthesis of DNA (Zhou et al, 
2013). 
Dependent on iron for proper 
functioning (Kayyali et al, 
2001). 




Initiation of DNA replication 
and progression of DNA 
replication fork (MacNeill, 
2010). 
 
Table 4.1: List of genes significantly down-regulated on treatment with CP655 showing greater 




















Gene Name Fold 




    
CACNB4 Calcium Channel, 
Voltage-dependent, 
beta 4 subunit 
1.15305 Plays a role in Calcium 
channel functioning by 
controlling G protein 
inhibition (Subramanyam et 
al, 2009). 
CDKN1A Cyclin-Dependent 
Kinase Inhibitor 1A  
1.15253 Blocks cellular proliferation 
by inhibiting cyclin-
dependent kinase activity. At 
low concentrations promotes 
CyclinD-CDK4 complex 
formation and nuclear 
localization, but at high 
concentrations, inhibits 
CyclinD-CDK2/4 activity. 
Can selectively bind to metal 
ions (Yu et al, 2007) 




1.1182 Regulation of growth and 
differentiation via positive 
control of Apoptotic 
pathways. Gene expression 
up-regulated due to growth 
arrest after cellular stress and 
activates stress responses 
(Saletta et al, 2011). 
TNFAIP2 Tumour Necrosis 
Factor Alpha-
inducible Protein 2 
1.11122 It is a retinoic acid target 
gene, whose expression is 
induced by TNF-alpha and 
promotes cellular migration 
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in carcinomas (Chen et al, 
2011). 
TGFB1 Transforming Growth 
Factor, beta 1 
1.06621 Mature protein regulates 
cellular proliferation, 
adhesion, migration and 
differentiation. Frequently 
up-regulated in several 
tumour cells (Xu et al, 2007). 
CDCA4 Cell Division Cycle 
Associated Protein 4 
1.03991 Regulation of cell division 
and cell proliferation via 
E2F/RB pathway. 
Organization of the spindle 
apparatus during pro-
metaphase (Wang et al, 
2008). 
MIR503 Micro-RNA 503 1.03019 Increased expression 
associated with inhibition of 
proliferation and metastasis in 
Hepatocellular Carcinoma 
(Zhou et al, 2013).  
MIR99A Micro-RNA 99A 1.00657 Potentially involved in 
promoting myeloid leukemia 
by promoting proliferation 
and inhibiting apoptosis 
(Zhang et al, 2014). Also 
shown to act as a tumour 
suppressor by inhibiting 
proliferation in bladder 
cancer (Feng et al, 2014). 
 
Table 4.2: List of genes significantly up-regualted on treatment with CP655 with greater than 






Figure 4.8: Hierarchical clustering for genes differentially changed (p<0.05) on treatment 
with CP655 in comparison to CP655OMe: Cells from five individual donors were either left 
unstimulated or stimulated with anti-CD3/CD28 beads and left untreated or treated with 
eitherCP655 or CP655OMe for 18 hours. Extracted mRNA was used for microarray 
hybridization and analysis. Heat map prepared by GeneSpring Software shows hierarchical 
clustering using Pearson correlation. Each row represents results from an individual 
microarray chip (n=15) showing three treatment conditions for each of the five donors. Each 
column represents an individual gene. Genes have been clustered according to similarities in 
patterns of expression as shown by the horizontal axis, as well as, by treatment condition in 
the vertical axis. Treatment conditions are colour coded with red showing CP655 treated 
cells, Orange bar showing CP655OMe treated and yellow showing Untreated cells. 
Difference in expression level can be distinguished on the heat map based on colour with 









The new list of 20 genes indicated that a large proportion of genes that were 
being differentially modulated were genes controlling for cell proliferation, 
growth and differentiation. Several cell cycle proteins, cyclinsand cdk 
inhibitors were amongst the genes significantly modulated by CP655 
treatment. These results were in accordance to the data discussed in the 
previous chapter where it was seen that the most prominent effect of chelator 
treatment was on inhibition and suppression of cell proliferation.  
Even though, the genes identified in this list showed a relatively modest fold 
change after treatment with CP655, the changes across the five donors tested 
were highly significant on treatment with CP655.  
Based on the indications provided by the microarray data, functional studies 
to look at the cell cycle block caused by CP655 in purified CD4+ T cells 
were conducted, and some of genes short-listed from this microarray data 















4.4  DISCUSSION AND CONCLUSION 
 
The main objective of this chapter was to use microarray analysis to identify 
specific pathways and genes that may be the target of CP655 and play a role 
in its mechanism. A microarray analysis on purified CD4+ T cells 
stimulated with anti-CD3/CD28 beads and treated with either the chelator, 
CP655 or the control compound, CP655OMe was considered to be ideal for 
discerning the specific genes or pathways that are getting modulated 
differentially due to treatment.  
To begin with, it was essential to identify the time point that would be most 
suitable for conducting the microarray and in which the most constructive 
results could be obtained. Stimulated CD4+ T cells with either CP655 or 
CP655OMe were kept in culture for various time points from 4 hours to 48 
hours. At each of the time points, proliferation was assessed by 3H-
Thymidine incorporation. The results indicated that, although a trend towards 
reduced proliferation after CP655 treatment began to emerge from as early as 
4 hours post stimulation and treatment, significant levels of proliferation and 
differences between treatments were observed only 18 hours onwards. 
Therefore, based on this 18 hours was chosen as the time point to conduct the 
microarray analysis on CD4+ T cells. 
The initial analysis of the micro-array results revealed that while there were 
highly significant changes in differentially expressed genes, the extent of the 
change that is indicated by the fold change were small. Another observation 
that was made during the initial analysis of the results was that there were a 
large number of unknown genes, and pseudo genes of no known function that 
appeared in the list of significantly modulated genes. A similar problem was 
reported by Yu and Richardson (2011) in a microarray conducted to study the 
role of cellular iron depletion using Dp44mT iron chelator. They showed that 
the majority of the genes significantly altered after treatment with Dp44mT 
were of unknown functions and they were unable to identify their molecular 
interactions. Several other studies in the past studying the effect on iron 
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chelation on various cellular and molecular processes via microarray analysis 
have revealed that the majority of the genes that are up-regulated on 
treatment with chelators are of unknown origin (Ducey et al, 2005; Saletta et 
al, 2010; Hernandez-Prieto et al, 2012).  
With the reassurance that the presence of large number of unknown genes in 
the list of differentially expressed genes was not an anomaly with the data, 
Principal Component Analysis (PCA) and pathway analysis was conducted to 
identify any overlying patterns and trends in the data. The pathway analysis 
showed that genes most significantly modulated belonged to cell signalling 
and cellular developmental pathways. A further analysis by KEGG pathway 
analysis and Gene-GO analysis revealed that the three most modulated 
pathways were Immune responses via the NKG2D signalling pathway, the 
Pyruvate metabolism pathway and the Immune responses in T cells pathway. 
However, due to the extremely low levels of fold change in the data set, none 
of these analyses revealed any significant patterns or pathways that could 
provide a concrete indication regarding the mechanism of the iron chelator. 
Therefore, from the initial list of genes a new list was generated that included 
only those genes that were significantly modulated between CP655 and 
CP655OMe treated samples with a fold change of at least 1 fold or more. 
This time instead of relying on pathway analysis software, it was decided to 
conduct a manual search on the genes and the various pathways that they 
belonged to and correlate them to a review of the literature to identify genes 
of interest.  
The main role played by iron in cellular signalling processes is concentrated 
around its control of the cell cycle and apoptotic pathways (Lewis et al, 1998; 
Darnell and Richardson, 1999; Deb et al, 2009). Saletta et al (2011) 
compared the effect of two different iron chelators and also demonstrated that 
the main pathways that seem to be differentially modulated by iron chelation 
were those controlling cellular proliferation, cell cycle and apoptosis. These 
results were encouraging as they corroborated the effect on inhibition of 
proliferation that had been observed in experiments conducted in this study. 
A review by Templeton and Liu (2003) suggested that due to the essential 
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role played by iron in cellular processes, changes in intracellular 
concentration of iron can result in a large number of changes in cellular, 
metabolical and physiological pathways. Although there is increasing 
evidence to suggest that the changes in cell cycle and cellular proliferation 
are one of the most prominent effects of cellular iron depletion. Gao and 
Richardson (2001) compared the effects of two iron chelators, DFO and 311, 
on a human neuroepithelioma cell line and showed that both were able to 
cause significant alterations in the expression of cell cycle regulators such as 
cyclin D1, D2, D3, cyclin A, cyclin B1, and phosphorylation of Rb. Also, 
they showed an increase in mRNA levels of p21 and GADD45G. Le and 
Richardson (2002) reviewed the various studies conducted on the role of iron 
in cell proliferation and division and concluded that the regulation of critical 
cell cycle molecules such as p21, p53, N-myc and c-myc by intra-cellular 
iron levels makes iron chelators a vital and effector anti-tumour tool.  
Another observation that was made while comparing the data to the literature 
on microarray analysis after iron chelation showed that several studies 
conducted the microarray at least 24 hours after the cells had been stimulated 
and treated with their respective iron chelators (Saletta et al, 2010; Yu and 
Richardson, 2011). Therefore, it was possible that the 18 hour time point 
chosen to conduct the microarray in this study was too early to visualize any 
significant changes in the expression of the genes of interest. Additionally, as 
seen in the previous chapter, the time point at which significant suppression 
of proliferation was observed varied based on method that was used. This 
discrepancy with the time point could be a reason for why the fold changes 
seen in the microarray experiment were smaller than expected. 
A review of the list of genes differentially modulated between CP655 and 
CP655OMe showed that out of the 20 most significantly modulated genes, 5 
genes were of unknown function, and out of the remaining 15 genes, 8 genes 
(CUL3, CENPO, TNFAIP2, ANAPC1, MAP3K8, MCM3, C10orf90 and 
DNMT3A) belonged to various pathways controlling cell cycle, DNA 
replication and cell proliferation. Additionally, it was also observed that there 
were several cyclins (cyclin F, cyclin B3, cyclin E1, cyclin B1), Cell 
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Division Cycle proteins (CDC25A, CDCA5, CDC16, CDC6) and CDK 
proteins (Cdk20, Cdk1, Cdk5) that were in the list of highly significantly 
modulated genes. This reinforced the information gathered from the literature 
suggesting the essential requirement of iron for cell cycle progression and its 
subsequent inhibition following iron depletion.  
In order to move ahead with the analysis, a list of 20 genes, 12 down-
regulated and 8 up-regulated genes was prepared, based on the literature and 
indications from the data so far. This list consisted of cell cycle proteins 
(CDC6, CDC25A, ANAPC1, CDKN1A, NAA35 and CDCA4), miRNAs 
(miRNA 320A, miRNA 99A and miRNA 503), genes involved in DNA 
replication (RRM1, GINS3, GINS4, CLSPN), genes involved in 
carcinogenesis and tumorigenesis (DLGAP5, GADD45G, TGFB1, 
TNFAIP2).  
Since it was beyond the scope of this study to analyse each of the 20 genes 
identified in order to determine which of these might be a potential target of 
the chelator CP655 and help point out a mechanism of action for the chelator, 
it was decided to further narrow down this list of genes and validate their 
expression by other techniques such as RT-PCR and Western Blotting. The 

































BIOLOGICAL VALIDATION OF MICROARRAY DATA  
 
5.1  INTRODUCTION 
 
Iron is essential for cell proliferation and viability and it is well established that 
disrupting the iron uptake and metabolism of cells can be harmful for the cells, 
causing cell cycle arrest (Bowlus, 2003). This indispensable role played by iron 
in cell growth and division has been exploited by the use of iron chelators whose 
anti-proliferative activity has been found to be beneficial for treating not only 
iron overload diseases but also for controlling tumour growth and excessive cell 
proliferation (Yu et al, 2006; Munoz et al, 2009) 
The following chapter aims to identify the mechanism of action of the iron 
chelator CP655. The results of the previous chapter highlighted that the main 
pathways as well as the main molecular targets of CP655 treatment were those 
controlling various aspects of the cell cycle. The chapter will begin by 
confirming the results of the microarray by conducting functional studies for 
assessing cell cycle progression in the presence of CP655. Genes that will be 
shortlisted from the microarray will then be validated by RT-PCR.  
As the most prominent effect of CP655 treatment was seen on the inhibition of 
proliferation, this chapter will then examine the effect of CP655 on one of the 
main pathways that control cell proliferation and growth – the IL-2 pathway. The 
chapter will aim to determine the effect that addition of exogenous IL-2 can have 
on CP655 or CP655OMe treated cells, in order to determine whether inability to 
respond to IL-2 stimulus could be one of the possible mechanisms of action of 
CP655. Following this, the effect of iron chelation on the down-stream molecules 
of the IL-2 pathway, STAT5, will be examined as another potential mechanism 
of action for CP655. 
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5.2 CHAPTER OBJECTIVES 
 
Based on the discussion above the specific aims for this final results chapter are 
as below: 
 
(a) Conducting functional analysis of cell cycle progression in CD4+ T cells 
(b) Validating genes short-listed after micro-array analysis and cell cycle studies 
(c) Elucidating potential mechanisms for CP655 action 
(i) Mechanism 1 – Effect of CP655 on cell cycle proteins 




















5.3.1 Effect of CP655 on cell cycle of Jurkat and human CD4+ T cells 
 
Analysis of the results obtained from the previous chapter highlighted that 
the genes which were most significantly modulated by CP655 treatment 
mostly belonged to pathways controlling cell cycle progression. In order to 
confirm the results obtained from the micro-array, it was essential to be able 
to replicate the results in a functional cell cycle assay. 
To begin with based on a study by Gharagozloo et al (2008) analysing the 
effect of iron chelator Silybin on cell cycle, Jurkat cells were cultured from 
24 hours - 72 hours either untreated or in the presence of CP655 or the 
control compound CP655Ome. At each time point, the nuclear material was 
stained with Propidium Iodide and analysed on the flow cytometer. After 24 
hours of culture, there was no difference in the cell cycle profile of the 
untreated or the chelator and control treated cells. The G1, S and G2/M phase 
of the cell cycle had the same percentage of cells under all the three treatment 
conditions (Fig 5.1 A, Fig 5.2 A). 
However, after 48 hours of culture, treatment with CP655 perturbed the 
normal cell cycle of the Jurkat cells. The percentage of cells in the G1 stage 
was significantly reduced in the cultures that were treated with CP655 but not 
in those that were treated with CP655OMe. Also, the percentage of cells in 
the S stage was significantly and consistently enhanced in the chelator treated 
cultures as compared to both the untreated and the control treated cells. A 
similar pattern was also observed 72 hours after culture (Fig 5.1 B, C; Fig 5.2 












Figure 5.1: Cell cycle arrest of Jurkat cells: Jurkat cells were either left untreated or treated 
with either 5µM CP655 or CP655OMe from 24 hours – 72 hours. Cells were lysed with cold 
100% ethanol and stained with Propidium Iodide and Ribonuclease A, before analysing the 
cells by flow cytometry. (A) 24 hours post cell culture. (B) 48 hours post cell culture. (C) 72 
hours post cell culture. FACS results from one representative experiment. 
(A) 
Untreated CP655 treated CP655OMe treated (B) 
Untreated CP655 treated CP655OMe treated 
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Figure 5.2: Cumulative data showing cell cycle arrest of Jurkat cells: Jurkat cells were 
either left untreated or treated with either 5µM CP655 or CP655OMe from 24 hours – 72 
hours. Cells were lysed with cold 100% ethanol and stained with Propidium Iodide and 
Ribonuclease A, before analysing the cells by flow cytometry (A) 24 hours post cell culture. 
(B) 48 hours post cell culture. (C) 72 hours post cell culture. ** p<0.01 calculated using 









Having successfully shown the effect of CP655 on altering cell cycle of 
Jurkat cells, the next step was to replicate the results using primary CD4+ T 
cells isolated from PBMCs of healthy donors to confirm whether a similar 
effect of the chelator can be seen in primary human cells. 24 hours after 
stimulation of cells with anti- CD3/CD28 beads, no cycling cells were visible 
via flow cytometry (Fig 5.3 A; Fig 5.4 A). However, after 48 hours of 
culture, cycling cells were visible. Approximately 50% of the stimulated 
CD4+ cells were seen in the G1 phase of the cell cycle. In the cell cultures 
that had been treated with CP655, it was seen that there was a consistent 
trend showing an increase in the percentage of cells arrested in the G1 phase. 
This led to a reduction in the percentage of cells entering the S phase, and a 
subsequent significant reduction in the percentage of cells present in the 
G2/M phase of the cell cycle. As previously seen, this effect was found only 
in cell cultures that had been treated with the iron chelator CP655 and not 
with the control compound CP655OMe, which consistently showed a profile 
similar to that of the untreated cells (Fig 5.3 B; Fig 5.4 B). The same trend 




















Figure 5.3: Cell cycle arrest of primary CD4+ T cells: CD4+ T cells were isolated from fresh 
PBMCs of healthy donors. Cells were either left unstimulated or stimulated with 1 : 5 bead: cells ratio 
of anti-CD3/CD28 beads in the presence or absence of either CP655 (5µM) or CP655OMe (5µM). 
Cells were lysed with cold 100% ethanol and stained with Propidium Iodide and Ribonuclease A, 
before analysis by flow cytometry. (A) 24 hours post cell culture. (B) 48 hours post cell culture. (C) 
72 hours post cell culture. Graphs represent FACS results from one representative experiment. 
(A) 
Untreated CP655 treated CP655OMe treated 
(B) 
(C) 
Untreated CP655 treated CP655OMe treated 
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Figure 5.4: Cumulative data showing cell cycle arrest of primary CD4+ T cells: CD4+ T cells were 
isolated from fresh PBMCs of healthy donors. Cells were either left unstimulated or stimulated with 
1:5 bead: cells ratio of anti-CD3/CD28 beads in the presence or absence of either CP655 (5µM) or 
CP655OMe (5µM). Cells were lysed with cold 100% ethanol and stained with Propidium Iodide and 
Ribonuclease A, before analysis by flow cytometry Cumulative results from n=4 donor. (A) After 
24hours of culture. (B) After 48 hours of culture. (C) After 72 hours of culture. * p<0.05 calculated 










These results corroborated the indications that were provided by the 
microarray data, confirming that CP655 treatment was indeed interfering 
with the normal progression of the cell cycle. The analysis revealed that 
CP655 was causing a block in the G1/S phase of the cell cycle. In order to 
decipher the mechanism that CP655 was using to cause this block it was 
decided to once again conduct a detailed review of the literature and 
correlate the findings with the list of 20 genes developed at the end of 
microarray analysis. Following this, genes that have been previously 
implicated in the literature for causing a G1/S phase block would be 
identified and used for further validation by RT-PCR.  
 
5.3.2 Quantitative Reverse-Transcription PCR to confirm Micro-array 
Data 
 
To begin with, based on the list of significantly down-regulated and up-
regulated genes compiled in the previous chapter (Table 4.1 and Table 4.2), 
the genes those were chosen for RT-PCR have been detailed in Table 5.1. 
The genes were chosen based on either fold change following CP655 
treatment or on the level of significance of differentially modulated genes. 
These were then correlated with literature and five genes were short-listed 
for analysis by RT-PCR.  
The five genes highlighted for detailed analysis were CDC6, ANAPC1, 
RRM1, CDKN1A and GADD45G (Table 5.1). The table highlights the 
detailed functions of each of the five genes selected for further analysis. The 
main pathways that are linked to each of the genes have also been indicated. 
It is evident that all the genes that were selected belonged to the same 







NAME FUNCTION PATHWAY 
(KEGG Pathway 
Database) 




1. Initiation of DNA 
replication  
2. Ensures complete 
replication of DNA 
before mitosis 
1. Cell cycle 
2. Regulation of 
DNA 
replication 




Inhibitor 1A  
(a.k.a p21) 





2. At low concentrations 
promotes CyclinD-CDK4 
complex formation and 
nuclear localization 
3. At high 
concentrations, inhibits 
CyclinD-CDK2/4 activity 
4. Can selectively bind 
to metal ions 

















1. E3-ubiquitin ligase 
that controls the 
progression of cells 
through G1 phase of cell 
cycle by ubiquitination 
and degradation of target 
proteins 




















1. Synthesis of deoxy-
ribonucleotides from 
ribonucleotides, 


















1. Regulation of growth 
and differentiation via 
positive control of 
Apoptotic pathways 
2. Gene expression up-
regulated due to growth 
arrest after cellular stress 
and activates stress 
responses 






Table 5.1: Genes for validation by RT-PCR 
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One of the possible explanations regarding why the micro-array experiment 
yielded small fold-change levels was that the time point chosen for analysis, 
18 hours, may have been either too early or too late due to which the peak 
of gene expression had not been captured in the single experiment. In order 
to ensure that the changes over time can be identified, RT-PCR experiments 
were conducted over several different time points.  
Five individual donors were selected to conduct the RT-PCR analysis, out 
of which one of the donors was the same as that used in the initial 
microarray analysis. The isolated cells were either left unstimulated or 
stimulated with anti-CD3/CD28 beads for 4-48 hours in the presence of 
either CP655 or CP655OMe and RNA extracted from the cells as 
previously described. The quality and quantity of the RNA extracted was 
assessed using Nanodrop, and was reconfirmed by checking the RIN score 
obtained from the Agilent 2100 Bioanalyzer. The RNA is given a score of 
between 1 to 10 for each sample, with 10 denoting good quality and fully 
intact RNA, and a score of 0 indicating bad quality, degraded RNA. Score 
for all the samples used in this experiment showed a RIN score of greater 
than 9, indicating good quality and intact RNA 
Once the quality and quantity of RNA was established it was converted into 
cDNA by the procedure described earlier (Section 2.12). The cDNA was 
used for RT-PCR on a TaqMan based detection system on a ViiA™ 7 Dx 
Real-Time PCR instrument (Life technologies). The relative levels of 
mRNA expression for each target gene were calculated by normalizing it to 
the relative expression of house-keeping gene, 18s mRNA levels in the 
respective sample.  
Initially, RT-PCR was conducted on the time points ranging from 4 -12 
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Figure 5.5: Effect of CP655 and CP655OMe on mRNA expression levels of genes: CD4+ T cells 
were isolated from fresh PBMCs of healthy donors. Cells were either left unstimulated or stimulated 
with 1:20 bead: cells ratio of anti-CD3/CD28 beads in the presence or absence of either CP655 (5µM) 
or CP655OMe (5µM) for 4 hours, 7 hours or 12 hours. At each time point, RNA was extracted from 
the cells and used for RT-PCR. Gene expression levels were normalized to 18s mRNA level. The 
results represent fold change in expression level relative to control (Dotted line), which is the 







The results were normalized to the samples that were not stimulated with anti-
CD3/CD28 beads and had been left untreated. The relative change in mRNA 
expression was calculated by taking mRNA expression of the control samples as 1. 
The results indicated that each of the genes chosen for analysis showed a wide range 
of expression levels, over the different time points tested, as well as between 
individual donors. It was also evident that there were large inter-sample variations in 
the expression levels of the chosen targets, which can be seen by the large range of 
the Standard Error of Mean (SEM) (Fig 5.5). As a result of this, no significant 
changes were seen on treatment with either the chelator or the control compounds. 
The low levels of fold change of each of the genes can be attributed to the low levels 
of proliferation that are visible during the first 12 hours of cell culture. As shown by 
the proliferation data in the previous chapter, a significant effect of CP655 on cell 
proliferation becomes visible only 18 hours post stimulation and treatment.  
Since no significant observations were made in the initial three time points the 
analysis of the target genes was continued at the three later time points that is from 
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Figure 5.6: Effect of CP655 and CP655OMe on mRNA expression levels of genes: CD4+ T cells 
were isolated from fresh PBMCs of healthy donors. Cells were either left unstimulated or stimulated 
with 1:20 bead: cells ratio of anti-CD3/CD28 beads in the presence or absence of either CP655 (5µM) 
or CP655OMe (5µM) for 18 hours, 24 hours or 48 hours. At each time point, RNA was extracted 
from the cells and used for RT-PCR. Gene expression levels were normalized to 18s mRNA level. 
The results represent fold change in expression level relative to control (Dotted line), which is the 




The results indicated that the mRNA expression levels for CDC6 showed a 
consistent increase through all the time points, even in cultures that were 
treated with CP655. Similarly, RRM1 mRNA expression levels were also 
increased and did not support the data so far. As compared to the relative 
expression of mRNA levels for CDKN1A at the earlier time points, there 
was a gradual increase in the mRNA levels at the three later time points 
measured. In fact, the last time point of 48 hours showed more than 5-time 
increased fold change in CDKN1A mRNA expression. However, as 
previously noticed, no significant differences in mRNA levels were seen on 
treatment with either the chelator or the control. Although, it was observed 
that while most of the target genes showed a gradual increase in mRNA 
expression levels, CDKN1A was the only candidate where expression levels 
were dramatically increased from 24 hours to 48 hours for each of the 
treatment conditions. Furthermore, at 48 hours, the most prominent increase 
in CDKN1A mRNA expression was observed in the group that had been 
treated with the chelator CP655 as compared to the untreated as well as the 
CP655OMe treated conditions. 
ANAPC1 and GADD45G mRNA expression levels were similar to those 
observed in the earlier 4 hour – 12 hour time points, and no significant 
patterns or trends were observed. 
Therefore, keeping in mind the previous results obtained from micro-array 
analysis along with the results of the RT-PCR, the gene that had so far been 
most consistent in its expression trend was CDKN1A (p21). As a result of 
this, it was decided to focus further analysis on this gene in order to 







5.3.3 Effect of CP655 on cell cycle inhibitor, CDKN1A (p21) 
 
Based on the results of the microarray and RT-PCR, the protein that has so far 
been consistently modulated by CP655 was the cell-dependent kinase inhibitor 
CDKN1A (p21). Therefore, in order to confirm whether CP655 was able to 
modify the expression of p21 at the protein level the protein expression was 
analysed by western blot. 
 
Initially Jurkat cells were used to look at the protein expression of p21. This was 
based on the proviso that since Jurkat cells are continuously dividing cancer cell 
lines, their expression of cell cycle proteins will be prolonged in comparison to 
primary cells which show cell cycle protein expression following stimulation and 
only for short periods of time. Jurkats were either left untreated or treated with 
either the chelator or the control for 1-48 hours before being lysed and used for 





Figure 5.7: Effect of CP655 treatment on p21 protein expression in Jurkat cells: Jurkat 
cells were either left untreated or treated with CP655 (5µM) or CP655OMe (5µM). After 
4hours of culture, p21 expression was analysed by western blot. (A) Results from one 
representative experiment. (B) *p<0.05, calculated using student’s paired t-test. Results 
represented as Mean + SEM from n=3 different cultures. 
 
The western blot experiments clearly demonstrated that CP655 was successful in 
significantly up-regulating proteins expression of p21 in RNA from jurkat cells. 
This was in accordance to the microarray as well as RT-PCR data, showing 
increased expression of p21 mRNA. Although, Fu and Richardson (2007) show 
that iron chelation decreases p21 protein levels, due to ubiquitin-independent 
degradation pathways, the results of this study were able to consistently 






The next step was to replicate the above results on primary CD4+ T cells and 
determine the effect of CP655 treatment the expression level of p21 in these 
cells (Fig 5.8). 
 
Figure 5.8: Effect of CP655 treatment on p21 protein expression in primary cells: CD4+ T 
cells were isolated from PBMCs of healthy donors and either left unstimulated (USUT) or 
stimulated with anti-CD3/CD28 beads (1:20) in the presence or absence of either CP655 
(5µM) or CP655OMe (5µM). After 4hours of culture, p21 expression was analysed by 
western blot. (A) Results from one representative experiment. (B) Results represented as 
Mean + SEM from n=4 individual donors. 
 
Similar to the observations made using Jurkat cells, treatment of primary 
CD4+ T cells with CP655 also resulted in an increased expression of p21 
protein at 4 hours post treatment. The increase was not found to be 
significantly more than the control CP655OMe treated or the untreated cells, 
but this may be due to the wide spread of expression level between donors 





Therefore, based on the results of the western blot experiments it was 
confirmed that one of the mechanisms via which CP655 was exerting its anti-
proliferative effects on CD4+ T cells, was its ability to up-regulate the cell 
cycle inhibitor, p21, hence causing a block in the cell cycle at the G1/S phase 
as demonstrated. 
5.3.4 Effect of CP655 and CP655OMe treatment on IL-2 pathway and its 
downstream target molecules 
 
The results obtained so far show that the main effect of the chelator was on 
inhibition of proliferation. This was further confirmed in the previous section 
where it was demonstrated that an increased expression of p21 was 
responsible for the G1/S block of the CD4+ T cells.  
In order to uncover other mechanisms that could be used by CP655 to cause a 
block in cell proliferation it was decided to look into the IL-2 pathway, which 
is one of the main pathways controlling cell proliferation. The cytokine IL-2 
is essential for T cell development and proliferation and is produced mostly 
by CD4+ cells that have been activated by antigen stimulation. An important 
aspect of IL-2 is its ability to upregulate the expression of its own receptors 
by signalling in a positive feedback loop, which is essential for the 
differentiation of activated cells. Hence, not only is the production of IL-2 
important for the proliferation of cells, but the ability of these cells to respond 
to IL-2 is also important for them to be able to differentiate (Busse et al, 
2010).  
To begin with, the ability of the antigen activated CD4+ T cells to respond to 
exogenous IL-2 in the presence or absence of the iron chelator CP655 was 
analysed. CD4+ and CD14+ cells were isolated from PBMC’s of healthy 
donors. The cells were co-cultured in a ratio of 2:1 (CD4+:CD14+), and 
either left unstimulated or stimulated with the antigen, Tetanus Toxoid. The 
co-cultures were then left untreated or treated with either CP655, CP655 
along with recombinant human IL-2 or just recombinant human IL-2 by 
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itself. Proliferation and cytokine production was measured from these cells 









































2 5 0 0
3 0 0 0
3 5 0 0
4 0 0 0
4 5 0 0
5 0 0 0
*  p = 0 .0 1





































































1 0 0 0
1 2 5 0
1 5 0 0
1 7 5 0
2 0 0 0
2 2 5 0
2 5 0 0
*  p = 0 .0 1











































































































1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
3 0 0 0
4 0 0 0
5 0 0 0
































































1 0 0 0
2 0 0 0
3 0 0 0


















































1 0 0 0
1 5 0 0
2 0 0 0













Figure 5.9: Effect of exogenous IL-2 on CP655 treatment: CD4+ T cells and CD14+ monocytes 
were isolated from fresh PBMCs of healthy donors. Cells were stimulated with Tetanus Toxoid in 
the presence or absence of either CP655 (5µM), CP655 with 100IU of rhIL-2 or just 100IU of rh 
IL 2.  After 6 days of culture, proliferation was measured by tritiated thymidine incorporation and 
cytokine production by ELISA. (A-C) Results from one representative donor after 6 days of 
culture. (D-F) Cumulative data from n=5 individual donors. *p<0.05 and ** p<0.01, calculated 
using student’s paired t-test. Results represented as Mean + SEM. 
  
 
(A) (B) (C) 
(D) (E) (F) 
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Results indicated that treatment of the cells with CP655 led to reduced 
proliferation and inflammatory cytokine production from the cell cultures as 
previously seen. The addition of exogenous recombinant-human IL -2 was 
able to overcome the suppression caused by CP655, and in fact in some of 
the donors tested, the cytokines produced were almost as high as those 
produced by cell cultures stimulated only by tetanus toxoid and IL-2. The 
experimental set-up described above was then repeated in the presence of the 
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 Figure 5.10: Effect of exogenous IL-2 on CP655 and CP655OMe treatment: CD4+ T cells 
and CD14+ monocytes were isolated from fresh PBMCs of healthy donors. Cells were 
stimulated with Tetanus Toxoid in the presence or absence of either CP655 (5µM), 
CP655OMe (5µM), CP655 with 100IU of rhIL-2 or just 100IU of rh IL 2.  After 6 days of 
culture, proliferation was measured by tritiated thymidine incorporation. Results shown as 





As seen previously, treatment with CP655 led to a significant decrease in the 
proliferation of cells as compared to untreated cells as well as the cells 
treated with CP655OMe. Addition of exogenous IL-2 to cells treated with 
CP655 was able to significantly overcome the inhibition of proliferation. 
Exogenous IL-2 added to CP655OMe containing cells further increased their 
proliferative response. These results suggested that treatment with CP655 
does not alter the ability of cells to respond to exogenous IL-2, but may be 
interfering with their ability to produce IL-2. Also, this supported the 
previous claim that treatment with the iron chelator does not cause any 
toxicities in the cell cultures and the cells retain their ability to mount a 
response to exogenous stimuli. 
However, it was interesting to observe that when the same experimental set-
up was repeated with only CD4+ T cells stimulated using anti-CD3/CD28 
beads, the addition of exogenous IL-2 was unable to overcome the 
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* *  p = 0 .0 0 1
* *  p = 0 .0 0 1
* *  p = 0 .0 0 1
Figure 5.11: Effect of exogenous IL-2 on CP655 and CP655OMe treatment: CD4+ T cells 
were isolated from fresh PBMCs of healthy donors. Cells were stimulated anti-CD3/CD28 
beads in a ratio of 1:20, in the presence or absence of either CP655 (5µM), CP655OMe 
(5µM), CP655 with 100IU of rhIL-2 or just 100IU of rh IL 2.  After 24hours of culture, 
proliferation was measured by tritiated thymidine incorporation. Results shown as Mean + 
SEM from n=3 individual donors. ** p<0.01, ***p<0.001 calculated using paired t-test. 
 
The reason behind this could be the presence of CD14+ monocytes in the 
previous cell culture. Monocytes can be activated by IL-2, therefore it is 
possible that the revival of proliferation seen is due to the CD14+ monocytes 
being activated on exogenous IL-2 addition. Additionally, this study has 
previously shown that CD14+ monocytes are not affected by CP655 
treatment, the main targets of which are CD4+ T cells. Therefore, when only 
CD4+ T cells were present in culture (Fig 5.11), the addition of exogenous 
IL-2 was unable to overcome the block in proliferation of these cells. This 
demonstrated that CP655 may be interfering with the IL-2 signalling pathway 




To confirm this, the effect of the chelator on the downstream signalling 
molecules of the IL-2 pathway were determined. Aberrations in the signalling 
of IL-2 can affect transcription of several genes that are important for T cell 
activation and proliferation. 
 
Binding of IL-2 to its receptor leads to the activation of several signalling 
pathways. One of these is the JAK3-STAT5 pathway which has been 
implication to play an important role in diseases such as Rheumatoid 
Arthritis (Walker and Smith, 2005). STAT5 plays a role in the transcription 
of genes such as NF-kB, NF-AT and AP-1 (Bromberg and Darnell, 2000).  
Hence, the next set of experiments looked at the effect of CP655 treatment on 
the phosphorylation of STAT5 in stimulated CD4+ T cells. CD4+ T cells 
were isolated from blood of healthy controls. The cells were stimulated with 
anti- CD3/CD28 beads either in the presence or absence of the chelator 
CP655, or the control CP655OMe for three different time points, starting 
from 24 hours - 72 hours. The protein expression for pSTAT5 was 
normalized to the expression of GAPDH in the cell lysates. Results showed 
that there was a small but consistent reduction in the phosphorylation of 
STAT5, 48 hours after stimulation in cells that had been treated with CP655 
as compared to the untreated samples as well as those treated with 
CP655OMe (Fig. 5.13). No significant changes or discernible patterns were 





Figure 5.12: Effect of CP655 treatment on pSTAT5 expression 24 hours post stimulation: 
CD4+ T cells were isolated from fresh PBMCs of healthy donors. Cells were either left 
unstimulated (USUT) or stimulated with anti-CD3/CD28 beads in the presence or absence of 
CP655 (5µM) or CP655OMe (5µM). After 24 hours of culture, pSTAT5 expression was 
analysed by western blot. (A) Results from one representative donor. (B) Data represented as 








Figure 5.13: Effect of CP655 treatment on pSTAT5 expression 48 hours post stimulation: CD4+ T 
cells were isolated from fresh PBMCs of healthy donors. Cells were either left unstimulated (USUT) 
or stimulated with anti-CD3/CD28 beads in the presence or absence of CP655 (5µM) or CP655OMe 
(5µM). After 48 hours of culture, pSTAT5 expression was analysed by western blot. (A) Results from 













Figure 5.14: Effect of CP655 treatment on pSTAT5 expression 72 hours post stimulation: CD4+ 
T cells were isolated from fresh PBMCs of healthy donors. Cells were either left unstimulated 
(USUT) or stimulated with anti-CD3/CD28 beads in the presence or absence of CP655 (5µM) or 
CP655OMe (5µM). After 72 hours of culture, pSTAT5 expression was analysed by western blot. 









These results suggested that the inability of the cells to respond to IL-2 in the 
presence of CP655 as seen in Fig 5.11 could be due to the effect of the iron 
chelator on downstream signalling molecules of the IL-2 pathway such as the 
phosphorylation of STAT5.  
The dysregulated STAT5 signalling in CD4+ T cells, as a result of treatment with 
CP655 is suggested to be another possible mechanism used by the chelator to 
cause inhibition of cell proliferation.  
 
5.3.5 Kinetic Analysis of CP655 and CP655OMe treatment 
An important question while trying to identify the mechanism of action of the iron 
chelator is to determine the most appropriate time point at which the cells must be 
exposed to the chelator for it to exert the effects observed so far.  
In order to address this two different sets of kinetic experiments were set-up. In 
the first set of experiments, isolated CD4+ T cells were pre-treated with either the 
chelator or the control compound for varying lengths of time starting from 2 hours 
- 48 hours. After each time point, the cells were washed out of their respective 
treatments and were then stimulated with anti-CD3/CD28 beads for an additional 
24 hours (Fig. 5.15 A). Additionally, parallel experiments were set up where the 
cells were not washed out of the treatment, but after each treatment time point, 
anti-CD3/CD28 bead stimulation was added directly into the cell cultures for 24 










2 h rs 4 h rs 2 4 h rs 4 8 h rs
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0
U T  U S
S t im u la t e d
C P 6 5 5























2 h rs 4 h rs 2 4 h rs 4 8 h rs 2 h rs 4 h rs 2 4 h rs 4 8 h rs
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0



























Figure 5.15: Kinetics of CP655 Pre-treatment: CD4+ T cells were isolated from PBMCs of 
healthy donors. Cells were pre-treated with either CP655 or the control CP655OMe for the 
indicated time. (A) After each time point, cells were washed and either left unstimulated 
(UTUS) or stimulated with anti-CD3/CD28 in a 1:20 bead: cells ratio for 24 hours (n=4). (B) 
In parallel experiments, cells were either washed out of the treatment or left unwashed for 
each of the time points and then left unstimulated or stimulated with anti-CD3/CD28 bead 
for 24hours. Proliferation was measured by 3H thymidine incorporation. Results are 
expressed as Mean + SEM from n=3 individual donors. ** p<0.01 calculated using paired t-
test. 
 
Results showed that when the iron chelator CP655 and the control compound 
CP655OMe were washed out after pre-treatment in each of the time points, 
no effect on the proliferation of CD4+ T cells was visible. However, in 
contrast, when the cells were not washed out of their respective treatments 





of the chelator or the control, the effect on inhibition of proliferation was 
maintained as seen previously following CP655 treatment.  
These results indicated that it is essential for the chelator to be present at the 
time of stimulation of the cells for it to be able to exert its effects.  
In order to confirm this, a second set of kinetic experiments were conducted 
where isolated CD4+ T cells were first stimulated with anti-CD3/CD28 beads 
in the ratio of 1:20 for different time points, ranging from 2 hours - 48 hours. 
At the end of each time point, either CP655 or the control CP655OMe was 
added to the cell culture and left for an additional 24 hours. Proliferation was 
measured by 3H thymidine incorporation at the end of the 24 hours of 
treatment (Fig 5.16). 
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Figure 5.16: Kinetics of CP655 after pre-stimulation with anti-CD3/CD28 beads: CD4+ T cells 
were isolated from fresh PBMCs of healthy donors. Cells were stimulated with either anti-CD3/CD28 
beads (1:20) for time points ranging from 2 hours to 48 hours. After each time point, cells were either 
left untreated or treated with either the control or the chelator CP655 for 24 hours. UT US = 
Untreated, unstimulated cells. Proliferation was measured by 3H thymidine incorporation. Results are 




Results showed that addition of the iron chelator after stimulation of the cells 
was effective in reducing proliferation of the CD4+ T cells. Even cultures 
where the cells had been stimulated for 48 hours before being treated with 
CP655 and CP655OMe showed significantly reduced proliferation after 24 
hours of CP655 treatment and no effect after CP655OMe treatment. 
This further confirmed the results obtained from the initial set of kinetic 
experiments. The results indicated that another mechanism via which CP655 
could be exercising its effect is by interfering with signalling through the T-
cell receptor. This justified the need for the chelator to be present in the cell 
cultures at the time when the signalling events, post stimulation of the cells, 
are taking place for it to be able to interfere with specific signalling pathways. 
Signalling via the TCR is essential for transcription and production of 
proliferative cytokines such as IL-2. Therefore, the inhibition of proliferation 
of CD4+ T cells could also be attributed to the reduction in IL-2 production 
due to aberrant TCR signalling. This also provides support to previous 
experiments which showed that addition of exogenous IL-2 can restore 













5.4 DISCUSSION AND CONCLUSION 
 
Since review of the literature and analysis of the microarray data discussed in the 
previous chapter revealed that the pathways being affected most by CP655 
treatment were those controlling for various aspects of the cell cycle, it was 
decided to conduct a functional cell cycle analysis of the effect of CP655 on 
primary human CD4+ T cells as well Jurkat cells. This was essential especially in 
order to help narrow down the list of 20 genes short-listed from the microarray 
data and identify genes that could be further validated by RT-PCR and western 
blotting. 
To begin with, the effect of CP655 on Jurkat cells was determined, by using 
Propidium Iodide (PI) staining of the DNA to determine cell cycle profile of the 
cultured cells. Using PI to analyse cell cycle is based on the understanding that 
cells in the S phase of the cell cycle have more DNA than the cells in the G1 
phase of the cell cycle and hence they absorb more PI and have a brighter 
fluorescence. Similarly, cells in the G2 phase will have twice as much DNA as 
the G1 phase since the cells would have doubled their DNA content by this phase. 
Therefore, the cell cycle profile is based on the number of cells and the DNA 
content of the cells to determine their phase (Shapiro, 1988). The analysis was 
conducted at three different time points, 24 hours, 48 hours and 72 hours post 
treatment with CP655 and CP655OMe, to help resolve the issue of the most 
appropriate time point of visualizing modulations in gene and protein expression 
of the cells. Also, a kinetic analysis of the effect of iron chelation was essential to 
establish whether the effect of the treatment is permanent or diminishes over time. 
The results revealed that after 24 hours of culture of Jurkats, a very small 
percentage of cycling cells were present, and most of the cells were still in the G1 
phase of the cell cycle. 48 hours post culture a definite cell cycle profile of the 
cells became visible. Under untreated conditions, around 50% of the cells were in 
G1 phase, 35% cells in S phase and around 15% of total cells in G2 phase of the 
cell cycle. However, the cell cycle profile was dramatically altered on treatment 
with CP655. The transition from G1 to S phase was unclear, and majority of the 
cells seemed to be arrested in between the two stages, or arrested in the S phase. 
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Once again, in accordance with the previous results CP655OMe treatment had no 
effect on the cell cycle profile of the Jurkat cells, which looked the same as the 
untreated control cells. Consistently results showed that CP655 treatment led to a 
block in the G1/S phase of the cell cycle and an arrest of the cells in the S phase 
preventing them from completing their proliferation. Another interesting 
observation that was made was that the effect of the iron chelation was not 
permanent, and the effects began to wear off by 72 hours. Even though, the trend 
and pattern in the cell cycle profile was visible, the results were no longer as 
prominent or significant.  
Previously, experiments using different iron chelators on Jurkat cells showed that, 
although they were all capable of causing a significant block in the cell cycle, but 
they affect different stages of the cell cycle. Also, the effect was seen to be dose-
dependent. Gharagozloo et al (2008) showed that treatment of Jurkat cells with 
Silybin, a plant flavanoid with iron chelating properties, arrested the cells in the S 
phase of the cell cycle. However, when they treated Jurkat cells with DFO, at 
higher concentrations (200µM - 400µM) the cells were arrested in the G1 phase, 
but treatment with lower concentrations of DFO (50µM - 100µM) led to 
accumulation of cells in the S phase of the cell cycle. Others have also shown that 
treatment of Jurkat cell lines with iron chelator results in two separate blocks of 
the cell cycle – one in the early G1 phase and the second one in the S phase 
(Siriwardana and Seligman, 2013).   
Moving on from Jurkat cells, the same experimental set-up was used to analyse 
purified human CD4+ T cells. Similar to what was seen with Jurkat cells, no 
cycling cells were seen in the first 24 hours of culture and most of the cells were 
in the G1 phase. But by 48 hours post stimulation, 60-70% of the cells were in G1 
phase, around 20% in the S phase and the remaining 10-15% in the G2 phase. 
Treatment with CP655 once again significantly altered the cell cycle profile of the 
cells. In contrast to the Jurkat cells, most of the CP655 treated cells could be 
clearly seen to be arrested in the G1 phase, with fewer numbers of cells entering 
the S phase and subsequently, a significantly lower number of cells reaching the 
G2 phase. The results from these functional experiments confirmed the 
indications that developed following the microarray data analysis. As seen 
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previously with Jurkat cells, the effect of the chelator was diminished by 72 
hours, although the trend remained visible. The impact of intracellular iron 
depletion on the cell cycle has been described by few studies in the past. Several 
different iron chelators such as Mimosines, Dp44mT, DFO and Silymarin have 
been shown to be able to arrest cells at the boundary of the G1-S phase in various 
different cell types (Kulp and Vullient, 1996; Gao and Richardson, 2001; Clement 
et al, 2002; Szuts and Krude, 2004). 
The aberrations in the cell cycle caused following iron chelation have been linked 
to the inhibition of the DNA synthesis enzyme Ribonucleotide Reductase (RR), 
which is dependent on iron for its proper functioning (Renton and Jeitner, 1996; 
Kayyali et al, 2001). Bi-dentate chelators such as the HPO chelators used in this 
study have been shown to inhibit the activity of RR faster, by quickly binding to 
the iron molecules in the core of the enzyme, as compared to larger hexadentate 
chelators such as DFO (Abeysinghe et al, 1996; Cooper et al, 1996). This can be 
attributed to the ability of HPO chelators to diffuse faster across cellular 
membranes due to their lower molecular weight and neutral charge (Hoyes et al, 
1992). RR has become a popular target for anti-cancer drugs due to its central role 
in DNA synthesis and replication (Kolberg et al, 2004; Cerqueira et al, 2007; 
Zhou et al, 2013). Ribonucleotide Reductase is made up of two subunits, the 
larger α subunit (RRM1) and the smaller β subunit (RRM2). Both of these 
subunits are required in equimolar concentrations for the enzyme to function 
effectively. Any alterations in either of the subunits can render the enzyme 
inactive (Larsson and Sjoberg, 1986; Richard, 1993). The data generated from the 
microarray conducted in this study had revealed that RRM1 was one of the genes 
that was significantly modulated (p=0.02) and was down-regulated by 1.02 fold 
on treatment with CP655 as compared to CP655OMe. Therefore, since the 
importance of this enzyme and its subunits had been clearly established in the 
literature, and it had been shown to be one of the main mechanisms by which iron 
chelation inhibits cellular proliferation, it was decided to short-list RRM1 as one 
of the final five genes that would be validated by RT-PCR. 
Apart from their ability to inhibit RR enzyme, iron chelators have been shown to 
cause inhibition of the cell cycle by their ability to directly target various cell 
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cycle proteins in different stages of the cell cycle (Darnell and Richardson, 1999; 
Yu et al, 2007; Gharagozloo et al, 2008). Cyclins and CDKs are essential 
components of the cell cycle and it is the interplay between different cyclins, cdks 
and other proteins that control the transition between the different cell cycle 
stages (Kulp et al, 1996; Sherr and Roberts, 1999). 
Chelation has been shown to affect several cyclins and cdk proteins (Simonart et 
al, 2000; Fu and Richardson, 2007). D-type cyclins, along with C- and E-type 
cyclins, are the main type of cyclin proteins that control the progression of the cell 
cycle through the G1 phase. Depletion of iron using iron chelators has been 
shown to reduce the expression of different D-type cyclins such as D1, D2 and 
D3.  The D-type cyclins need to form complexes with cdk4 in order to become 
active and push the cell through the G1 phase (Malumbres and Barbacid, 2005). 
Studies have demonstrated that iron chelation can reduce expression of cdk4 and 
also inhibit the ability of Cyclin-D1 and cdk4 to form active complexes (Gao and 
Richardson, 2001). Although CyclinD1 was reduced in the microarray 
experiment, the reduction was not significant hence, despite being a good 
candidate for the mechanism of the chelator, it was decided not to conduct further 
examination of this protein. An interesting observation that was made from the 
microarray data was that the expression of cdk4 was significantly increased after 
treatment with CP655. This might be an attempt, albeit unsuccessful, from the cell 
to continue the progression of the cell cycle by increasing cdk4 expression in 
response to the reduced expression of cyclin D1. Terrada et al (1991) reported a 
similar pattern in the expression of cyclin E and cdk2, where cyclin E levels were 
elevated from iron chelation but were unable to over the block in the cell cycle 
due to reduced cdk2 expression. One cell division cycle protein (CDC6) is 
amongst the earliest proteins that initiate the process of DNA replication by 
binding with the Origin recognition complex (ORC) to form the Replication 
Complex (RC). The activation of this complex is responsible for initiating DNA 
replication and the movement of the cell from the G1 phase into the S phase 
(Krude, 2006). As a result of this, the expression of CDC6 is very tightly 
controlled throughout the progression of the cell cycle (Boronat and Campbell, 
2006). The results from the microarray experiment in this study showed that 
176 
 
CDC6 was significantly (p=0.004) down-regulated by 1.22 fold after CP655 
treatment. In fact, in the list of 20 genes generated after correlating the microarray 
results and the literature, CDC6 was on the top of the list of highly down-
regulated genes.  Due to its indispensible role in controlling cell cycle progression 
and its prominent down-regulation in the microarray analysis, it was decided to 
further validate the expression of CDC6 via RT-PCR.  
Another gene that was of interest was the Anaphase Promoting Complex 1 
(ANAPC1) gene. It is a E3-ubiquitin ligase that target cell cycle regulatory 
proteins for degradation and helps initiate Anaphase and subsequently the 
completion of the cell cycle. It has been shown to interact with several Cdk and 
cdc proteins (Kraft et al, 2003). Apart from being highlighted in the literature as 
being important for cell cycle regulation, ANAPC1 was of statistical importance 
to this study as it was one of the top 10 genes that were highly significantly and 
differentially down-regulated on treatment with CP655. Therefore, it was decided 
that the effect of CP655 on ANAPC1 would be further investigated by RT-PCR.  
Another family of genes closely associated with maintaining normal cell cycle 
progression, regulating growth and development and also known to be influenced 
by changes in intra-cellular iron concentrations are the Growth Arrest and DNA 
Damage (GADD) family genes (Darnell and Richardson, 1999; Tamura et al, 
2012). The GADD family is made up of three members GADD34, GADD45 and 
GADD153 each of which are involved in various stress responses in the body (Yu 
et al, 2007). GADD45 has been implicated to play an essential role regulating 
DNA repair, controlling cell cycle progression, apoptosis etc. It has been shown 
that GADD45 group of proteins play an essential role during the G2/M phase 
check point of the cell cycle (Zerbini and Libermann, 2005). The GADD45 
proteins which are highly expressed during the G1 phase of the cell cycle, are 
immediately up-regulated following DNA damage and bring about an arrest of the 
cell cycle and are involved in various DNA repair mechanisms (Kearsey et al, 
1995; Garcia et al, 2005).  
The importance of GADD45 proteins can be visualized from their extensive use 
in several cancer therapeutic agents. In fact, it has been suggested that anti-cancer 
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drugs as well as certain Non-Steroidal anti-inflammatory drugs (NSAIDs) depend 
on up-regulating GADD45 to cause cell cycle arrest and apoptosis, as a 
mechanism of their action and effect (Zerbini et al, 2006). Studies using different 
iron chelators, on several different cell lines have shown significant accumulation 
and time-dependent increase in GADD45 concentration following treatment 
(Darnell and Richardson, 1999; Saletta et al, 2011). Proteins of the GADD45 
family have been shown to interact with several cell cycle proteins such as cdc2, 
CyclinB1, p21 and p38MAPK. It is therefore suggested that the GADD45 
mediated inhibition of the cell cycle caused following iron-depletion could be 
attributed to the changes in the expression level of its various interacting proteins 
such as cdc2 and CyclinB1 (Vairapandi et al, 2002; Lee et al, 2006). The results 
from the microarray in this study showed that GADD45γ levels were significantly 
(p=0.002) up regulated by 1.12 fold after CP655 treatment. Furthermore, this was 
supported by a subsequent down regulation of CyclinB1 levels by 1.1 fold after 
treatment with CP655 (p=0.02). Although levels of GADD45α and GADD45β 
expression levels were increased by around 1 fold after treatment with the 
chelator, the changes in expression were not significant and hence these genes 
were not considered for further analysis. Based on the close relation between 
GADD45 proteins and regulation of the cell cycle, as well as the effect of iron 
depletion on the expression of this protein it was decided to further analyse and 
validate the effect of CP655 on GADD45γ via RT-PCR. 
While reviewing the literature on cell cycle regulation and the effect on iron 
chelators on progression of the cell cycle, a protein that was discussed in several 
studies due to its important role in different signaling pathways was p21CIP1/WAF1 
(CDKN1A). The Cdk Inhibitor, p21, is one of the most crucial molecules 
involved in regulating the cell cycle (Xiong et al, 1993; Harper et al, 1993). In 
most normal mammalian cells the cell cycle is controlled by a group of enzymes 
known as the cell-dependent kinases (cdk), which are in turn controlled by their 
regulatory sub-units, the cyclins. These are accompanied by the Proliferating Cell 
Nuclear Antigen (PCNA) and the p21 protein. Early studies showed that in 
several transformed cancerous cells, the PCNA and p21 proteins are lost from this 
quaternary structure as a result of which these cells show extensive, 
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uncontrollable proliferation. Therefore, the role of p21 was suggested to involve 
the inactivation of cyclin/cdk complexes leading to inhibition of proliferation and 
control of the cell cycle (Xiong et al, 1992; Zhang et al, 1993). p21 has been 
shown to arrest the cell cycle in the G1/S phase transition by inhibiting 
phosphorylation of pRb  due to its ability to bind to the cyclin E/cdk2 complex 
and render it inactive (Vidal and Koff, 2000).  
Apart from interfering with cyclin and cdk complexes, p21 also directly alters the 
expression of several transcription factors such as E2F1 and c-myc (Delavaine 
and La Thangue, 1999). The activation of p21 is controlled by two different 
signaling pathways, one is via the p53 pathway and the other in a p53-
independent manner through its own transcription factors such as AP2 
(Wajapeyee and Somasundaram, 2003). An important aspect of the p21-mediated 
regulation of the cell cycle is that it can have both positive as well as negative 
effects on the cell cycle. It has been shown that proper activation and cyclin-cdk 
complex formation requires low levels of p21 expression. However, the same 
protein in higher concentrations can inhibit the cyclin-cdk complex formation as 
well (Cheng et al, 1999).  
Studies have demonstrated that depletion of intra-cellular iron can have 
contrasting effects on the expression of p21 mRNA levels and p21 protein levels. 
Iron chelators such as DFO and 311 have been shown to significantly increase 
p21 mRNA levels, in a p53 independent pathway leading to G1/S phase arrest of 
the cell cycle. However, other studies showed a decrease in p21 protein level after 
iron depletion (Fukuchi et al, 1999; Abeysinghe et al, 2001). It has been 
suggested that the decrease in p21 protein expression could be due to ubiquitin-
independent proteasomal degradation of the protein (Fu and Richardson, 2007). 
Goldie et al (2013) showed that Deferasirox can inhibit the proliferation of lung 
cancer and neuroepithelioma cell lines by causing an up-regulation of p21mRNA 
levels. As p21 is one of the key molecules regulating cell cycle progression and 
since the changes in expression of p21 vary based on the type of chelator used, to 
the cell types etc it was decided to further investigate the effect of CP655 on p21 
expression level and hence was chosen as the final gene for validation via RT-
PCR.    
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Therefore, the functional experiments to analyse cell cycle aberrations following 
iron chelation were successful in assisting to short-list and identify five genes 
that could serve as potential targets for CP655. These genes Ribonucleotide 
Reductase, CDC6, ANAPC1, GADD45γ and CDKN1A were hence chosen for 
further validation by RT-PCR. 
Finally, before moving ahead to the validation of the above genes, another 
important observation that came to light following the cell cycle analysis was 
that the time point at which the effects of the chelator became visible was in fact 
48 hours, much later than what was previously hypothesized based on the results 
of the proliferation assays using Tritiated thymidine. But, still in accordance 
with the results of the CFSE-based proliferation assays. This further 
strengthened the view that the time point chosen to conduct the microarray was 
too early to visualize any significant effects relating to the effect of the chelation 
as discussed previously. 
CDKN1A mRNA and protein levels up-regulated following iron depletion 
using CP655 
 
Dallas et al (2005) showed that one of the best techniques for validating 
microarray results is by RT-PCR. Therefore, once the five genes had been 
identified, RT-PCR was carried out in order to establish whether the results of 
the microarray could be replicated at the mRNA level. Since it was believed that 
one of the reasons why the microarray did not reveal high fold change results 
was due to the time point of the experiment not being appropriate, it was 
decided to conduct the RT-PCR analysis of the chosen genes at several different 
time points, starting from as early as 4 hours post-stimulation until 48 hours 
post-stimulation. Additionally, the expression of various cell cycle proteins is 
cyclical and varies from time to time, depending on the phase of the cell cycle 
(Fitzgerald-Hayes and Reichsman, 2010). Therefore, in order to ensure that any 
changes in mRNA levels of the five chosen genes could be observed it was 
essential to have a wide time point range for analysis. Four out of the five genes 
that were examined, namely CDC6, RRM1, GADD45G and ANAPC1 did not 
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reflect the alterations in mRNA expression level as were predicted by the 
microarray analysis. 
For genes such as RRM1 the mRNA expression patterns were the opposite of 
what was predicted by the microarray analysis. At all of the time points 
analysed, RRM1 mRNA was either unchanged or increased in comparison to the 
untreated as well as the CP655OMe treated cells. This was very surprising as 
RRM1, one of the two major sub-units of the DNA synthesis enzyme 
Ribonucleotide reductase, is responsible for causing and controlling cellular 
proliferation. So far, CP655 had been able to significantly inhibit proliferation 
by at least 50% but did not seem to have any effect on the mRNA levels of 
RRM1. One of the explanations for this could be that although the RRM1 sub-
unit contains the main active site of the enzyme, it is the second sub-unit RRM2 
that contains the Fe-core, hence making it more susceptible to iron chelation 
(Shao et al, 2013; Zhou et al, 2013). Therefore, while subtle changes in RRM1 
were observed in the microarray, the changes were not substantial enough to 
elicit significant changes at the mRNA level.  
Moving on, genes such as CDC6 and ANAPC1, which showed highly 
significant, albeit small, fold changes in expression level in the microarray did 
not illustrate any significant patterns in their mRNA profiles. Once again, 
similar to the results with RRM1, the mRNA levels were mostly unchanged in 
comparison to the untreated or the CP655OMe treated cells. Although, the 
literature had suggested that CDC6 and ANAPC1 are indispensible parts of the 
cell cycle machinery, there were no reports linking either of these proteins to 
iron chelation, nor were there any studies highlighting their dependence on iron 
for proper functioning. Hence, it may be possible that the changes seen in these 
genes in the microarray were in downstream effects of the chelator inhibiting 
other cell cycle controlling proteins. As a result of which no significant changes 
at the mRNA level were observed for these genes.  
GADD45 family genes had been shown in the literature to be affected by iron 
chelation. This observation was supported by the result of the microarray, where 
GADD45G was significantly up-regulated after iron chelation. However, once 
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again similar to other results, this up-regulation was not reproduced in the RT-
PCR. A pattern towards increased GADD45G mRNA was noticed in the 24 
hours and 48 hours time point, but it was not found to be statistically significant. 
Further examination of the literature revealed that more than GADD45G, it was 
in fact GADD45A, which interacted with several cell cycle proteins such as p21 
and was even shown to be affected by iron depletion (Darnell and Richardson, 
1999).  
Another observation that was made was that there was very high inter-sample 
variation while conducting the RT-PCR, as can be seen by the large error bars in 
the results. This was also one of the reasons why it was not possible to get 
significant differences in mRNA levels.  
Finally, after several inconsistent and disappointing results, the only gene that 
maintained the same trend and pattern as that suggested by the microarray data 
was the tumour suppressor gene, CDKN1A (p21). As compared to the other 
genes, where expression levels seemed almost constant or showed small gradual 
increases over time, the mRNA expression of p21 showed a dramatic increase at 
12 hours post stimulation and then once again at 48 hours post stimulation. 
Additionally, even though due to the large inter-sample variations the results 
were not significant the pattern in expression of mRNA was relatively clear. It 
was evident that at the 48 hour time point, there was an increase in p21 mRNA 
levels after treatment with CP655 as compared to the untreated or the 
CP655OMe treated cells. These results were encouraging, especially since there 
were a large number of studies implicating p21 as the protein responsible for 
causing cell cycle arrest following iron chelation. 
In order to confirm the results obtained following the RT-PCR, Western Blotting 
was used to further confirm and validate the effect of CP655 on p21 expression 
levels.  
The effect of iron chelation on the expression of p21 has been discussed in 
several studies and the discrepancy between mRNA and protein level 
expressions go on to suggest that p21 is regulated not only at a transcriptional 
level but also post-transcriptionally. Fu and Richardson (2007) showed that 
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depleting intra-cellular iron led to an increase in p21 mRNA, but this was not 
reciprocated at the protein level. In fact, p21 protein levels were reduced after 
iron chelation due to proteasomal degradation of the protein. In a previous study 
by Fukuchi et al (1998) they showed that using a DNA-damaging agent led to 
increase in p21 expression at both the mRNA as well as protein level, suggesting 
that DNA damage was important to illicit an increase in p21 protein levels. In 
this study, we analysed the effect of CP655 and the control CP655OMe on p21 
protein levels from Jurkat cells as well as primary human CD4+ T cells. 
Western blot experiments for assessing p21 protein expression were conducted 
at different time points in order to ensure that the effect of CP655 can be 
visualized. The results showed that, contrary to other data so far, the only time 
point at which p21 protein expression was significantly affected was at 4 hours 
post treatment and culture. At this time point, a significant increase in p21 
protein level was observed between CP655 treated cells and both the untreated 
as well as the CP655OMe treated cells.  
Therefore, the consistent results obtained from the micro-array, RT-PCR and 
western blot experiments indicated that one of the target molecules for CP655, 
through which it exerts its effects on human CD4+ T cells, was the tumour 
suppressor Cell-Dependent Kinase Inhibitor, CDKN1A (p21). 
Moving on to the second set of experiments, since the suppression of 
proliferation of CD4+ T cells by CP655 was the strongest phenotype observed 
in this study so far it was only logical to assess the impact of CP655 on 
signalling pathways that are directly related to cell proliferation such as the IL-2 
pathway.  
The IL-2 family of cytokines, which includes IL-4, IL-7, Il-9 and IL-15 apart 
from IL-2, play an essential role in the development of the immune system and 
immune responses. The expression of IL-2 receptor (IL-2R) on the surface of T 
cells is important for initiating proliferation. The receptor is made up of three 
chains – the α chain that binds IL-2 with low affinity, the β- and γ- chains that 
bind IL-2 with intermediate affinity, and a receptor made out of the combination 
of each of these three chains bind IL-2 with high affinity. Binding of IL-2 to the 
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intermediate or high affinity receptors provides the signal to initiate transition 
from G1 to the S phase of the cell cycle and begin the process of proliferation 
(Kim et al, 1993). In fact, IL-2 provides a signal strong enough to initiate 
proliferation of resting T-cells even in the absence of an antigen (Nakamura et 
al, 1991).  
Binding of IL-2 to either the intermediate or the high-affinity receptor leads to 
dimerization and stabilization of the IL-2 receptor and initiates a cascade of 
downstream signalling events. The cytoplasmic tails of the β- and γ- receptor 
chains have docking sites for Janus-Associated Kinase (JAK) molecules as well 
as several tyrosine residues, phosphorylation of which leads to the recruitment 
of several signalling molecules. Activating the IL-2 receptor leads to a sudden 
increase in the recruitment of JAK1 and JAK3 to the receptor tails, which 
phosphorylate themselves and the receptor and attract other signalling molecules 
to the site. Phosphorylation of the tyrosine residues by JAK1 and JAK3 converts 
them into docking sites for other signalling molecules such as the Signal 
Transducers and Activators of Transcription 5a (STAT5a) and STAT5b. Once 
the STAT5a and STAT5b proteins are attracted to the phosphorylated tyrosine 
docking sites, they are phosphorylated and activated by the JAK1 and JAK3 
proteins. The activated and phosphorylated STAT proteins dissociate from the 
receptor, dimerize and then translocate to the nucleus where they bind to the 
specific DNA binding sites to begin transcription of their target genes that cause 
cellular growth, development and proliferation (Lin and Leonard, 2000). In fact, 
the importance of the IL-2 signalling pathway via JAK3-STAT5 can be 
appreciated from the several studies that have highlighted this signalling 
pathway in T-cell driven chronic inflammatory diseases such as Rheumatoid 
Arthritis. JAK inhibitors have been in trial for treating people with RA, based on 
the hypothesis that JAK3 is essential for the activation, differentiation and 
proliferation of lymphocytes that drive the disease (Kremer et al, 2009; Patel et 
al, 2011).  
There were two distinct aspects of the IL-2 pathway that we were interested in 
covering as a part of this study. First was to assess whether the cells cultured 
with CP655 were able to respond to exogenous IL-2, or was this ability 
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compromised after treatment. The second aspect was to determine whether 
CP655 treatment was affecting the downstream signalling events involved in the 
IL-2 signalling pathway. 
To address the first aspect, exogenous IL-2 was added to CD4+ and CD14+ co-
culture in the presence of CP655 and proliferation as well as cytokine 
production from these cells was measured. It was observed that while CP655 
caused inhibition of proliferation and IFN-γ and IL-17 production as before, the 
addition of IL-2 was able to overcome the suppression caused by the chelation 
and these cells proliferated and produced cytokines at the same level as 
untreated and control cells. These results indicated that the inhibitory effects 
caused by CP655 were not permanent or damaging to the cells, as they still 
retained their ability to respond to exogenous IL-2. However, when only CD4+ 
T cells were treated with CP655, addition of exogenous IL-2 was unable to 
overcome the suppression caused by CP655 treatment. Since experiments during 
the initial part of this study showed that the main targets of CP655 treatment are 
the CD4+ T cells, it is suggested that the presence of CD14+ monocytes in the 
cell culture were responsible for the restoration of proliferative response on 
addition of exogenous IL-2. Additionally, IL-2 has been shown to be a strong 
activator of human CD14+ monocytes, causing them to produce large amount of 
growth factors and cytokines such as IL-6 and IFN-γ, which can in turn further 
activate the CD4+ T cells (Musso et al, 1992; Gusella et al, 1993; Bosco et al, 
2000). Therefore, the inhibition caused by the treatment with CP655 cannot be 
overcome by the addition of exogenous IL-2 in CD4+ T cells, suggesting that 
CP655 may in fact, be interfering with the IL-2 signalling pathway as another 
possible mechanism of its action. 
Therefore, in order to confirm this, the second aspect of the IL-2 pathway was 
addressed. It was decided to look at one of the most essential downstream 
signalling molecules of the IL-2 proliferation pathway, STAT5, and see if it was 
being affected by CP655 treatment. When the effect of the iron chelation was 
assessed on phosphorylation of STAT5, it was encouraging to see that CP655 
was successful in reducing the phosphorylation of STAT5 in comparison to cells 
that did not receive the chelator, as well as those that received the control 
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compound, CP655OMe. Additionally, it was once again noticed that the time 
point at which the most prominent reduction in the phosphorylation of STAT5 
was observed was 48 hours post stimulation and treatment, similar to what had 
been seen in previous experiments so far. This suggested that another reason 
why CP655 treatment was inhibiting proliferation of cells was due to its ability 
to inhibit phosphorylation of STAT5, which is important for cell proliferation.  
Another set of interesting kinetic experiments set-up in this study revealed that 
pre-treating the CD4+ T cells with CP655 and then washing it out before the 
cells were stimulated with anti-CD3/CD28 beads did not affect the proliferation 
observed in the cells. However, if the cells were first stimulated with anti-
CD3/CD28 beads and then treated with the chelator in the presence of the beads, 
led to the significant inhibition of proliferation as previously observed. These 
results suggested that it was important for the chelator to be present at the time 
the T-cell receptor was being stimulated in order to exert its effect on cell 
proliferation. Therefore, it can be hypothesized that CP655 may be interfering 
with some of the downstream signalling molecules of the T-cell receptor. 
These results also linked in with the data showing reduced STAT5 
phosphorylation, since the activation of the TCR is one of the main pathways for 
producing IL-2 in CD4+ T cells. Therefore, reduced IL-2 production due to 
aberrations in the T-cell signalling pathway could also be responsible for 
reduced phosphorylation of STAT5 that was previously observed. So, it can be 
suggested that apart from repressing the ability of CD4+ T cells to respond to 
IL-2 by reducing STAT5 phosphorylation, CP655 may potentially also be 
reducing the production of IL-2 due to aberrant TCR signalling. 
Therefore, in conclusion, apart from directly affecting cell cycle proteins such as 
p21, CP655 can inhibit CD4+ T cell proliferation by affecting the IL-2 pathway 
and its downstream signalling molecule STAT5 and may also interfere with 
































6.1 GENERAL DISCUSSION 
The critical role played by iron in supporting life via its ability to promote 
cell growth, division and proliferation has been well established. The 
importance of iron for cellular processes can be judged by the various 
pathways that it plays a part in such as Electron transport, cellular respiration, 
DNA and RNA synthesis, cellular proliferation and regulation of gene 
expression. Additionally, several organs of the body are involved in iron 
metabolism such as the testis, brain, intestines and liver further highlighting 
the importance of its homeostasis (Boldt, 1999; Lieu et al, 2001; 
Koskenkorva-Frank et al, 2013). However the potentially toxic nature of iron 
and its ability to promote infectious diseases by aiding invading 
microorganisms cannot be ignored either. Microorganisms such as 
Mycobacterium tuberculosis and Corynebacterium diphtheria, have several 
mechanisms through which they source iron from the body and even steal it 
from iron storage sites such as Ferritin, in order to maintain a sufficient 
supply for survival and proliferation (Crouch et al, 2008; Cassat and Skaar, 
2013). Therefore, it is evident that maintaining a balance in the availability of 
iron within the human body is of utmost importance (Lieu et al, 2001). 
The importance of iron for metabolically active cells is pivotal, especially for 
thymocytes and activated T cells. Due to their high rate of metabolism and 
increased proliferation, their dependence on iron is greater than most other 
cell types in the human body (Kuvibidila et al, 2001). As a result of this iron 
forms an essential co-factor of the human immune system (Bowlus, 2003). 
Iron deficiency is believed to be one of the contributing factors responsible 
for thymic atrophy which results in reduced cell-mediated immunity due to 
reduction in the number of circulating T lymphocytes (Savino, 2002).  
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Therefore, whether it is carrying oxygen in haemoglobin, acting as an 
electron donor or acceptor in various enzymes or producing damaging free 
hydroxyl radicals and promoting microorganism growth, the impact of iron 
deficiency or iron overload can lead to several immune dysfunctions, 
disorders and even autoimmunity (Bowlus, 2003; Nairz et al, 2014).  
One of the most frequently cited examples for understanding the relationship 
between Iron and immunity is that of the Anaemia of Chronic Disease 
(ACD). The main pathology of the disease stems from accumulation of iron 
within monocytes leading to impaired formation of the hormone 
Erythropoietin (Epo) and impaired proliferation of Erythroid progenitor cells. 
It is most commonly found in patients suffering from chronic inflammatory 
diseases such as Rheumatoid Arthritis (RA) and Cancers (Weiss and 
Goodnough, 2005).   
Previously Blake et al (1985) used an iron chelator, Deferrioxamine (DFO) to 
investigate and elaborate on the role that iron accumulation plays in 
inflammatory diseases such as RA. This was based on previous observations 
from Muirden and Peace (1969) and Blake et al (1983), where DFO had been 
successful in reducing both acute and chronic inflammation in animal models 
of acute inflammation. Seven patients with RA were given DFO during this 
trial, however the study had to be terminated early due to adverse side 
effects, in the form of cerebral and ocular toxicities, caused due to the use of 
the chelator. However, these effects were attributed to the low specificity of 
DFO to iron and its ability to bind intra-cellular copper as well. While initial 
studies using DFO for treating inflammation in patients with RA had severe 
side effects, some of the trial patients did demonstrate good clinical responses 
to RA by showing a sharp reduction in the acute phase response (Blake et al, 
1985).  
DFO was the only iron chelator approved by the US Food and Drug 
Association (FDA) to be given parenterally to patients with iron overload. 
But in the past decade, the FDA has approved two more iron chelators for 
oral use in humans, Deferiprone and Deferasirox (Sheth, 2014). A lot of 
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advancements have been made in the field of iron chelation over the past few 
years. Several novel iron chelators have been developed and tested in various 
models of disease.  
In this present study, I have investigated the effect of novel HPO iron 
chelator treatment on human CD4+ T lymphocytes. I have also explored the 
various mechanisms by which iron chelation exerts its effect on human CD4+ 
T cells. Implications of the findings of this study are discussed below. 
Having tested several different HPO iron chelators on mixed cultures of 
human CD4+ and CD14+ cells, it was evident that CP655 was most effective 
in reducing inflammatory cytokine production and proliferation of the cells. 
During the initial part of this study, it was also established that the main 
target cell of these HPO iron chelators, specifically CP655, are the purified 
CD4+ T cells. Furthermore, these experiments indicated that the main effect 
of iron chelation was on inhibition of proliferation of CD4+ T cells. In order 
to determine the mechanism of action of the iron chelators, all the subsequent 














SUGGESTED MECHANISM – 1 
 
6.1.1 CP655 inhibits cellular proliferation by interfering with cell growth 
and development signalling pathways 
Having uncovered the first step towards identifying the mechanism of CP655 
action by identifying CD4+ T cells as the main targets of chelation, the next 
aim was to try and identify the various pathways that may be altered after 
treatment with CP655. It was decided that conducting a whole genome 
microarray on anti-CD3/CD28 stimulated CD4+ T cells would help to 
identify novel genes and targets of chelation by CP655. 
The microarray revealed a large number of unknown genes that were 
modulated by iron chelation. Additionally, most of the known genes that 
were highly significantly upregulated on treated with CP655 as compared to 
the untreated or the CP655OMe control treated cells showed only small fold 
changes in expression. As a result of this, it was difficult to identify clear 
patterns and trends in the data in order to highlight specific pathways that 
may be getting affected following chelator treatment. However, a manual 
review of the data indicated that majority of the genes that were significantly 
modulated by treatment with CP655 were those involved with MAPK 
signalling, cell proliferation and cell growth and division pathways. This was 
in correlation with the previous in-vitro results where inhibition of 
proliferation of the main phenotype being altered after treatment with 
chelator. 
A further observation was that there were a large number of microRNAs, 
which appeared in the list of significantly modulated genes. MicroRNAs 
(miRNAs) are 20-25 nucleotides long, non-coding small RNAs that act as 
post-transcriptional regulators of gene expression by binding to 3’UTR of 
target mRNAs causing inhibition of translation and degradation (Lai, 2002; 
Qu et al, 2013). Several studies have highlighted the role of miRNAs in 
tumorigenesis, either in the form of oncogenes promoting tumour growths 
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and excessive cellular proliferation or in the form of tumour suppressors, 
inhibiting tumours and cellular proliferation (Bushati and Cohen, 2007; Budd 
et al, 2012; Zhang et al, 2012; Nadiminty et al, 2012). For instance, miRNA 
503 has been found to be associated with hepatocellular carcinoma. It acts as 
a tumour suppressor and its expression results in blocking of the cell cycle, 
apoptosis and tumour suppression (Wang et al, 2014).  
The microarray conducted in this study revealed a significantly increased fold 
expression of miRNA 503 after treatment with CP655. It has been suggested 
that miRNA 503 inhibits cellular proliferation by directly targeting two cell 
cycle proteins, cyclin D3 and E2F3 (Xiao et al, 2013). While there were other 
miRNAs such as miRNA 99A that was significantly upregulated in this study 
and the literature suggests several contradictory roles for this miRNA. Feng 
et al (2012) demonstrated that miRNA 99a acts as a tumour suppressor and 
inhibits proliferation in bladder cancer. Another study (Hu et al, 2014) 
showed that miRNA 99a inhibits proliferation by its ability to cause a cell 
cycle arrest via the m-TOR pathway. However, contradictory to this Chen et 
al (2015) suggest that in certain cancers such as Non-small cell lung cancer, 
miRNA 99A can promote proliferation and cell migration. 
During this process of reviewing the literature, and correlating the findings to 
the results of the microarray experiment it became evident that even though 
software analyses did not show any significantly enriched pathway due to the 
small fold changes in the gene, most of the genes that were significantly 
modulated, belonged to a few common pathways. One of the drawbacks of 
microarray analysis is to decide where to put the cut-off point in terms of fold 
change for genes. If a low cut-off point is chosen such as 0.5 or 1.0 fold, it 
can increase the chances of false positive results. However, if a high cut-off 
is chosen it can lead to some important genes being left out of analysis. It has 
been suggested that there might be some genes that are crucial for specific 
pathways or processes to take place, but they often do not show large fold 
changes in expression (Chin and Moldin, 2001). Therefore, in order to move 
ahead with the analysis of the data generated it was decided to prepare a 
manual list of genes that were differentially modulated in the micro-array 
192 
 
following CP655 treatment after cross-linking and consultation with the 
literature. This list consisted of several cell cycle proteins, some microRNAs 
as well as those involved in carcinogenesis and tumorigenesis. Since it was 
not possible to validate each of these 20 genes by RT-PCR due to limited 
time and resources, a functional analysis of the effect of CP655 was 
conducted in order to further narrow down the list of prospective targets. This 
was done by conducting cell cycle analysis on CD4+ T cells, since most of 
these in the list were involved in controlling different aspects of the cell 
cycle. 
 
6.1.2 CP655 causes G1/S phase arrest of human CD4+ T cells and Jurkat 
cell lines 
Treatment of both Jurkat cells, and primary human CD4+ T cells with CP655 
led to a functional block in the cell cycle progression of these cells. In both 
cases, the kinetics of the effect of treatment was maintained and significant 
block of the cell cycle was observed only 48hours after treatment with 
CP655. In Jurkat cells, the transition from the G1 to the S phase was 
significantly altered with most of the cells getting arrested between the two 
stages.  
A similar pattern was observed in primary CD4+ T cells, although the results 
were not as prominent as those observed in the Jurkat cells. At 48 hours post 
treatment, most of the cells were arrested in the G1 phase of the cycle with 
significantly fewer cells entering the G2/M phase. These results were 
consistent with previous studies that have used several different types of iron 
chelators and shown similar results in several different cell types (Clement et 
al, 2002; Szuts and Krude, 2004; Gharagazloo et al, 2008). 
The results from these functional studies helped to narrow down the list of 20 
genes developed following the microarray to five genes that could potentially 




6.1.3 Potential mechanism of action for CP655 via increased CDKN1A 
expression 
 
The five genes short-listed for validation were CDC6, CDKN1A (p21), 
RRM1, GADD45G and ANAPC1. RT-PCR at various time points ranging 
from 4 hours to 48 hours post treatment. Results indicated that the only gene 
where mRNA expression correlated with the functional analysis so far was 
p21. This gene showed increased expression following treatment with CP655 
at 12 hours and also at 48 hours post treatment. The increased expression of 
p21 was replicated in Western blot experiments were p21 protein expression 
was significantly increased in Jurkat cells, as well as primary CD4+ T cells 
following CP655 treatment. However, the time point continued to remain a 
point of concern, as increased protein expression was only observed at early 
time points of 4 hours post treatment. 
The increased expression of CDKN1A (p21) can be attributed to two 
individual pathways – a p53 dependent pathway and a p53 independent 
pathway. 
One of the suggested mechanisms through which iron chelation causes 
increased expression of p53 and hence p21, is via the JNK and p38 MAPK 
signalling pathways. It has been shown that iron chelation leads to the 
dissociation of the Apoptosis-Signal Regulating Kinase1 (ASK1) and 
Theoredoxin (Trx) complex. The dissociation of Ask1 and its increased 
phosphorylation leads to the initiation of a signalling cascade causing 
increased phosphorylation of the JNK and p38 MAPK pathways, which are 
tumour suppressor pathways having p53 as their immediate down-stream 
target (Yu and Richardson, 2011). In fact, p38 has been shown to cause 
increased phosphorylation and activation of p53, leading to G1/S phase arrest 
of the cell cycle via its downstream targets such as p21. JNK as well, has 
been shown to phosphorylate p53 leading to its activation (Wilkinson and 
Millar, 2000). Another more commonly discussed mechanism via which iron 
chelation leads to increased p53 expression, is through its interaction with the 
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Hypoxia-Inducible factor-1α (HIF-1α). Hypoxia caused due to iron chelation 
leads to increased concentration of HIF-1α, which directly binds to and 
stabilizes p53 and promotes p53-dependent activities (Suzuki et al, 2001). 
p21 forms an integral part of the growth and cell cycle arrest pathways 
mediated by p53 (El-Deiry et al, 1994) and has been well established as a 
downstream target effector of p53 (Harper et al, 1993; Xiong et al, 1993). 
Therefore, one of the ways that CP655 inhibits cellular proliferation and 
causes a block in the G1/S phase of the cell cycle could be due to the 
activation of the p53 pathway, which leads to activation and over expression 
of p21 (Fig 6.1). 
 
Figure 6.1: Effect of Iron chelation on cell cycle proteins.  




Apart from a p53-dependent pathway, p21 can also be upregulated in a p53-
independent manner. There are several transcription factors, such as 
Activating Protein 2 (AP2), E2F1, Specificity Protein 1 (Sp1),  that have 
DNA-binding sites within the promoter region of p21 suggested that these 
transcription factors may be responsible for the p53-independent up-
regulation of p21. The tumour suppressor protein, BRCA1, has also been 
suggested to be one of the transactivators of p21 in a p53 independent 
manner (Gartel and Tyner, 1999). 
 
SUGGESTED MECHANISM – 2 
 
6.1.4 CP655 inhibits cellular proliferation by suppressing the IL-2 pathway 
and reducing STAT5 phosphorylation 
 
It is well established in the literature that iron is essential for the proper 
functioning of the immune system, and iron deficiency or iron depletion can 
result in reduced or dysfunctional cell-mediated immunity. Additionally, as 
discussed previously iron deficiency affects the proper functioning of the 
Thymus and impaired proliferation of T cells. Therefore, reduced iron 
content may affect the production of IL-2 from T cells. A study on children 
with Iron-Deficiency Anaemia, reported that they also had low levels of IL-2 
(Jason et al, 2001; Suega and Bakta, 2010). Another interesting study linking 
iron metabolism to the JAK2-STAT5 axis was conducted by Kerenyi et al 
(2008). In this study, they used mice completely lacking STAT5 (STAT5-/-) 
and showed that these animals suffered from microcytic anaemia. 
Additionally, the erythroid cells in these animals showed a marked reduction 
in the cell surface expression of TfR1, which they showed was due to the 
marked reduction in the expression of IRP2, a direct target of STAT5 
transcription. They were successful in proving this relation between IRP2 and 
STAT5 by showing that the promoter region of the IRP2 gene had three 
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functional binding sites for STAT5 thereby suggesting that a reduction in 
phosphorylation of STAT5 would lead to impaired development and 
functioning of IRP2 and hence TfR1, upsetting the intracellular iron 
metabolism. 
In a second set of mechanistic experiments, CP655 or control treated cells 
were supplemented with exogenous IL-2. CD4+ and CD14+ cells cultures 
treated with CP655 when supplemented with IL-2 were able to overcome the 
suppression of proliferation. However, when only CD4+ T cells were 
supplemented with IL 2 following CP655, the cells were unable to overcome 
the suppression suggesting that CP655 was interfering with the IL-2 
signalling pathway. pSTAT5 western blot were conducted in order to 
elaborate on the mechanism by which CP655 was inhibiting the IL 2 pathway 
and thereby affecting proliferation in turn. CP655 was able to consistently 
reduce pSTAT5 expression in stimulated CD4+ T cells suggesting another 
possible route of affect. 
The link between STAT5, proliferation and G1/S phase cell cycle transition 
has been elaborated upon by studies showing that several D-type cyclins that 
control progression through the G1 phase are direct targets of the 
transcription factor STAT5. Therefore binding of IL-2 to its receptor thus 
activating STAT5 transcription factor leads to cell proliferation due to 
activation of various cyclin proteins. In fact, cyclin E has also been suggested 
to be a target of STAT5 and up-regulated in response to IL-2 signalling 
(Moon and Nelson, 2001; Moon et al, 2004; Kerenyi et al, 2008). However, 
the role of STAT5a and STAT5b on the cell cycle has been contested, as 
there have been studies showing that these transcription factors negatively 
regulate the cell cycle, by activating and inducing the expression of inhibitors 
such as CDKN1A (Yu JH et al, 2010).    
To summarize, it can be hypothesized that due to the impaired development 
and functioning of T cells, and the reduced phosphorylation of STAT5 
following CP655 treatment, the ability of T cell to respond to IL-2 was 
compromised leading to repressed proliferation. Additionally, reduced 
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STAT5 phosphorylation could also be affecting the transcription of other cell 
cycle controlling genes such as cyclin D1 and cyclin E also leading to a block 
in the cell cycle.  
6.1.5 CP655 may interfere with signalling via the T-cell Receptor 
Previous studies have showed that iron chelation can influence T cell 
stimulation by down-regulating CD28 co-stimulatory molecule from the 
surface of the cell. Engagement of the CD3/TCR complex along with the 
CD28 co-stimulatory molecule is essential for proper TCR signalling and cell 
proliferation (Kuvibidila and Porretta, 2003). Another study conducted by 
Kuvibidila et al (1999) showed that iron chelation reduced Protein Kinase C-
θ (PKC-θ) activity in murine lymphocytes which was responsible for altered 
proliferation of the cells. PKC-θ is an important serine/threonine kinase that 
is activated following signal from the TCR and the CD28 molecule, and it 
further activates transcription factors such as NF-κB, NF-AT and AP-1 which 
are responsible for T cell activation, differentiation and proliferation (Wang 
et al, 2012). Furthermore, some of these transcription factors, such as NF-AT 
and AP-1, have been implicated in the production of IL-2 (Chow et al, 1999). 
Preliminary experiments using different kinetics of CP655 treatment of CD4+ 
T cells revealed that CP655 is required to be present along with the cells 
during the time of TCR stimulation. That is, pre-treating the cells with CP655 
and removing it before stimulating the TCR did not show any effect on 
inhibition of proliferation. Therefore, a third possible mechanism of action of 
CP655 could involve its ability to interfere with proteins downstream of TCR 
signalling that affect the ability of T cells to proliferation. However, due to 
time constraints, no further work was done to elucidate this possible 
mechanism of CP655 and could potentially be one of the aspects to be looked 
at in future studies. 
An interesting observation made during the course of these final experiments 
was that the strength of the stimulation provided to T cells could have an 
effect on the action of CP655. During the initial part of the study, when 
experiments were conducted to identify the target cell type for CP655, CD4+ 
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T cells and CD14+ monocytes were treated separately with CP655 for 24 
hours and then the chelator was washed out before the cells were cultured 
together and stimulated with the antigen, Tetanus Toxoid. In such as 
experimental set-up, CP655 was able to significantly inhibit cellular 
proliferation and IFN-γ and IL-17 production. However, the experiments 
discussed in this last section showed that when CD4+ T cells were pre-treated 
with CP655 and then stimulated with anti-CD3/CD28 beads after washing 
out the chelator, no effect of CP655 was seen. This suggested that there was a 
possibility that the strength of the signal provided to the CD4+ T cells 
following TCR stimulation with an antigen was not very strong and CP655 
was able to cause a suppression of its effects. Whereas, stimulation using 
anti-CD3/CD28 beads may provide a much stronger signal for proliferation 
to CD4+ T cells, making it difficult for CP655 to overcome it and exert its 
effect. Therefore, in the case of a stronger stimulus, CP655 needs to be 
present at the time of TCR stimulation in order to maintain its effect on 
signalling molecules.  
Nicholson et al (1997) and Murtaza et al (1999) showed that the strength of 
TCR stimulation as well as the strength of co-stimulation affect the 
differentiation as well as the proliferative ability of CD4+ T cells, that is, a 
stronger stimulus meant greater proliferative ability of the CD4+ T cells. 
Similar results were obtained in murine experiments conducted previously in 
our laboratory. CD4+ and CD14+ cells obtained murine spleen and lymph 
nodes were stimulated with Tetanus Toxoid and then treated with the iron 
chelator, which was able to successfully reduce proliferation and cytokine 
production from these cells. However, when these cells were stimulated with 
Concanavalin A (Con A), a strong mitogen, the chelators were unable to 







The essential role of iron within the human body has been known for years. 
The ability of iron to promote and up-hold cell mediated immunity, 
participate in various metabolical and physiological pathways along with its 
ability to cause toxicities and promote infection has been discussed in several 
studies. As a result of this crucial balance that is required by the body, various 
pathways involved in iron metabolism have been studied extensively. Iron 
has been implicated to play a role in several autoimmune inflammatory 
disorders such as Rheumatoid Arthritis, in several cancers and even in several 
neuro-physiological disorders such as Alzheimers and Multiple Sclerosis. 
 
In this study, iron chelators have been used to modulate the function of 
human CD4+ T cells with the aim that these chelators could potentially be 
used to treat CD4 driven diseases characterised by excessive cellular 
proliferation and inflammation. The chelator used in this study, CP655, is a 
novel HPO chelator that has been shown to be more specific, and have higher 
affinity to intracellular iron as compared to previously used iron chelators 
such as DFO. The results have established that CP655 inhibits proliferation 
and inflammatory cytokine production from CD4+ T cells. This study was 
successful in demonstrating that the effect caused by CP655, in suppressing 
cell proliferation, was an iron dependent effect by using a structurally similar 
analogue to CP655 that does not chelate iron (CP655OMe). Additionally, this 
study suggests three individual, yet overlapping, mechanisms by which 
CP655 could potentially be exerting its effects on CD4+ T cells. 
 
Firstly, this study demonstrated that CP655 was causing a block in the G1/S 
phase of the cell cycle which was responsible for the inhibition of 
proliferation observed by tritiated thymidine incorporation as well as CFSE 
staining. The block in the cell cycle was suggested by data generated from 
microarray studies and was further confirmed by functional studies by 
Propidium Iodide staining of the cells. Potential target proteins of the chelator 
were then identified after correlating results to the literature out of which one 
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protein, CDKN1A (p21) was found to be consistently affected by CP655 
treatment. CDKN1A, which is a tumour suppressor, was upregulated in 
microarray analysis as well as in RT-PCR studies and was also confirmed by 
western blot analysis. Upregulation of this protein causes a block in the cell 
cycle, and is one of the mechanism by which CP655 could be affecting CD4+ 
T cells. 
 
The second mechanism explored in this study was the effect of CP655 on the 
IL-2 pathway and its downstream signaling molecule, STAT5. Treatment 
with CP655 led to reduced phosphorylation of STAT5 which has been shown 
to be essential for causing proliferation of CD4+ T cells. STAT5 is also an 
essential factor for several other cell proliferation and cell cycle progression 
proteins such as D-type cyclins, cyclin E1 etc. This suggested that the 
reduced phosphorylation of STAT5 due to CP655 treatment could also lead to 
an aberration in the progression of the cell cycle. 
 
Lastly, kinetic analysis of the effect of CP655 revealed that the chelator needs 
to be present in the cell during the time of TCR stimulation, suggesting that it 
may be acting on T cells by interfering with TCR signaling pathways. This 
potential mechanism was not analysed in this study, but could be an 
interesting option to explore in future studies. 
 
The possible mechanisms by which CP655 inhibits cell proliferation are 
summarized in Figure 6.2. 
 
This study clearly showed that the chelator was not responsible for any 
toxicities in the different cell types used. Hence, it can be an interesting 
therapeutic mechanism for treating several diseases resulting in ACD such as 
Rheumatoid Arthritis, diseases causing excessive cellular proliferation such 


























6.3 LIMITATIONS AND FUTURE WORK 
 
All the experiments in this study were done, in vitro, on cells isolated from 
healthy human controls or on cell lines. As a result of this, it is difficult to 
correlate the data to in vivo studies. 
 
The initial experiments on CD4+ and CD14+ cell cultures were conducted 
using only Tetanus toxoid as the antigen for stimulation, or using anti-
CD3/CD28 bead stimulation for purified CD4+ cell cultures. Future work 
could include using different stimulants such as PHA or other antigens in 
order to get a better idea on the mechanism of CP655 action. 
 
One of the main limitations of this study is related to the microarray analysis 
that was conducted in order to understand the mechanism of the chelator. Due 
to time and financial constraints, the experiment could only be conducted 
once. Therefore, a specific time point had to be chosen which would provide 
the most relevant results for this study. The 18 hour time point chosen in this 
study may not have been most appropriate. Future work could include 
conducting a microarray at several different time points, using synchronized 
cells so as to get a better idea of how CP655 affects genes over time. 
Additionally, the cells used to conduct the microarray experiments had not 
been synchronized before being used. Use of synchronized cells may have 
provided more consistent and prominent results. Another limitation 
associated with this study is that it was unable to identify a specific time 
point around which the chelator shows the most prominent effect. While 
some assays reveal 48 hours post treatment to be the ideal time point to 
visualize the effect of CP655, other experiments such as the Western blots 
suggest that the changes take place as early as 4 hours post treatment with 
CP655. This problem can be overcome by using cell lines rather than primary 
cells to see more consistent effects and reduce any inter-donor variation that 





Similar time and financial constraints were in place while conducting RT-
PCR and western blot analysis on the short-listed genes. Under ideal 
conditions, there would have been several other genes and proteins that I 
would have liked to analyse but for this study it was decided that it would be 
better to focus on one specific gene/protein after consulting with the 
literature. The effect of CP655 on some other proteins involved in the cell 
cycle progression forms an important part of the future work that is required 
to follow this study. Several other genes belonging to the p21 pathway such 
as p53, pRb as well as other cell cycle controlling proteins such as Cyclin D1 
could be analysed by western blot and RT-PCR in the future. 
 
Another important aspect to be elucidated upon is identifying the location of 
the chelator within the cells. The fluorescent nature of CP655 can help to 
identify its localization within the cell by imaging.  
 
Furthermore, the IL-2 and TCR signalling pathways are important for the 
proliferation of CD4+ T cells, this study has added to the literature regarding the 
effect that iron chelation can have on these pathways. However, there is still a lot 
of unanswered questions and studying the effect on different T cell signalling 
molecules may be an interesting option for conducting future studies. Zap 70 and 
PKC θ have previously shown to be modulated on treatment with iron chelators 
and could be important targets to look at following CP655 treatment. Also, as 
mentioned earlier, using different types of stimulus for the CD4+ T cells can help to 
identify specific target molecules. Lastly, experiments elucidating the different 
effects CP655 may have on antigen-stimulated cells versus anti-CD3/CD28 
stimulated cell could also add to the literature on the effect of signal strength 
on T cell proliferation and activation. 
The future therapeutic applications of this compound could include use in 
anti-cancer drugs due to its ability to significantly inhibit proliferation. Iron 
chelation has recently been used for the treatment of several neurological 
disorders such as Alzheimer’s and Parkinson’s, where studies have shown 
increased accumulation of iron in the brain. The small size and faster 
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8.1 RECIPES AND BUFFERS 
 
Cell Isolation MACS buffer 
1xPBS (PAA, Austria) + 2mM EDTA (Lonza) + 0.5% FCS (PAA) 
 
FACS Washing Buffer 
1xPBS + 0.1% Sodium Azide (Sigma Aldrich) 
 
FACS Staining Buffer 
1xPBS + 0.1% Sodium Azide (Sigma Aldrich) + 2% BSA 
 
10x Running Buffer for Western Blot 
35 mM SDS (10.08 g) 
250 mM Tris (30.3 g) 
1.92 M glycine (144 g) 
 
10x Transfer Buffer for Western Blot 
25 mM Tris (3.03 g) 
192 mM glycine (14.4g) 
 
In 800 mL final volume of water. Add 200 mL of methanol 100% 
 
 
 
